var title_f37_35_38448="Hamilton Rating Scale - page 3";
var content_f37_35_38448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F73164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F73164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Hamilton Rating Scale for Depression, page 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 760px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Hamilton, M. A rating scale for depression. J Neurosurg Psychiatry 1960; 23:56.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38448=[""].join("\n");
var outline_f37_35_38448=null;
var title_f37_35_38449="Loculated pleural hematoma CT";
var content_f37_35_38449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Loculated pleural hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Loculated pleural hematoma in left hemithorax after CABG. The loculated collection of blood has higher attenuation than the chest wall musculature.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38449=[""].join("\n");
var outline_f37_35_38449=null;
var title_f37_35_38450="Benign macrofollicular thyroid lesion high power view";
var content_f37_35_38450=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F64419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F64419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benign macrofollicular thyroid lesion: Findings on fine needle aspirate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-power view of a fine needle aspirate of a thyroid nodule. The follicular cells are small, uniform in size, flat, and noncrowded, with smeared colloid in the background. These findings can be seen in a normal thyroid gland, benign sporadic goiter, or a true benign macrofollicular monoclonal tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38450=[""].join("\n");
var outline_f37_35_38450=null;
var title_f37_35_38451="Ingenol mebutate: Drug information";
var content_f37_35_38451=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ingenol mebutate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/23/16756?source=see_link\">",
"    see \"Ingenol mebutate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14204999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Picato&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13743063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13825973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Actinic keratoses:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Face and scalp: Apply 0.015% gel once daily to affected area for 3 consecutive days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trunk/extremities: Apply 0.05% gel once daily to affected area for 2 consecutive days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13825974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13830538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Picato&reg;: 0.015% (3s); 0.05% (2s) [contains benzyl alcohol, isopropyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13825948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13825976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply to one contiguous affected area of skin using one unit-dose tube; one unit-dose tube will cover ~5 cm x 5 cm (~25 cm",
"     <sup>",
"      2",
"     </sup>",
"     or ~2 inch x 2 inch). Spread evenly then allow gel to dry for 15 minutes. Do not cover with bandages or occlusive dressings. Wash hands immediately after applying and avoid transferring gel to any other areas. Avoid washing or touching the treatment area for at least 6 hours, and following this period of time, patients may wash the area with a mild soap.  Not for oral, ophthalmic, or intravaginal use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13743068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of actinic keratosis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13825960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Dermatologic: Erythema (92% to 94%), flaking/scaling (85% to 90%), crusting (74% to 80%), swelling (64% to 79%), vesiculation/pustulation (44% to 56%), erosion/ulceration (26% to 32%), application site pain (2% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Application site pruritus (8%), application site irritation (4%), application site infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Periorbital edema (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Eyelid edema, eye pain, conjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13825952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13825953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dermatologic reactions: Severe reactions including erythema, crusting, swelling, vesiculation/pustulation, and erosion/ulceration can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular: Severe eye pain, eyelid edema, eyelid ptosis, and periorbital edema can occur after exposure. Avoid contact with the periocular area. Patients should wash their hands immediately after applying and avoid transferring to the eye area.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Apply to intact and nonirritated skin only. Instruct patients to wash hands well after applying and to avoid contact with the periocular area during and after application. Avoid touching the treated area for 6 hours after application. If inadvertent exposure to other area(s) occurs, flush the area with water and seek medical care as soon as possible. Avoid inadvertent transfer to other individuals. Administration of ingenol mebutate gel is not recommended until the skin is healed from any previous drug or surgical treatment. For topical use only; not for oral, ophthalmic, or intravaginal use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13853563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13853561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13825949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13825950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies following I.V. administration of ingenol mebutate. Absorption is limited in humans following topical application.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13825951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion into breast milk is unknown; absorption is limited following topical application",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Picato External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.015% (3): $708.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (2): $708.00",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13829598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ingenol mebutate appears to induce primary necrosis of actinic keratosis with a subsequent neutrophil-mediated inflammatory response with antibody-dependent cytotoxicity of residual disease cells; killing residual disease cells may prevent future relapse.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13825967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Absorption through the skin is minimal (with proper use); expected systemic exposure is &lt;0.1 ng/mL.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lebwohl M, Swanson N, Anderson LL, et al, &ldquo;Ingenol Mebutate Gel for Actinic Keratosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(11):1010-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/35/38451/abstract-text/22417254/pubmed\" id=\"22417254\" target=\"_blank\">",
"        22417254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramsay JR, Suhrbier A, Aylward JH, et al, &ldquo;The Sap From",
"      <i>",
"       Euphorbia peplus",
"      </i>",
"      is Effective Against Human Nonmelanoma Skin Cancers,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2011, 164(3):633-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/35/38451/abstract-text/21375515/pubmed\" id=\"21375515\" target=\"_blank\">",
"        21375515",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siler G, Rosen R, Freeman M, et al, &ldquo;PEP005 (Ingenol Mebutate) Gel for the Topical Treatment of Superficial Basal Cell Carcinoma: Results of a Randomized Phase IIa Trial,&rdquo;",
"      <i>",
"       Australas J Dermatol",
"      </i>",
"      , 2010, 51(2):99&ndash;105.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/35/38451/abstract-text/20546215/pubmed\" id=\"20546215\" target=\"_blank\">",
"        20546215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17140 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38451=[""].join("\n");
var outline_f37_35_38451=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14204999\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13743063\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825973\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825974\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13830538\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825948\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825976\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13743068\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825960\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825952\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825953\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853563\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853561\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825949\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825950\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825951\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322928\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13829598\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825967\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17140\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17140|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/23/16756?source=related_link\">",
"      Ingenol mebutate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_35_38452="Abdominal actinomycosis";
var content_f37_35_38452=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Abdominal actinomycosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38452/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38452/contributors\">",
"     Louis-Michel Wong Kee Song, MD, FRCP(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38452/contributors\">",
"     Norman E Marcon, MD, FRCP(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38452/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38452/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38452/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38452/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/35/38452/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of disorders are associated with lesions in the ileocecal region. Examples frequently encountered in developed countries include colon cancer, Crohn's disease, and less commonly, infection due to Yersinia enterocolitica and Y. pseudotuberculosis. (See related topic reviews.) Many other infectious, neoplastic, and drug-related causes of ileocecal lesions have been described.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of abdominal actinomycosis, which is one of the causes of ileocecal lesions that are frequently considered in specific clinical settings or when more frequent causes have been excluded or are unlikely. The others (including mucoceles, tuberculosis, typhlitis, carcinoid, and lesions due to NSAIDs) are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Actinomycosis is an uncommon, chronic granulomatous disease caused by filamentous, gram-positive, anaerobic bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/1\">",
"     1",
"    </a>",
"    ]. Actinomyces israelii is the major human pathogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Actinomycosis has a worldwide distribution, affects mostly middle-aged individuals, and is two to four times more common in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1710869925\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Actinomycetes are commensal inhabitants of the oral cavity and intestinal tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/5\">",
"     5",
"    </a>",
"    ], but acquire pathogenicity through invasion of breached or necrotic tissue. As the infection progresses, granulomatous tissue, extensive reactive fibrosis and necrosis, abscesses, draining sinuses, and fistulas are formed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection involving the cervicofacial area is most common (50 percent), followed by abdominal involvement (20 percent), and thoracic involvement (15 to 20 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/1\">",
"     1",
"    </a>",
"    ]. In abdominal actinomycosis, the appendix and ileocecal region are usually involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. The disease tends to remain localized as the infection spreads by contiguity, disregarding tissue planes. Lymphadenopathy is not a clinical feature. Hematogenous dissemination is also rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21559?source=see_link\">",
"     \"Cervicofacial actinomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Actinomycotic abscesses can also present in the abdomen following cholecystectomy complicated by spilled gallstones during gallbladder removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Because of the slow-growth characteristics of the pathogen, such patients may present months to years after cholecystectomy.",
"   </p>",
"   <p>",
"    Factors that predispose to abdominal actinomycosis include recent abdominal surgery, trauma, neoplasia, or a perforated viscus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, there have been multiple reports of abdominopelvic actinomycosis associated with the use of intrauterine contraceptive devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Actinomycosis is a difficult disease to diagnose preoperatively by virtue of its rarity, nonspecific symptoms, and imitation of more common conditions such as malignancy, Crohn's disease, and tuberculosis. It has been estimated that fewer than 10 percent of cases are diagnosed preoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. As a result, a high index of suspicion is required in patients presenting with constitutional or nonspecific abdominal symptoms and an abdominal mass. The disease is characterized by a chronic, indolent course with symptoms such as fatigue, fever, weight loss, and abdominal pain. Physical findings may include a palpable mass, visible sinus tracts, or fistulas. Laboratory abnormalities may show anemia and leukocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal actinomycosis can be easily confused with Crohn's disease, tuberculosis (TB), or carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. The diagnosis is usually made postoperatively, since most patients undergo exploratory laparotomy for a suspected neoplasm. The presence of extraintestinal manifestations of inflammatory bowel disease (eg, uveitis, ankylosing spondylitis) may be helpful in distinguishing ileocecal Crohn's disease from actinomycosis. The lack of improvement with conventional antiinflammatory or immunosuppressive drugs for a presumptive diagnosis of Crohn's disease usually leads to surgery, where a diagnosis of actinomycosis is eventually made. Clues in differentiating TB from actinomycosis include the presence of multisystem involvement (eg, lungs) in patients at high risk for TB. In contrast, actinomycosis is usually a localized, single organ disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Radiologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiologic findings are nonspecific in abdominal actinomycosis.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    enema may show luminal narrowing, extrinsic compression, or fistulization. Computed tomography (CT) is the most useful imaging modality; it determines the location and extent of disease, occasionally contributes to an accurate preoperative diagnosis through fine-needle aspiration, and is used for monitoring the radiologic response to treatment on follow-up exams [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ]. CT may show the infiltrative nature of the disease with disruption of tissue planes, and demonstrate one or more solid masses with focal low-attenuation areas or cystic masses with thickened walls (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76062 \" href=\"mobipreview.htm?42/41/43665\">",
"     image 1",
"    </a>",
"    ). However, these findings are nonspecific and, in one study, were felt to be indicative of a malignant process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When feasible, CT-guided percutaneous aspiration may permit identification of the characteristic actinomycotic sulfur granules in pus, and is also a good means of collecting material for culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/11\">",
"     11",
"    </a>",
"    ]. In conjunction with antibiotics, this maneuver can be therapeutic, thus precluding a surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Colonoscopic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopic findings are varied and include normal or thickened appearing mucosa, colitis, ulceration, a nodular lesion, and button-like elevation of an inverted appendiceal orifice (",
"    <a class=\"graphic graphic_picture graphicRef67936 \" href=\"mobipreview.htm?2/2/2082\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/6,13-17\">",
"     6,13-17",
"    </a>",
"    ]. The main differential diagnoses at endoscopy include neoplasia, Crohn's disease, and tuberculosis. Endoscopic biopsies occasionally allow a preoperative diagnosis to be made when characteristic histologic findings are found (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/6,10\">",
"     6,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Histologic findings and culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis is usually based upon histologic identification of actinomycotic sulfur granules",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    culture of Actinomyces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/1\">",
"     1",
"    </a>",
"    ]. The preferred specimen for culture is pus.",
"   </p>",
"   <p>",
"    Sulfur granules represent colonies of Actinomyces and are characterized by a zone of granulation tissue surrounding one or more oval eosinophilic granules. Beaded or filamentous, nonacid-fast, gram-positive bacilli radiate from these granules (",
"    <a class=\"graphic graphic_figure graphicRef81782 \" href=\"mobipreview.htm?33/19/34096\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/9\">",
"     9",
"    </a>",
"    ]. The sulfur granules are scarce so that multiple tissue sections should be studied. Sulfur granules are highly suggestive but not pathognomonic of actinomycosis, since organisms like Nocardia or Aspergillus spp can have a similar appearance.",
"   </p>",
"   <p>",
"    Actinomyces are indistinguishable from Nocardia on Gram stain, but only the latter are positive on modified acid fast staining. Culture is more specific, but the diagnosis is confirmed by culture in less than 50 percent of suspected cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An anaerobic environment is required for isolation of the organism, and the specimen should be sent under anaerobic conditions. Growth is faster in semi-selective medium (five to seven days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/3\">",
"     3",
"    </a>",
"    ], but identification can often take two to four weeks even after growth has initially been observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, many patients undergo resection before the diagnosis has been established. Initial medical treatment is reasonable in patients in whom the diagnosis is established prior to surgery. Penicillin is the preferred choice. Initial intravenous therapy is required for larger lesions with abdominal abscesses or draining sinus tracts. The recommended dose is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (10 to 20 million units per day divided every four to six hours) for four to six weeks, followed by oral penicillin (2 to 4",
"    <span class=\"nowrap\">",
"     g/d)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    for 6 to 12 months. For penicillin-allergic patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    are acceptable alternatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/2-4,14\">",
"     2-4,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery is usually reserved for patients with extensive lesions with severe necrosis and large abscess formation, and for removal of persistent fistulas, recurrent disease, or inability to rule out neoplasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/4,17\">",
"     4,17",
"    </a>",
"    ]. Patients who undergo resection should also be treated with high-dose antibiotic therapy.",
"   </p>",
"   <p>",
"    With combined medical and surgical treatment, the outcome is favorable in more than 90 percent of cases. Mortality is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38452/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1710869848\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Actinomycosis is an uncommon, chronic granulomatous disease caused by filamentous, gram-positive, anaerobic bacteria. Actinomyces israelii is the major human pathogen. Actinomycosis has a worldwide distribution, affects mostly middle-aged individuals, and is two to four times more common in men. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Actinomycetes are commensal inhabitants of the oral cavity and intestinal tract, but acquire pathogenicity through invasion of breached or necrotic tissue. As the infection progresses, granulomatous tissue, extensive reactive fibrosis and necrosis, abscesses, draining sinuses, and fistulas are formed. (See",
"      <a class=\"local\" href=\"#H1710869925\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Actinomycosis is a difficult disease to diagnose preoperatively by virtue of its rarity, nonspecific symptoms, and imitation of more common conditions such as malignancy, Crohn's disease, and tuberculosis. It has been estimated that fewer than 10 percent of cases are diagnosed preoperatively. As a result, a high index of suspicion is required in patients presenting with constitutional or nonspecific abdominal symptoms and an abdominal mass. The disease is characterized by a chronic, indolent course with symptoms such as fatigue, fever, weight loss, and abdominal pain. Physical findings may include a palpable mass, visible sinus tracts, or fistulas. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiologic findings are nonspecific in abdominal actinomycosis. Computed tomography is the most useful imaging modality; it determines the location and extent of disease, occasionally contributes to an accurate preoperative diagnosis through fine-needle aspiration, and is used for monitoring the radiologic response to treatment on follow-up exams. CT may show the infiltrative nature of the disease with disruption of tissue planes, and demonstrate one or more solid masses with focal low-attenuation areas or cystic masses with thickened walls (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef76062 \" href=\"mobipreview.htm?42/41/43665\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A definitive diagnosis is usually based upon histologic identification of actinomycotic sulfur granules",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      culture of Actinomyces. The preferred specimen for culture is pus. Sulfur granules represent colonies of Actinomyces and are characterized by a zone of granulation tissue surrounding one or more oval eosinophilic granules. Beaded or filamentous, nonacid-fast, gram-positive bacilli radiate from these granules (",
"      <a class=\"graphic graphic_figure graphicRef81782 \" href=\"mobipreview.htm?33/19/34096\">",
"       figure 1",
"      </a>",
"      ). Actinomyces are indistinguishable from Nocardia on Gram stain, but only the latter are positive on modified acid fast staining. An anaerobic environment is required for isolation of the organism. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Histologic findings and culture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients undergo resection before the diagnosis has been established. Initial medical treatment is reasonable in patients in whom the diagnosis is established prior to surgery. Penicillin is the preferred choice. Initial intravenous therapy is required for larger lesions with abdominal abscesses or draining sinus tracts. The recommended dose is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      10 to 20 million units per day divided every four to six hours for four to six weeks, followed by oral penicillin (2 to 4 g per day) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      for 6 to 12 months. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/1\">",
"      Wong VK, Turmezei TD, Weston VC. Actinomycosis. BMJ 2011; 343:d6099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/2\">",
"      Cintron JR, Del Pino A, Duarte B, Wood D. Abdominal actinomycosis. Dis Colon Rectum 1996; 39:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/3\">",
"      Ferrari TC, Couto CA, Murta-Oliveira C, et al. Actinomycosis of the colon: a rare form of presentation. Scand J Gastroenterol 2000; 35:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/4\">",
"      Yeg&uuml;ez JF, Martinez SA, Sands LR, Hellinger MD. Pelvic actinomycosis presenting as malignant large bowel obstruction: a case report and a review of the literature. Am Surg 2000; 66:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/5\">",
"      Dayan K, Neufeld D, Zissin R, et al. Actinomycosis of the large bowel: unusual presentations and their surgical treatment. Eur J Surg 1996; 162:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/6\">",
"      Piper MH, Schaberg DR, Ross JM, et al. Endoscopic detection and therapy of colonic actinomycosis. Am J Gastroenterol 1992; 87:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/7\">",
"      Vyas JM, Kasmar A, Chang HR, et al. Abdominal abscesses due to actinomycosis after laparoscopic cholecystectomy: case reports and review. Clin Infect Dis 2007; 44:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/8\">",
"      Ramia JM, Mansilla A, Villar J, et al. Retroperitoneal actinomycosis due to dropped gallstones. Surg Endosc 2004; 18:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/9\">",
"      Harris LA, DeCosse JJ, Dannenberg A. Abdominal actinomycosis: evaluation by computed tomography. Am J Gastroenterol 1989; 84:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/10\">",
"      Litt HI, Levine MS, Maki DD, et al. Ileal actinomycosis in a patient with AIDS. AJR Am J Roentgenol 1999; 172:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/11\">",
"      Ha HK, Lee HJ, Kim H, et al. Abdominal actinomycosis: CT findings in 10 patients. AJR Am J Roentgenol 1993; 161:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/12\">",
"      Lee IJ, Ha HK, Park CM, et al. Abdominopelvic actinomycosis involving the gastrointestinal tract: CT features. Radiology 2001; 220:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/13\">",
"      Higaki S, Matsuura S, Awaya N, et al. A case of colonic actinomycosis difficult to distinguish from advanced colonic carcinoma. Endoscopy 1995; 27:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/14\">",
"      Yang SH, Li AF, Lin JK. Colonoscopy in abdominal actinomycosis. Gastrointest Endosc 2000; 51:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/15\">",
"      Kim JC, Ahn BY, Kim HC, et al. Efficiency of combined colonoscopy and computed tomography for diagnosis of colonic actinomycosis: a retrospective evaluation of eight consecutive patients. Int J Colorectal Dis 2000; 15:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/16\">",
"      Morini S, Hassan C, Lorenzetti R, et al. Submucosal nodules containing purulent fluid: a colonoscopic sign of actinomycosis? Gastrointest Endosc 2004; 59:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38452/abstract/17\">",
"      Kim JB, Han DS, Lee HL, et al. Diagnosis and partial treatment of actinomycosis by colonoscopic biopsy. Gastrointest Endosc 2004; 60:162.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2691 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-16712FB15A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38452=[""].join("\n");
var outline_f37_35_38452=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1710869848\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1710869925\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Radiologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Colonoscopic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Histologic findings and culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1710869848\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2691\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2691|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/41/43665\" title=\"diagnostic image 1\">",
"      Actinomycosis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2691|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/19/34096\" title=\"figure 1\">",
"      Actinomyces sulfur granules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2691|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/2/2082\" title=\"picture 1\">",
"      Actinomyces infection Endosc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21559?source=related_link\">",
"      Cervicofacial actinomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_35_38453="Squamous CA keratin Light";
var content_f37_35_38453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Keratinization in lung cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Keratin (arrow) appears as waxy, darkly staining eosinophilic cytoplasm in this high powered photomicrograph of a well differentiated squamous cell carcinoma of the lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38453=[""].join("\n");
var outline_f37_35_38453=null;
var title_f37_35_38454="Obstetrical management of omphalocele";
var content_f37_35_38454=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Obstetrical management of omphalocele",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38454/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38454/contributors\">",
"     Courtney D Stephenson, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38454/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38454/contributors\">",
"     Andrew P MacKenzie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38454/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38454/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38454/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38454/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38454/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/35/38454/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widespread use of antenatal ultrasound examination and maternal serum alpha-fetoprotein screening has led to increasing detection of fetal abdominal wall defects in the second trimester of pregnancy. Omphalocele is one such abnormality. It refers to a defect in the anterior abdominal wall through which intraabdominal contents are extruded into the base of the umbilical cord; an amnioperitoneal membrane typically covers the defect (but may rupture before or at the time of delivery). The abdominal herniation usually includes small bowel and may include large bowel",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated omphalocele occurs in approximately 1 in 5000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/1\">",
"     1",
"    </a>",
"    ]. Interestingly, the occurrence of omphalocele appears to be more common in women at the extremes of reproductive age. In women less than 20 or greater than 40 years of age, the odds ratio for developing omphalocele compared to the general obstetric population is 2.45 (95% CI 1.22-4.86) and 8.76 (95% CI 4.02-19.32), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/2\">",
"     2",
"    </a>",
"    ]. Modest associations with maternal obesity and in utero SSRI exposure have also been reported in some studies, while others have found no association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal abdominal wall defects form as a result of disturbances in organogenesis during the embryonic period. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34247?source=see_link&amp;anchor=H2#H2\">",
"     \"Prenatal sonographic diagnosis of fetal abdominal wall defects\", section on 'Embryology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are three theories on the etiology of omphalocele formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistence of the primitive body stalk",
"     </li>",
"     <li>",
"      Failure of the bowel to return to the abdomen",
"     </li>",
"     <li>",
"      Failure of complete lateral-body fold migration and body wall closure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The latter theory helps to explain why some omphalocele sacs contain liver.",
"   </p>",
"   <p>",
"    Most omphaloceles occur sporadically. They are associated with a high frequency of concomitant chromosomal abnormality when the liver is intracorporeal and the omphalocele sac contains only small bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Karyotypic abnormalities include trisomies 13, 15, 16, and 18, and Beckwith-Wiedemann syndrome. In one series of 250 fetuses with omphalocele and an abnormal karyotype, the spectrum of karyotypes was: trisomy 18 (n = 158; 63 percent), trisomy 13 (n = 44; 17 percent), trisomy 21 (n = 9; 4 percent), Turner syndrome (n = 15; 6 percent), triploidy (n = 12; 5 percent), and rare chromosomal deletions (n = 12; 5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/8\">",
"     8",
"    </a>",
"    ]. Omphalocele containing extracorporeal liver often, but not invariably, have a normal karyotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/7,9\">",
"     7,9",
"    </a>",
"    ], but exteriorization of the liver is associated with a poorer neonatal outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND ASSOCIATED ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic findings of omphalocele are an anterior abdominal mass at the site of cord insertion with a covering membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/11\">",
"     11",
"    </a>",
"    ], although the covering membrane may be difficult to see. Fetal ascites may be present. Ninety-five percent of omphaloceles can be accurately diagnosed with ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34247?source=see_link&amp;anchor=H4#H4\">",
"     \"Prenatal sonographic diagnosis of fetal abdominal wall defects\", section on 'Omphalocele'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of associated anomalies ranges from 50 to 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/13\">",
"     13",
"    </a>",
"    ], but has been reported to be as high as 89 percent in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The anomalies are not confined to the gastrointestinal tract, but can involve the heart (up to 40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/16\">",
"     16",
"    </a>",
"    ], neural tube [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/17\">",
"     17",
"    </a>",
"    ],",
"    <span class=\"nowrap\">",
"     lip/palate,",
"    </span>",
"    or cloaca. Some studies suggest that smaller defects (&lt;4 cm) correlate with gastrointestinal defects, while larger defects are more likely to be associated with cardiac defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/18\">",
"     18",
"    </a>",
"    ]. An association between maternal SSRI use and fetal omphalocele has been reported, but is controversial since it has not been observed consistently. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/0/28682?source=see_link&amp;anchor=H10#H10\">",
"     \"Depression in pregnant women: Management\", section on 'SSRI composite data'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chromosomal abnormalities are common (50 to 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/15,19\">",
"     15,19",
"    </a>",
"    ]) when any of the following features are present: associated anomalies, absence of liver in the herniated sac, hydramnios, or oligohydramnios.",
"   </p>",
"   <p>",
"    Beckwith-Wiedemann syndrome (BWS) is a disorder of growth characterized by macrosomia, macroglossia, visceromegaly, embryonal tumors, omphalocele, neonatal hypoglycemia, ear",
"    <span class=\"nowrap\">",
"     creases/pits,",
"    </span>",
"    adrenocortical cytomegaly, and renal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/20\">",
"     20",
"    </a>",
"    ]. There is a 10 to 20 percent risk of BWS in fetuses with isolated omphalocele. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24473?source=see_link\">",
"     \"Beckwith-Wiedemann syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maternal serum alpha-fetoprotein concentration (MSAFP) is elevated (mean 4.18 MoM) in 70 percent of pregnancies in which omphalocele is noted on routine second trimester ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/21\">",
"     21",
"    </a>",
"    ]. Human chorionic gonadotropin (hCG) and unconjugated estriol (uE3) are not significantly altered, thus they are not useful in diagnosis of abdominal wall defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OBSTETRICAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Work-up of omphalocele may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fetal karyotype",
"     </li>",
"     <li>",
"      Testing for Beckwith-Wiedemann syndrome",
"     </li>",
"     <li>",
"      Amniotic fluid alpha-fetoprotein",
"     </li>",
"     <li>",
"      Fetal echocardiogram",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fetal chromosomal analysis by amniocentesis (or alternative technique) should be offered if omphalocele or related body fold defects are identified prenatally, because of the high risk of karyotype abnormalities (see above). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is reasonable to offer amniocentesis for genetic testing for BWS, but this testing is complicated and should be discussed with a geneticist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/22\">",
"     22",
"    </a>",
"    ]. Cytogenetically detectable abnormalities involving 11p15 are found in &le;1 percent of BWS cases. Additional molecular genetic testing can increase the detection rate (positive findings include loss of methylation of DMR2, gain of methylation of DMR1, presence of paternal uniparental disomy for 11p15, or mutations in sequencing of CDKN1C). For individuals with a family history of BWS, prenatal diagnosis can be performed when the genetic mechanism is known. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24473?source=see_link\">",
"     \"Beckwith-Wiedemann syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Amniotic fluid alpha-fetoprotein concentration is commonly elevated, but the amniotic fluid electrophoretic gel density ratio for",
"    <span class=\"nowrap\">",
"     acetylcholinesterase/pseudo-cholinesterase",
"    </span>",
"    is lower with abdominal wall defects than with open neural tube defects (&lt;0.10 versus 0.27) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/21\">",
"     21",
"    </a>",
"    ]. If acetylcholinesterase levels are elevated, one should be suspicious of a concomitant neural tube defect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A fetal echocardiogram is suggested, given the increased incidence of cardiac abnormalities.",
"   </p>",
"   <p>",
"    After the prenatal diagnosis is established, parents benefit from additional expertise and perspective provided by a team of maternal fetal medicine specialists, neonatologists, pediatric surgeons, and genetic counselors working in collaboration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Follow-up obstetrical care",
"    </span>",
"    &nbsp;&mdash;&nbsp;We follow most pregnancies complicated by omphalocele with serial ultrasound examination every two weeks to evaluate fetal growth and weekly nonstress testing or biophysical profile monitoring after 32 weeks of gestation to assess fetal well-being. Fetuses with an omphalocele frequently deliver preterm (26 to 65 percent) and show signs of growth restriction (6 to 35 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/23\">",
"     23",
"    </a>",
"    ]. Nonreassuring fetal testing or cessation of fetal growth at or near term are indications for delivery.",
"   </p>",
"   <p>",
"    Omphalocele associated with pulmonary hypoplasia from Pentalogy of Cantrell (epigastric omphalocele, defective sternum, ventral diaphragmatic defect, intrinsic cardiac abnormality, anterior pericardial deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/24\">",
"     24",
"    </a>",
"    ]), trisomy 13 or 18, or triploidy carries a dismal prognosis; therefore, interventions such as fetal monitoring and cesarean delivery are generally avoided in these cases. Management should be individualized, however, since, with modern neonatal and surgical care, survival is possible in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Planning delivery at a tertiary care center, as opposed to transporting a critically ill infant, has been shown to provide optimal outcome for the newborn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/13\">",
"     13",
"    </a>",
"    ]. Increased morbidity in \"outborn\" neonates may be related to factors such as temperature and hydration status, care of the defect, and vascular compromise of prolapsed gut during prolonged transportation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence that cesarean delivery improves outcome in uncomplicated omphalocele; surgery should be reserved for usual obstetric indications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/13,23,27-29\">",
"     13,23,27-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14682?source=see_link\">",
"     \"Cesarean delivery: Technique\"",
"    </a>",
"    .) This conclusion is supported by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series assessed neonatal outcome of 102 fetuses with isolated ventral wall defects (omphalocele or gastroschisis) according to mode of delivery (n = 66 cesarean, n = 36 vaginal) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/27\">",
"       27",
"      </a>",
"      ]. The size of the defect, length of bowel resected, and type of abdominal wall closure performed were considered in analyzing outcome. Omphaloceles with extracorporeal liver and cesarean deliveries performed for obstetric indications were excluded. Route of delivery did not affect neonatal length of stay, number of days to enteral feeding, or rate of primary closure. Three cases of fetal visceral trauma occurred, all following cesarean delivery.",
"     </li>",
"     <li>",
"      A meta-analysis of 15 studies did not find a significant relationship between route of delivery and rate of primary fascial repair (pooled relative risk [RR] 1.22, 95 percent CI 0.99 to 1.51), neonatal sepsis (pooled RR 0.70, 95 percent CI 0.30 to 1.62), or pediatric mortality (pooled RR 1.14, 95 percent CI 0.59 to 2.21) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/30\">",
"       30",
"      </a>",
"      ]. Route of delivery was also not a factor in time until enteral feeding or length of hospital stay.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, some groups have elected to deliver fetuses with \"giant\" omphaloceles (defined as an omphalocele containing &gt;75 percent of the liver) by cesarean delivery in an attempt to avoid dystocia, rupture, infection, and hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     APPROACH TO THE NEONATE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Delivery room",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immediate care of the newborn with omphalocele involves sterile wrapping of the bowel to preserve heat and minimize insensible fluid loss, insertion of an orogastric tube to decompress the stomach, stabilizing the airway to ensure adequate ventilation, and establishing peripheral intravenous access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. One approach is to wrap the defect with gauze dressings soaked in sterile saline that is thermally neutral and cover the dressing with Saran Wrap; some use a plastic bag that encloses the infant up to the chest. Excessively wet dressings should be avoided because they can macerate the omphalocele sac and cause the newborn's temperature to drop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/1\">",
"     1",
"    </a>",
"    ]. Intravenous fluids are administered in conjunction with broad spectrum antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/1\">",
"     1",
"    </a>",
"    ]. Cardiorespiratory and fluid status should be monitored closely and a thorough physical examination performed to identify additional malformations. The neonate should be maintained in a thermoneutral environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Synopsis of surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small defects (&lt;2 cm) can generally be managed by primary direct closure, while medium to large defects require a staged procedure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary closure reduces the risk of bacterial contamination, sepsis, acidosis, and hypothermia, but can be difficult when the size of the abdominal cavity is limited. It should be carried out only if excess tension can be avoided to minimize the risk of wound breakdown.",
"     </li>",
"     <li>",
"      For moderate to large defects (2 to 9 cm), most surgeons place a Dacron-reinforced silastic silo as a temporary cover for the bowel. The silo can be reduced gradually over three to seven days in the intensive care unit, after which the infant is returned to the operating room for final closure of the abdominal wall [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/1,32\">",
"       1,32",
"      </a>",
"      ]. Reducing a large defect or one that contains liver can be done with Doppler ultrasound guidance to ensure the inferior vena cava and hepatic outflow tract are not compromised during the silo reduction. In unusual cases of an extremely large (&gt;10 cm) lesion or a premature infant having respiratory difficulties, a topical sclerosing agent can be used as a temporary measure until definitive therapy can be performed on a more stable patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After omphalocele reduction, the neonate may require prolonged mechanical ventilation because of respiratory difficulties created by the increased intraabdominal pressure, which can impair diaphragm excursion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/13,31\">",
"     13,31",
"    </a>",
"    ]. Infants with very large omphaloceles containing most of the liver may require multiple surgeries and have the potential for long-term morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported survival rates vary and reflect the ability to diagnosis abdominal wall defects prenatally and the decision of many families to proceed with termination of pregnancy when severe or multiple anomalies are present. Neonatal morbidity and mortality rates are directly correlated with the presence or absence of associated anatomic and chromosomal anomalies; thus, the severity of the associated anomalies is closely linked to fetal and neonatal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/15,33-35\">",
"     15,33-35",
"    </a>",
"    ]. The range of outcomes is illustrated in the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One review of 43 cases of omphalocele diagnosed prenatally found associated malformations in as many as 67 percent, approximately 80 percent of which were major [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. Eighty percent of fetuses with coexisting malformations died. Amniotic fluid abnormalities (attributed to anomalies of the genitourinary, central nervous, or gastrointestinal systems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/36\">",
"       36",
"      </a>",
"      ]) were also associated with a poor prognosis. By comparison, all ten of the infants who survived had either minor or no associated malformations.",
"     </li>",
"     <li>",
"      In another large series of 90 prenatally diagnosed omphaloceles, 69 fetuses were terminated or died in utero and 21 survived [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/15\">",
"       15",
"      </a>",
"      ]. Of the survivors, 13 were born with associated anomalies (5 with septal defects, 2 with Beckwith-Wiedemann, and single cases of assorted other defects) and 8 were born without chromosomal or structural anomalies and were healthy at follow-up six months to 17 years after birth, but two of these 8 children had an impairment (one psychomotor delay, one deafness and absence of speech).",
"     </li>",
"     <li>",
"      In a study including 26 children with omphalocele and 40 children with gastroschisis, 75 percent of the children had no gastrointestinal problems, or suffered from these rarely [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/16\">",
"       16",
"      </a>",
"      ]. Almost all of the children were of normal weight and height, but physical and intellectual development were delayed in one third. Initial developmental delays were made up during the first two years of life.",
"     </li>",
"     <li>",
"      Another study that compared long-term outcomes of survivors with minor or giant defects reported there was no difference between the two groups in quality of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/37\">",
"       37",
"      </a>",
"      ]. Mortality in neonates with isolated giant defects appears to be low, but repair can be a long and arduous process [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/38\">",
"       38",
"      </a>",
"      ]. Multiple surgeries are sometimes required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RECURRENCE RATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases are sporadic. The recurrence risk is dependent on the underlying cause. If the fetus is found to have a chromosomal abnormality, the recurrence risk is 1 percent. For isolated omphalocele with normal karyotype, the recurrence risk is less than 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38454/abstract/39\">",
"     39",
"    </a>",
"    ]. However, the risk of recurrence increases if a parental balanced translocation is detected. Omphalocele associated with Beckwith-Wiedemann syndrome (macroglossia, visceromegaly, gigantism, and either umbilical hernia or omphalocele) should prompt chromosomal analysis to determine if there are duplications or abnormalities of chromosome 11p15, since familial cases of Beckwith-Wiedemann syndrome can be autosomal dominant and have a 50 percent recurrence risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24473?source=see_link\">",
"     \"Beckwith-Wiedemann syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Omphalocele is a defect in the anterior abdominal wall through which intraabdominal contents are extruded into the base of the umbilical cord. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases are sporadic. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Recurrence rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fetuses with an omphalocele containing liver typically, but not invariably, have a normal karyotype. If an intracorporeal liver is present, the risk of chromosomal abnormality is high. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend ultrasound examination for diagnosis as well as for looking for associated anomalies, which are common. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis and associated anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest determining the fetal karyotype because of the increased risk of chromosomal abnormality in these fetuses. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Obstetrical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest serial ultrasound examination to follow fetal growth and nonstress tests to assess fetal well-being. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Obstetrical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest avoiding routine cesarean delivery of fetuses with omphalocele, but perform this surgery for usual obstetric indications. There is no evidence that cesarean delivery improves outcome in uncomplicated omphalocele. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the delivery room, we suggest covering the defect with gauze dressings soaked in thermally neutral sterile saline, covering the dressing with Saran Wrap, inserting an orogastric tube to decompress the stomach, stabilizing the airway to ensure adequate ventilation, and establishing peripheral intravenous access. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Approach to the neonate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall survival is 79 percent. This high survival rate reflects the ability to diagnosis abdominal wall defects prenatally and the decision of many families to proceed with termination of pregnancy when severe or multiple anomalies are present. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Townsend. Abdomen. In: Sabiston Textbook of Surgery, 16th ed, WB Saunders Co, Philadelphia 2001. p.1478.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/2\">",
"      Byron-Scott R, Haan E, Chan A, et al. A population-based study of abdominal wall defects in South Australia and Western Australia. Paediatr Perinat Epidemiol 1998; 12:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/3\">",
"      Waller DK, Shaw GM, Rasmussen SA, et al. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med 2007; 161:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/4\">",
"      Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356:2684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/5\">",
"      Duhamel B. Embryology of Exomphalos and Allied Malformations. Arch Dis Child 1963; 38:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/6\">",
"      Sermer M, Benzie RJ, Pitson L, et al. Prenatal diagnosis and management of congenital defects of the anterior abdominal wall. Am J Obstet Gynecol 1987; 156:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/7\">",
"      Nyberg DA, Fitzsimmons J, Mack LA, et al. Chromosomal abnormalities in fetuses with omphalocele. Significance of omphalocele contents. J Ultrasound Med 1989; 8:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/8\">",
"      Lakasing L, Cicero S, Davenport M, et al. Current outcome of antenatally diagnosed exomphalos: an 11 year review. J Pediatr Surg 2006; 41:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/9\">",
"      Benacerraf BR, Saltzman DH, Estroff JA, Frigoletto FD Jr. Abnormal karyotype of fetuses with omphalocele: prediction based on omphalocele contents. Obstet Gynecol 1990; 75:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/10\">",
"      Nicholas SS, Stamilio DM, Dicke JM, et al. Predicting adverse neonatal outcomes in fetuses with abdominal wall defects using prenatal risk factors. Am J Obstet Gynecol 2009; 201:383.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/11\">",
"      Bair JH, Russ PD, Pretorius DH, et al. Fetal omphalocele and gastroschisis: a review of 24 cases. AJR Am J Roentgenol 1986; 147:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/12\">",
"      Fisher R, Attah A, Partington A, Dykes E. Impact of antenatal diagnosis on incidence and prognosis in abdominal wall defects. J Pediatr Surg 1996; 31:538.",
"     </a>",
"    </li>",
"    <li>",
"     Bianchi DW, Crombleholme TM, D'Alton ME. Omphalocele. In: Fetology, McGraw Hill, New York 2000. p.483.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/14\">",
"      Mayer T, Black R, Matlak ME, Johnson DG. Gastroschisis and omphalocele. An eight-year review. Ann Surg 1980; 192:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/15\">",
"      Brantberg A, Blaas HG, Haugen SE, Eik-Nes SH. Characteristics and outcome of 90 cases of fetal omphalocele. Ultrasound Obstet Gynecol 2005; 26:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/16\">",
"      Henrich K, Huemmer HP, Reingruber B, Weber PG. Gastroschisis and omphalocele: treatments and long-term outcomes. Pediatr Surg Int 2008; 24:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/17\">",
"      Ardinger HH, Williamson RA, Grant S. Association of neural tube defects with omphalocele in chromosomally normal fetuses. Am J Med Genet 1987; 27:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/18\">",
"      Kumar HR, Jester AL, Ladd AP. Impact of omphalocele size on associated conditions. J Pediatr Surg 2008; 43:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/19\">",
"      Kleinrouweler CE, Kuijper CF, van Zalen-Sprock MM, et al. Characteristics and outcome and the omphalocele circumference/abdominal circumference ratio in prenatally diagnosed fetal omphalocele. Fetal Diagn Ther 2011; 30:60.",
"     </a>",
"    </li>",
"    <li>",
"     www.genetests.org/servlet/access (Accessed on August 31, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/21\">",
"      Saller DN Jr, Canick JA, Palomaki GE, et al. Second-trimester maternal serum alpha-fetoprotein, unconjugated estriol, and hCG levels in pregnancies with ventral wall defects. Obstet Gynecol 1994; 84:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/22\">",
"      Porter A, Benson CB, Hawley P, Wilkins-Haug L. Outcome of fetuses with a prenatal ultrasound diagnosis of isolated omphalocele. Prenat Diagn 2009; 29:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/23\">",
"      Carpenter MW, Curci MR, Dibbins AW, Haddow JE. Perinatal management of ventral wall defects. Obstet Gynecol 1984; 64:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/24\">",
"      Toyama WM. Combined congenital defects of the anterior abdominal wall, sternum, diaphragm, pericardium, and heart: a case report and review of the syndrome. Pediatrics 1972; 50:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/25\">",
"      van Hoorn JH, Moonen RM, Huysentruyt CJ, et al. Pentalogy of Cantrell: two patients and a review to determine prognostic factors for optimal approach. Eur J Pediatr 2008; 167:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/26\">",
"      Kitchanan S, Patole SK, Muller R, Whitehall JS. Neonatal outcome of gastroschisis and exomphalos: a 10-year review. J Paediatr Child Health 2000; 36:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/27\">",
"      How HY, Harris BJ, Pietrantoni M, et al. Is vaginal delivery preferable to elective cesarean delivery in fetuses with a known ventral wall defect? Am J Obstet Gynecol 2000; 182:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/28\">",
"      Moretti M, Khoury A, Rodriquez J, et al. The effect of mode of delivery on the perinatal outcome in fetuses with abdominal wall defects. Am J Obstet Gynecol 1990; 163:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/29\">",
"      Lewis DF, Towers CV, Garite TJ, et al. Fetal gastroschisis and omphalocele: is cesarean section the best mode of delivery? Am J Obstet Gynecol 1990; 163:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/30\">",
"      Segel SY, Marder SJ, Parry S, Macones GA. Fetal abdominal wall defects and mode of delivery: a systematic review. Obstet Gynecol 2001; 98:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/31\">",
"      Biard JM, Wilson RD, Johnson MP, et al. Prenatally diagnosed giant omphaloceles: short- and long-term outcomes. Prenat Diagn 2004; 24:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/32\">",
"      Pacilli M, Spitz L, Kiely EM, et al. Staged repair of giant omphalocele in the neonatal period. J Pediatr Surg 2005; 40:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/33\">",
"      Poznanski AK. Fetal omphalocele: prenatal US detection of concurrent anomalies and other predictors of outcome. Radiology 1990; 177:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/34\">",
"      Hughes MD, Nyberg DA, Mack LA, Pretorius DH. Fetal omphalocele: prenatal US detection of concurrent anomalies and other predictors of outcome. Radiology 1989; 173:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/35\">",
"      Heider AL, Strauss RA, Kuller JA. Omphalocele: clinical outcomes in cases with normal karyotypes. Am J Obstet Gynecol 2004; 190:135.",
"     </a>",
"    </li>",
"    <li>",
"     Angtuaco TL. Fetal Anterior Abdominal Wall Defect. In: Ultrasonography in Obstetrics and Gynecology, 4th ed, WB Saunders Co, Philadelphia 2000. p.489.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/37\">",
"      van Eijck FC, Hoogeveen YL, van Weel C, et al. Minor and giant omphalocele: long-term outcomes and quality of life. J Pediatr Surg 2009; 44:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38454/abstract/38\">",
"      Mitanchez D, Walter-Nicolet E, Humblot A, et al. Neonatal care in patients with giant ompholocele: arduous management but favorable outcomes. J Pediatr Surg 2010; 45:1727.",
"     </a>",
"    </li>",
"    <li>",
"     Romero R. Prenatal Diagnosis of Congenital Anomalies, Appleton and Lange, East Norwalk CT 1988. p.220.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6763 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38454=[""].join("\n");
var outline_f37_35_38454=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS AND ASSOCIATED ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OBSTETRICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Follow-up obstetrical care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      APPROACH TO THE NEONATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Delivery room",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Synopsis of surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RECURRENCE RATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24473?source=related_link\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14682?source=related_link\">",
"      Cesarean delivery: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=related_link\">",
"      Prenatal screening and diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34247?source=related_link\">",
"      Prenatal sonographic diagnosis of fetal abdominal wall defects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_35_38455="Symptomatic treatment of acute pharyngitis in adults";
var content_f37_35_38455=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Symptomatic treatment of acute pharyngitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38455/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38455/contributors\">",
"     Wendy Stead, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38455/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38455/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38455/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38455/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/35/38455/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2014875\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pharyngitis is one of the most common conditions encountered in office practice, accounting for 12 million ambulatory visits in the United States annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of illness causing sore throat in adults is viral. Additionally, even when treating documented bacterial pathogens such as group A streptococcus, antibiotics contribute minimally to the speed with which symptoms of pharyngitis improve. Nonetheless, overtreatment of acute pharyngitis continues to represent a major cause of inappropriate antibiotic use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will address options for the symptomatic relief of throat pain in adults with pharyngitis. Treatment of oropharyngeal pain secondary to",
"    <span class=\"nowrap\">",
"     surgical/endoscopic",
"    </span>",
"    procedures or chemotherapeutic agents will not be addressed. The evaluation of the adult patient with acute pharyngitis and the antibiotic treatment of streptococcal tonsillopharyngitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5738?source=see_link\">",
"     \"Evaluation of acute pharyngitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H278213413\">",
"    <span class=\"h1\">",
"     PATIENT EXPECTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many providers have preconceptions that acquiring an antibiotic prescription is the most important priority for patients who are visiting a primary care clinic for acute sore throat, despite evidence to the contrary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Prescribing antibiotics that are not indicated for a specific infection puts the individual at risk for antibiotic side effects and increases the community risk of bacterial resistance. Additionally, prescribing antibiotics for sore throat increases the likelihood that a patient will make return visits to medical providers for similar symptoms, presumably due to &ldquo;medicalization&rdquo; of a typically self-limited illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational evidence about prescribing practices for sore throat suggests that, rather than hoping specifically for an antibiotic prescription, many patients are more interested in pain relief, reassurance, and information about their illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A cross-sectional survey of 298 consecutive patients in Belgium who visited family physicians for acute sore throat was designed to understand the most important reasons patients presented for provider evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/4\">",
"     4",
"    </a>",
"    ]. Hope for an antibiotic ranked 11th of 13 items, with only 37.6 percent of patients rating it as",
"    <span class=\"nowrap\">",
"     very/rather",
"    </span>",
"    important. The three most commonly reported reasons for a physician visit, all ranked as",
"    <span class=\"nowrap\">",
"     very/rather",
"    </span>",
"    important reasons for the visit by &gt;80 percent of patients, were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To establish the cause of the symptoms",
"     </li>",
"     <li>",
"      To obtain pain relief",
"     </li>",
"     <li>",
"      To receive information regarding the expected course of illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The subgroup of patients who considered receipt of an antibiotic",
"    <span class=\"nowrap\">",
"     very/rather",
"    </span>",
"    important valued pain relief significantly more than those who considered an antibiotic",
"    <span class=\"nowrap\">",
"     little/not",
"    </span>",
"    important. Hope for pain relief remained a strong predictor of the desire to receive an antibiotic prescription in the multivariate analysis, suggesting that patients who hope for an antibiotic may most desire an intervention to provide pain relief and believe an antibiotic offers the best approach for achieving this end. This finding raises the possibility that unnecessary antibiotic prescriptions might be avoided by a shift in provider focus to non-antibiotic pain relief interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2014882\">",
"    <span class=\"h1\">",
"     TOPICAL/LOCAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite its common occurrence, data examining treatments for symptomatic management of acute pharyngitis in adults are limited. Nonpharmacologic therapies such as salt water gargles are often recommended on the basis of anecdotal response, though there are no studies to confirm that these are effective for sore throat pain relief. Several local therapies for sore throat in the form of throat sprays, gargles,",
"    <span class=\"nowrap\">",
"     lozenges/drops",
"    </span>",
"    and teas have been studied to varying degrees for relief of pain related to pharyngitis. One study used scintigraphy to compare the delivery efficacy of technetium-labeled lozenges, tablets, sprays and gargles in the mouth and throat of healthy volunteers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/6\">",
"     6",
"    </a>",
"    ]. Lozenges and tablets to be sucked achieved higher initial deposition in the mouth and throat and had slower rates of clearance compared with throat sprays and gargles, suggesting that lozenges and tablets could be more effective for symptomatic treatment of pharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/6\">",
"     6",
"    </a>",
"    ]. Advantages of local therapies include direct application of the pain relief intervention in high concentration to the area of inflammation, and decreased risk of toxicity compared to systemic administration of certain agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2014889\">",
"    <span class=\"h2\">",
"     Lozenges",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different kinds of lozenges and throat drops are marketed for over-the-counter (OTC) use for symptomatic treatment of sore throat. Several OTC products for this purpose contain the active ingredient menthol, either alone (as with many cough drop brands) or in combination with other agents. Menthol has been shown to possess anesthetic properties, although has not been studied specifically for symptomatic treatment of pharyngitis pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/7\">",
"     7",
"    </a>",
"    ]. Other topical anesthetics found in OTC lozenges include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/46/26338?source=see_link\">",
"     dyclonine",
"    </a>",
"    (Sucrets),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    (Cepacol, Chloraseptic lozenges), and a combination of amylmetacresol and 2.4-dichlorobenzyl alcohol",
"    <span class=\"nowrap\">",
"     (AMC/DCBA)",
"    </span>",
"    available in the UK (Strepsils).",
"   </p>",
"   <p>",
"    Lozenges containing ambroxol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , or amylmetacresol and 2,4-dichlorobenzyl alcohol",
"    <span class=\"nowrap\">",
"     (AMC/DCBA)",
"    </span>",
"    have been the most studied for use in treating sore throat pain. At least one nonsteroidal anti-inflammatory drug,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/42/33440?source=see_link\">",
"     flurbiprofen",
"    </a>",
"    , has also been studied in lozenge form for relief of sore throat pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This agent, marketed in the United Kingdom, is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2014983\">",
"    <span class=\"h3\">",
"     Ambroxol lozenges",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lozenges containing ambroxol, a local anesthetic, have been evaluated in multiple, industry sponsored, randomized placebo-controlled trials in ambulatory adult patients in Germany [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. A review of five such randomized trials examined the effect of ambroxol lozenges among 1713 patients with acute, uncomplicated sore throat of recent onset, without signs suggesting bacterial infection, who complained of at least &ldquo;moderate&rdquo; or &ldquo;severe&rdquo; sore throat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/12\">",
"     12",
"    </a>",
"    ]. In four of the five trials, the relief of sore throat pain by sucking a first lozenge containing 20 mg ambroxol was significantly greater than placebo starting at 30 minutes after dosing and lasting at least three hours. Treatment was well-tolerated, though numbness of the",
"    <span class=\"nowrap\">",
"     tongue/oral",
"    </span>",
"    cavity and changes in taste perception were noted, particularly in patients with less severe sore throat at baseline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2014990\">",
"    <span class=\"h3\">",
"     Lidocaine lozenges",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized placebo-controlled single-center phase III study in Germany examined pain relief from lozenges containing 8 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    hydrochloride in 240 adult patients with at least moderate to severe throat pain of recent onset without evidence of bacterial etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/13\">",
"     13",
"    </a>",
"    ]. Significant improvement in pain intensity over two hours after the first dose persisted during two days of follow-up, during which patients were allowed to use up to 11 additional lidocaine lozenges. Treatment was well-tolerated without an increase in adverse effects in the lidocaine-treated group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2014997\">",
"    <span class=\"h3\">",
"     Benzocaine lozenges",
"    </span>",
"    &nbsp;&mdash;&nbsp;One small trial in Germany prospectively evaluated the pain-relieving effects of two different formulations of local",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    therapy (a newly formulated lozenge versus a previously marketed pastille), both containing 8 mg of benzocaine, in 246 adult patients with acute viral pharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/14\">",
"     14",
"    </a>",
"    ]. Pain intensity was reduced by a minimum of 50 percent in 23.6 percent of patients after the first lozenge dose with no significant difference between groups. This response rate was lower than expected. A smaller trial of",
"    <span class=\"nowrap\">",
"     benzocaine/cetylpyridium",
"    </span>",
"    lozenges in 43 patients reported alleviation of pain in 83.7 percent of patients within 15 minutes of the dose, although the degree of pain relief was not quantified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/15\">",
"     15",
"    </a>",
"    ]. A randomized controlled trial evaluated the effects of 8 mg benzocaine lozenges versus placebo in 165 patients with uncomplicated sore throat and found a significant decrease in pain and faster time to pain relief in the benzocaine group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/16\">",
"     16",
"    </a>",
"    ]. Though adverse reactions to benzocaine lozenges are rare, it should be noted that the US Food and Drug Administration (FDA) issued a public health advisory in 2006 regarding the risk of methemoglobinemia associated with benzocaine sprays, and the agency continues to receive reports of this rare, but serious and potentially fatal, adverse effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H781451489\">",
"    <span class=\"h3\">",
"     AMC/DCBA lozenges",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two industry-sponsored randomized controlled trials in the UK have evaluated the pain-relieving effects of amylmetacresol and 2,4-dichlorobenzyl alcohol lozenges",
"    <span class=\"nowrap\">",
"     (AMC/DCBA,",
"    </span>",
"    Strepsils) in patients with acute sore throat due to upper respiratory tract infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In both trials, when compared with placebo lozenges, use of",
"    <span class=\"nowrap\">",
"     AMC/DCBA",
"    </span>",
"    lozenges was associated with a significant decrease in throat soreness that started within five minutes of lozenge use and persisted at two hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2014896\">",
"    <span class=\"h2\">",
"     Throat sprays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many over-the-counter throat sprays marketed in the United States for relief of sore throat pain (eg, Chloraseptic) contain phenol as their active ingredient. Phenol is described to have both antiseptic and anesthetic properties. Although there is some in vitro evidence that certain topical antiseptics may act to block neuronal sodium channels to exert local anesthetic effects in sore throat treatment, phenol sprays have not been rigorously studied in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized controlled trial in Turkey assessed the pain-reducing effect of a seven-day course of mouth spray containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    (a topical antiseptic) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/45/6867?source=see_link\">",
"     benzydamine",
"    </a>",
"    hydrochloride (a topical antiinflammatory) self-administered four times per day compared with placebo spray, both in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    500 mg four times daily, in 164 patients with acute viral pharyngitis. The treatment group reported significantly less pain on a visual analogue scale on both day three and day seven of treatment compared with placebo spray with no significant difference in side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/20\">",
"     20",
"    </a>",
"    ]. The same investigators also performed a randomized controlled trial assessing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    <span class=\"nowrap\">",
"     gluconate/benzydamine",
"    </span>",
"    hydrochloride mouth spray versus placebo spray, both in combination with oral penicillin therapy, in 147 patients with GAS tonsillopharyngitis. A significant improvement in the &ldquo;clinical sign intensity score&rdquo; (including rating of subjects&rsquo; report of sore throat along with several clinical signs of tonsillopharyngitis) was seen in the treatment group compared with controls at the end of 10 days of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/21\">",
"     21",
"    </a>",
"    ]. This product (Difflam-C) is not available in the United States.",
"   </p>",
"   <p>",
"    A randomized trial from Switzerland found that an herbal spray of echinacea and sage was as effective as a spray containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    for relief of sore throat pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/22\">",
"     22",
"    </a>",
"    ]. Neither product is available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2014903\">",
"    <span class=\"h1\">",
"     ALTERNATIVE REMEDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of 12 randomized trials of Chinese medicinal herbs for the relief of pharyngitis found significant methodologic flaws in ten of the studies and medium-quality evidence in two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/23\">",
"     23",
"    </a>",
"    ]. Although some Chinese herbal medicines were more effective than the comparators (other herbs, topical and systemic antibiotics in individual studies) in individual studies, definitive conclusions could not be drawn due to the lack of high-quality studies.",
"   </p>",
"   <p>",
"    Many teas and herbal drops are marketed in the United States for relief of sore throat pain, although this is also supported by a weak evidence base. These products may contain several active ingredients, often including agents identified as demulcents which are purported to relieve oral and pharyngeal mucosal irritation by forming a soothing film over mucous membranes due to their mucilaginous effects. Commonly used demulcents in such products include honey, pectin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    One herbal tea containing licorice root, elm inner bark, marshmallow root and licorice root aqueous dry extract (Throat Coat) is currently marketed in the United States for symptomatic treatment of pharyngitis. A small, multicenter, industry-sponsored, randomized, controlled trial of this herbal tea preparation was performed in 60 adult patients presenting to clinics in the US with acute pharyngitis. Throat Coat was found to significantly diminish sore throat pain compared with placebo during the 30 minutes after drinking the dose with no serious adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least one randomized controlled trial evaluating acupuncture versus sham laser acupuncture has examined immediate pain relieving effect in 60 patients with acute tonsillitis. A single acupuncture treatment was found to be no more effective than sham laser acupuncture for alleviation of sore throat pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2014910\">",
"    <span class=\"h1\">",
"     SYSTEMIC ANALGESICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several systemic analgesics for relief of sore throat pain have been investigated, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and non-steroidal antiinflammatory drugs (NSAIDS) remain the two most rigorously studied for this indication.",
"   </p>",
"   <p>",
"    A systematic review of 11 controlled trials investigating non-antibiotic interventions for sore throat pain in adults identified seven trials showing significant and rapid decreases in sore throat pain within 1 to 6 hours after taking doses of analgesics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/26\">",
"     26",
"    </a>",
"    ]. In studies involving adult patients with acute sore throat,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    800 mg decreased pain by 55 percent at one hour (and by 75 percent if combined with 64mg caffeine),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    200-400 mg decreased pain by 32 to 80 percent at two to four hours, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen (paracetamol)",
"    </a>",
"    1000 mg decreased pain by 50 percent after three hours compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the last decade several additional randomized trials have been published confirming the efficacy of systemic analgesics for treating acute sore throat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A double-blind, placebo-controlled trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , administered as two 400 mg effervescent tablet in water, was performed in 272 adult patients with acute sore throat associated with other symptoms of upper respiratory infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/30\">",
"       30",
"      </a>",
"      ]. A significant reduction in the intensity of sore throat pain was seen in the intervention group, compared with placebo, at two, four, and six hours. Headaches and muscle",
"      <span class=\"nowrap\">",
"       aches/pains",
"      </span>",
"      were also significantly reduced in the treatment group with no serious adverse events reported.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      , a formulation associated with more rapid absorption of acetaminophen than standard acetaminophen tablets, was found to provide rapid relief in a randomized controlled trial in 241 adult patients with acute sore throat [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/31\">",
"       31",
"      </a>",
"      ]. A single dose of acetaminophen 500",
"      <span class=\"nowrap\">",
"       mg/sodium",
"      </span>",
"      bicarbonate 630 mg resulted in significantly greater pain relief than placebo starting at 15 minutes post-dose and continuing through to six hours. This specific formulation is available outside the United States under the trade name Panadol ActiFast; effervescent products containing acetaminophen and sodium bicarbonate are available in the US in different dose ratios.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether one analgesic is better than another for sore throat treatment has not been well established, though data from several small randomized trials suggest that NSAIDs are more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . A randomized trial of 113 adults with acute sore throat in France compared analgesic activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    400 mg with paracetamol 1000 mg and found a significantly greater reduction in pain intensity in patients taking ibuprofen compared with paracetamol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/32\">",
"     32",
"    </a>",
"    ]. Another randomized double-blind trial of 120 outpatients with acute sore throat in the US compared analgesic activity of ibuprofen 400 mg with acetaminophen 1000 mg or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/28\">",
"     28",
"    </a>",
"    ]. Both ibuprofen and acetaminophen significantly reduced pain intensity at hourly intervals for six hours compared with placebo; however, ibuprofen was significantly more effective than acetaminophen at reducing pain intensity after two hours to the end of the six hour study. A randomized trial of 113 adult patients with acute sore throat presenting to a primary care practice in Zimbabwe compared the efficacy of ibuprofen 400 mg with acetaminophen 1000 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/33\">",
"     33",
"    </a>",
"    ]. Reduction in throat pain intensity was significantly greater with ibuprofen than acetaminophen, starting one hour after administration and continuing over the six-hour postdose evaluation period.",
"   </p>",
"   <p>",
"    Guidelines from the Infectious Disease Society of America (IDSA) advise use of either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or an NSAID as adjunctive treatment to antibiotic in the management of streptococcal pharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2014917\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of all the non-antibiotic options proposed for the treatment of symptoms of pharyngitis, the use of glucocorticoids (&ldquo;steroids&rdquo;) has been most fully reported in the peer-reviewed literature, yet remains the most controversial. Although there is evidence that glucocorticoid use can slightly decrease the duration of throat pain, analgesics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or NSAIDs are also effective with significantly less risk for toxicity. Guidelines from the Infectious Disease Society of America (IDSA) recommend against the use of glucocorticoids for patients with streptococcal pharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/34\">",
"     34",
"    </a>",
"    ]. We suggest not prescribing glucocorticoids on a routine basis for the relief of pain associated with an acute sore throat. The use of glucocorticoids should be restricted to the exceptional patient who presents with severe throat pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inability to swallow. The role of glucocorticoids in the treatment of throat pain and swelling associated with infectious mononucleosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31018?source=see_link&amp;anchor=H36#H36\">",
"     \"Infectious mononucleosis in adults and adolescents\", section on 'Symptomatic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several systematic reviews included randomized trials investigating the efficacy of glucocorticoid treatment for pain reduction in acute pharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. In the most recent review, six randomized trials (four included both adults and children) involving 374 adults (21 to 65 years), approximately 50 percent with Group A streptococcal pharyngitis, evaluated corticosteroids as adjunctive therapy to antibiotics for symptomatic relief of pharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38455/abstract/37\">",
"     37",
"    </a>",
"    ]. The doses of glucocorticoids used in the trials included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    10 mg (intramuscular or oral),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    8 mg intramuscular, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    60 mg for one or two days (oral). Compared to placebo, corticosteroids increased the proportion of patients with complete resolution of pain at 24 to 48 hours, and decreased the time to onset of pain relief by 6 hours and to complete resolution of pain by 14 hours.",
"   </p>",
"   <p>",
"    Despite these positive findings, there were several limitations to these data. The trials were heterogeneous in design, comparing different glucocorticoids (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ), given at different doses and time intervals by different routes of administration (mostly intramuscular, with some oral administration). Most of the trials were in the emergency setting, with uncertainty in generalizability to patients seen in an office practice. Antibiotics were co-administered in all of the trials reviewed, and use of concurrent analgesics was allowed and rarely controlled, making it difficult to isolate the pain-relieving effect of one treatment versus another. No serious adverse side effects of short-term glucocorticoid use were reported, but the sample size of patients was too small to detect potentially rare but serious toxicities resulting from even such limited steroid courses. Toxicities such as serious mood changes and hyperglycemia are well-described with short-term steroid use and need to be considered when contemplating the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio of steroid use in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/57/914?source=see_link\">",
"       \"Patient information: Sore throat in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/15/36082?source=see_link\">",
"       \"Patient information: Sore throat in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2014924\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overtreatment of acute pharyngitis represents a major cause of inappropriate antibiotic use. Contrary to provider preconceptions, receiving an antibiotic prescription is not a top priority for patients seeking care. However, pain relief is one of the most important reasons for patient visits. (See",
"      <a class=\"local\" href=\"#H278213413\">",
"       'Patient expectations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data examining treatments for symptomatic management of acute pharyngitis in adults are limited. Local therapies, in the form of lozenges, sprays, or teas, have the advantage of direct application to the affected area and minimal toxicity risk. Analgesics (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , and nonsteroidal antiinflammatories) have also been shown to provide for pain relief, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      appears to be somewhat more effective than acetaminophen. We recommend that patients with pain related to acute sore throat be advised to use a systemic analgesic (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This may reasonably be supplemented by a topical preparation; the choice of topical or systemic analgesic agent can be determined by patient preference. (See",
"      <a class=\"local\" href=\"#H2014882\">",
"       'Topical/local therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2014910\">",
"       'Systemic analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several randomized trials have shown that a short-term course of glucocorticoids can expedite the resolution of pain associated with acute sore throat. However, the generalizability of these findings to patients seen outside an emergency room setting is uncertain, and the trials were not powered sufficiently to evaluate the incidence of adverse effects related to glucocorticoid use. We suggest not prescribing glucocorticoids on a routine basis for the relief of pain associated with an acute sore throat (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The use of glucocorticoids should be restricted to the exceptional patient who presents with severe throat pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inability to swallow. (See",
"      <a class=\"local\" href=\"#H2014917\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/1\">",
"      Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2006. Natl Health Stat Report 2008; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/2\">",
"      Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database Syst Rev 2006; :CD000023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/3\">",
"      Butler CC, Rollnick S, Pill R, et al. Understanding the culture of prescribing: qualitative study of general practitioners' and patients' perceptions of antibiotics for sore throats. BMJ 1998; 317:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/4\">",
"      van Driel ML, De Sutter A, Deveugele M, et al. Are sore throat patients who hope for antibiotics actually asking for pain relief? Ann Fam Med 2006; 4:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/5\">",
"      Little P, Gould C, Williamson I, et al. Reattendance and complications in a randomised trial of prescribing strategies for sore throat: the medicalising effect of prescribing antibiotics. BMJ 1997; 315:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/6\">",
"      Limb M, Connor A, Pickford M, et al. Scintigraphy can be used to compare delivery of sore throat formulations. Int J Clin Pract 2009; 63:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/7\">",
"      Watt EE, Betts BA, Kotey FO, et al. Menthol shares general anesthetic activity and sites of action on the GABA(A) receptor with the intravenous agent, propofol. Eur J Pharmacol 2008; 590:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/8\">",
"      Watson N, Nimmo WS, Christian J, et al. Relief of sore throat with the anti-inflammatory throat lozenge flurbiprofen 8.75 mg: a randomised, double-blind, placebo-controlled study of efficacy and safety. Int J Clin Pract 2000; 54:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/9\">",
"      Blagden M, Christian J, Miller K, Charlesworth A. Multidose flurbiprofen 8.75 mg lozenges in the treatment of sore throat: a randomised, double-blind, placebo-controlled study in UK general practice centres. Int J Clin Pract 2002; 56:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/10\">",
"      Schutz A, Gund HJ, Pschorn U, et al. Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat. Clinical proof of concept. Arzneimittelforschung 2002; 52:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/11\">",
"      Fischer J, Pschorn U, Vix JM, et al. Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat. Randomised, double-blind, placebo-controlled trials regarding the local anaesthetic properties. Arzneimittelforschung 2002; 52:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/12\">",
"      de Mey C, Peil H, K&ouml;lsch S, et al. Efficacy and safety of ambroxol lozenges in the treatment of acute uncomplicated sore throat. EBM-based clinical documentation. Arzneimittelforschung 2008; 58:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/13\">",
"      Wonnemann M, Helm I, Stauss-Grabo M, et al. Lidocaine 8 mg sore throat lozenges in the treatment of acute pharyngitis. A new therapeutic option investigated in comparison to placebo treatment. Arzneimittelforschung 2007; 57:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/14\">",
"      Busch R, Graubaum HJ, Gr&uuml;nwald J, Schmidt M. Double-blind comparison of two types of benzocaine lozenges for the treatment of acute pharyngitis. Arzneimittelforschung 2010; 60:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/15\">",
"      Kagan G, Huddlestone L, Wolstencroft P. Two lozenges containing benzocaine assessed in the relief of sore throat. J Int Med Res 1982; 10:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/16\">",
"      Chrubasik S, Beime B, Magora F. Efficacy of a benzocaine lozenge in the treatment of uncomplicated sore throat. Eur Arch Otorhinolaryngol 2012; 269:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/17\">",
"      McNally D, Simpson M, Morris C, et al. Rapid relief of acute sore throat with AMC/DCBA throat lozenges: randomised controlled trial. Int J Clin Pract 2010; 64:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/18\">",
"      Wade AG, Morris C, Shephard A, et al. A multicentre, randomised, double-blind, single-dose study assessing the efficacy of AMC/DCBA Warm lozenge or AMC/DCBA Cool lozenge in the relief of acute sore throat. BMC Fam Pract 2011; 12:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/19\">",
"      Buchholz V, Leuwer M, Ahrens J, et al. Topical antiseptics for the treatment of sore throat block voltage-gated neuronal sodium channels in a local anaesthetic-like manner. Naunyn Schmiedebergs Arch Pharmacol 2009; 380:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/20\">",
"      Cingi C, Songu M, Ural A, et al. Effects of chlorhexidine/benzydamine mouth spray on pain and quality of life in acute viral pharyngitis: a prospective, randomized, double-blind, placebo-controlled, multicenter study. Ear Nose Throat J 2010; 89:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/21\">",
"      Cingi C, Songu M, Ural A, et al. Effect of chlorhexidine gluconate and benzydamine hydrochloride mouth spray on clinical signs and quality of life of patients with streptococcal tonsillopharyngitis: multicentre, prospective, randomised, double-blinded, placebo-controlled study. J Laryngol Otol 2011; 125:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/22\">",
"      Schapowal A, Berger D, Klein P, Suter A. Echinacea/sage or chlorhexidine/lidocaine for treating acute sore throats: a randomized double-blind trial. Eur J Med Res 2009; 14:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/23\">",
"      Huang Y, Wu T, Zeng L, Li S. Chinese medicinal herbs for sore throat. Cochrane Database Syst Rev 2012; 3:CD004877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/24\">",
"      Brinckmann J, Sigwart H, van Houten Taylor L. Safety and efficacy of a traditional herbal medicine (Throat Coat) in symptomatic temporary relief of pain in patients with acute pharyngitis: a multicenter, prospective, randomized, double-blinded, placebo-controlled study. J Altern Complement Med 2003; 9:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/25\">",
"      Fleckenstein J, Lill C, L&uuml;dtke R, et al. A single point acupuncture treatment at large intestine meridian: a randomized controlled trial in acute tonsillitis and pharyngitis. Clin J Pain 2009; 25:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/26\">",
"      Thomas M, Del Mar C, Glasziou P. How effective are treatments other than antibiotics for acute sore throat? Br J Gen Pract 2000; 50:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/27\">",
"      Schachtel BP, Fillingim JM, Lane AC, et al. Caffeine as an analgesic adjuvant. A double-blind study comparing aspirin with caffeine to aspirin and placebo in patients with sore throat. Arch Intern Med 1991; 151:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/28\">",
"      Schachtel BP, Fillingim JM, Thoden WR, et al. Sore throat pain in the evaluation of mild analgesics. Clin Pharmacol Ther 1988; 44:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/29\">",
"      Schachtel BP, Cleves GS, Konerman JP, et al. A placebo-controlled model to assay the onset of action of nonprescription-strength analgesic drugs. Clin Pharmacol Ther 1994; 55:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/30\">",
"      Eccles R, Loose I, Jawad M, Nyman L. Effects of acetylsalicylic acid on sore throat pain and other pain symptoms associated with acute upper respiratory tract infection. Pain Med 2003; 4:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/31\">",
"      Burnett I, Schachtel B, Sanner K, et al. Onset of analgesia of a paracetamol tablet containing sodium bicarbonate: A double-blind, placebo-controlled study in adult patients with acute sore throat. Clin Ther 2006; 28:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/32\">",
"      Boureau F, Pelen F, Verriere F, et al. Evaluation of Ibuprofen vs Paracetamol analgesic activity using a sore throat pain model. Clin Drug Investig 1999; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/33\">",
"      Lala I, Leech P, Montgomery L, Bhagat K. Use of a simple pain model to evaluate analgesic activity of ibuprofen versus paracetamol. East Afr Med J 2000; 77:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/34\">",
"      Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 55:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/35\">",
"      Korb K, Scherer M, Chenot JF. Steroids as adjuvant therapy for acute pharyngitis in ambulatory patients: a systematic review. Ann Fam Med 2010; 8:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/36\">",
"      Wing A, Villa-Roel C, Yeh B, et al. Effectiveness of corticosteroid treatment in acute pharyngitis: a systematic review of the literature. Acad Emerg Med 2010; 17:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38455/abstract/37\">",
"      Hayward G, Thompson MJ, Perera R, et al. Corticosteroids as standalone or add-on treatment for sore throat. Cochrane Database Syst Rev 2012; 10:CD008268.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14610 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FE8AB3007C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38455=[""].join("\n");
var outline_f37_35_38455=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2014924\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2014875\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H278213413\">",
"      PATIENT EXPECTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2014882\">",
"      TOPICAL/LOCAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2014889\">",
"      Lozenges",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2014983\">",
"      - Ambroxol lozenges",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2014990\">",
"      - Lidocaine lozenges",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2014997\">",
"      - Benzocaine lozenges",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H781451489\">",
"      - AMC/DCBA lozenges",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2014896\">",
"      Throat sprays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2014903\">",
"      ALTERNATIVE REMEDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2014910\">",
"      SYSTEMIC ANALGESICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2014917\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2014924\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5738?source=related_link\">",
"      Evaluation of acute pharyngitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/15/36082?source=related_link\">",
"      Patient information: Sore throat in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/57/914?source=related_link\">",
"      Patient information: Sore throat in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2666?source=related_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_35_38456="Drug allergy: Pathogenesis";
var content_f37_35_38456=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug allergy: Pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38456/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38456/contributors\">",
"     Werner J Pichler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38456/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38456/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38456/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38456/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/35/38456/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A drug allergy, or an allergic drug reaction, is an adverse drug reaction that results from a specific immunologic response to a medication.",
"   </p>",
"   <p>",
"    Recognition of drugs by the immune system and the pathogenesis of different types of drug allergic reactions will be reviewed here. The classification and clinical features of drug allergic reactions are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/11/1210?source=see_link\">",
"     \"Drug allergy: Classification and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERACTION OF DRUGS WITH THE IMMUNE SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs can elicit a drug specific immune response in two ways (",
"    <a class=\"graphic graphic_table graphicRef54199 \" href=\"mobipreview.htm?40/2/41004\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The drug may act as an antigen and elicit one of several classic immune responses.",
"     </li>",
"     <li>",
"      The drug may directly interact with immune receptors, and under certain circumstances, lead to activation of specific immune cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Drugs acting as antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most medications are small molecular weight compounds with simple chemical structures, which are not easily recognized by immune cells and are too small to interact with immune receptors with sufficient strength to activate T or B cells. Thus, most drugs are not effective antigens and are not immunogenic in their native state. However, if the drug is presented to lymphocytes by dendritic and other antigen presenting cells (either in its native or in a modified form after metabolism and processing) a specific immune response to the drug may develop. This drug-specific response can be solely T cell mediated, predominantly antibody-mediated, or have components of both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Stimulation of an antibody response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms though which an antigen gives rise to an antibody response are reviewed in detail separately. Briefly, most antigens are processed by antigen presenting cells and presented to T cells in the context of MHC. This results in activation of the T cell, which in turn produces cytokines that activate B cells. The B cell recognizes the antigen via its immunoglobulin (Ig) receptor, becomes activated, and subsequently produces antigen-specific immunoglobulins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Quite a few modern pharmaceuticals are proteins, which can stimulate antibody and T cells responses like other protein antigens. These agents are typically high molecular weight macromolecules that contain many repetitive",
"    <span class=\"nowrap\">",
"     motifs/epitopes.",
"    </span>",
"    The following are examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insulin and other hormones (both of animal and human origin)",
"     </li>",
"     <li>",
"      Enzymes, protamine",
"     </li>",
"     <li>",
"      Antisera",
"     </li>",
"     <li>",
"      Recombinant proteins, such as monoclonal antibodies, solubilized receptors, and cytokines",
"     </li>",
"     <li>",
"      Vaccines",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A limited number of drugs are high molecular weight macromolecules containing many repetitive",
"    <span class=\"nowrap\">",
"     motifs/epitopes,",
"    </span>",
"    which may even induce antibody formation without T cell help. There are also a few agents of low molecular weight that contain multiple recurrences of a single epitope and thus can act as",
"    <span class=\"nowrap\">",
"     antigens/allergens,",
"    </span>",
"    despite their small size. The best known examples are carboxymethyl cellulose, a stabilizing agent in injectable preparations for intramuscular administration, and the some quaternary ammonium compounds used as neuromuscular blockers in anesthesia induction (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , and others) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Allergic reactions to these agents are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42809?source=see_link\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Drugs as haptens and prohaptens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most drugs with small uncomplicated structures make poor antigens, as stated previously. However, small chemicals (ie, &lt;1 kilodalton in size) can become immunogenic by binding covalently to larger macromolecules -- usually host proteins on cell surfaces or in plasma. The drug is then referred to as a hapten, and the newly formed complex is called a hapten-carrier complex. Examples of cell surface molecules that may become bound by haptens include integrins or peptide-MHC complexes. Hapten-carrier complexes can induce T cell",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antibody responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Drugs that cannot act directly as haptens, but give rise to metabolites that can, are referred to as prohaptens.",
"   </p>",
"   <p>",
"    Penicillin is a drug that haptenates host proteins. When penicillin is administered and exposed to the physiologic conditions within the body, the beta-lactam ring structure readily breaks open. The opened ring reacts with lysine residues in proteins, forming a hapten-carrier protein complex referred to as the major penicilloyl determinant, which is capable of stimulating T cell",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antibody responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The majority of immediate allergic reactions to penicillin and other beta-lactam drugs arise from this mechanism. The pathogenesis of penicillin allergy is reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug manufacturers made efforts to avoid the introduction of new drugs that can spontaneously haptenate macromolecules, but the following groups of agents have this capability and are already in use:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Penicillins and other beta-lactam antibiotics (ie, cephalosporins, carbapenems, and monobactams)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"       Penicillamine",
"      </a>",
"     </li>",
"     <li>",
"      Heavy metals (eg, gold, cisplatinum)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Reactive metabolites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some drugs are unreactive with host macromolecules in their native state, but are converted into reactive intermediates during drug metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Drug metabolism occurs mainly in the liver through the actions of cytochrome P450-associated enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13754?source=see_link\">",
"     \"Drugs and the liver: Metabolism and mechanisms of injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During drug metabolism, reactive drug metabolites are often generated within hepatocytes. Some of these reactive metabolites may escape detoxification and subsequently bind to (haptenate) intracellular proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/11-13\">",
"     11-13",
"    </a>",
"    ] or may be secreted from the cell and further processed by antigen-presenting cells (APCs). Such drugs are called prohaptens. Drug metabolism can also occur within APCs directly, resulting in processing and presentation of drug antigens on the cell surface, and subsequent presentation to T cells. The T cells can then produce cytokines to stimulate B cells, in which case both T cell- and antibody-mediated responses would ensue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sulfonamide antimicrobials are examples of medications that form reactive metabolites. The sulfamethoxazole component of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX), is partly acetylated, giving rise to harmless compounds, and partly metabolized to sulfamethoxazole-hydroxylamine (SMX-NHOH). SMX-NHOH can be secreted in the urine, but is also oxidized to sulfamethoxazole-nitroso (SMX-NO), which is highly reactive with proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The SMX-NO-protein complexes can stimulate both T and B cell responses. The metabolism of sulfonamides and sulfonamide allergy are reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23594?source=see_link\">",
"     \"Sulfonamide allergy in non HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many drugs give rise to reactive intermediates during metabolism, but most are immediately neutralized (eg, by glutathione). The following drugs form reactive metabolites that may escape neutralization and lead to immunogenic hapten-protein complexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sulfonamide antimicrobials (but not other sulfonamide drugs)",
"     </li>",
"     <li>",
"      Phenacetin",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       Phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       Procainamide",
"      </a>",
"     </li>",
"     <li>",
"      Halothane",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pharmacological interaction of drugs with immune receptors (the p-i concept)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A novel mechanism was proposed for interaction of drugs by the immune system in the late 1990s. This theory arose from the observation that certain drugs, in their native state and without processing or metabolism, can stimulate T cells, even though the drugs are unable to bind covalently to larger protein structures in this state. This was called the \"p-i concept,\" for \"pharmacological interaction of drugs with immune receptors\" because the interaction is similar to that between a drug and its target therapeutic receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The p-i concept differs from preceding theories of drug hypersensitivity in its relative simplicity. It proposes that some drugs can interact directly with certain T cell receptors or HLA molecules. The only requirement is that the drug, or some piece of it, fit either into the antigen-binding site or otherwise interact with these molecules well enough to elicit a response from the T cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reactions arising from interactions between drugs and T cell receptors can be denoted as p-i TCR, and interactions between drugs and HLA-molecules, as p-i HLA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the p-i TCR model, a drug interacts with a particular TCR. In addition to this interaction, a second interaction between the TCR and MHC molecules on antigen presenting cells (APCs) is required to stimulate cellular proliferation, cytokine production, and cytotoxicity by the drug-stimulated T cells (",
"      <a class=\"graphic graphic_figure graphicRef66704 \" href=\"mobipreview.htm?13/57/14228\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/17-23\">",
"       17-23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the p-i HLA model, a drug binds preferentially to a certain HLA-molecule. This explains the strong association for some HLA alleles of some drug hypersensitivity reactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/24-28\">",
"       24-28",
"      </a>",
"      ]. The binding of drug on APCs can alter the conformation of the peptide-binding site [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/29\">",
"       29",
"      </a>",
"      ], which leads to stimulation by HLA-drug complexes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/30\">",
"       30",
"      </a>",
"      ]. Alternatively, the drug-altered MHC molecule allows the presentation of a different set of peptides to T cells. Since T cells are tolerant only to those MHC-restricted peptides to which they were exposed during development in the thymus, the alternate set of peptides may be interpreted as foreign by the T cells and result in an allo- or autoimmune like T cell reaction (investigated for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      only).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence for the p-i concept was initially based upon in vitro studies showing that drug-specific T cell clones can be stimulated directly by drugs in monomeric form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/18,21,23\">",
"     18,21,23",
"    </a>",
"    ]. Studies of cells from patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    -induced Stevens-Johnson syndrome or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    -induced T cell reactions later supported the p-i concept, and underlined the importance of a suitable, high affinity T cell receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Subsequently, in vitro evidence for this mechanism for abacavir, including the crystallographic structure of abacavir binding to the F-pocket of HLA-B*57:01 molecule, were published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/29,33,34\">",
"     29,33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21049?source=see_link\">",
"     \"Abacavir hypersensitivity reaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drugs that have this ability to interact with immune cells in this manner, at least in vitro, include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sulfamethoxazole",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       Allopurinol",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"       Mepivacaine",
"      </a>",
"     </li>",
"     <li>",
"      Some radiocontrast agents, such as iomeprol",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       Abacavir",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The p-i concept may be involved in drug-induced hypersensitivity syndromes, as well as severe exfoliative drug reactions (see",
"    <a class=\"local\" href=\"#H18\">",
"     'IVb'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'IVc'",
"    </a>",
"    below). T cells from blister fluid of patients with cotrimoxazole-induced Stevens-Johnson syndrome can be stimulated by exposure to the causative drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/22\">",
"     22",
"    </a>",
"    ]. The pathophysiology of Stevens-Johnson syndrome is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The interaction between drug and TCRs or HLA molecules occurs within seconds in vitro. However, hypersensitivity reactions appear days to weeks after the culprit drug is started. This may reflect the number of T cells that are stimulated by a particular drug. If many clones are stimulated, symptoms could appear rapidly. If just a few clones are stimulated, symptoms may take weeks to appear as those clones replicate and expand in number. If the patient is exposed again to the causative drug, symptoms appear more quickly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/11/1210?source=see_link&amp;anchor=H33#H33\">",
"     \"Drug allergy: Classification and clinical features\", section on 'Timing of type IV reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Overlap of mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that drugs stimulate immune reactions through more than one mechanism simultaneously. Some drugs believed to be stimulatory by the p-i mechanism also form hapten carrier compounds after metabolism, such as sulfamethoxazole,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/15,16,23\">",
"     15,16,23",
"    </a>",
"    ]. This overlap of mechanisms may result in a mixed clinical picture, which can imitate an array of disorders and may not even be recognized as a drug-related process. Indeed, drug allergy is such a common imitator of other diseases, that its role in 21st century medicine is reminiscent of that of syphilis or tuberculosis in earlier eras.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF SPECIFIC REACTION TYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, immunologic reactions, whether caused by drugs, infections, or autoimmune processes, have been divided into four categories according to the Gell and Coombs system (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"mobipreview.htm?13/11/13500\">",
"     table 2",
"    </a>",
"    ). Types I, II, and III are mediated by antibodies, while type IV is mediated by T cells.",
"   </p>",
"   <p>",
"    The Gell and Coombs classification was established before detailed analyses of T cell subsets and functions were technically possible. As new immunologic tools were developed, type IV reactions were further subdivided into types IVa, IVb, IVc, and IVd [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Subdivisions of type IV'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Type I (IgE mediated)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I reactions require the presence of drug-specific immunoglobulin E (IgE). Certain patients form drug-specific IgE upon exposure to a medication.",
"   </p>",
"   <p>",
"    As previously discussed, the drug or its metabolite may act as a hapten, forming hapten-carrier complexes that can be processed by antigen presenting cells (eg, penicillins, platinum agents). Less commonly, the drug may be a complete antigen in its native form (eg, foreign proteins). An additional mechanism by which IgE mediated reactions arise is previous sensitization to a cross-reacting agent (eg, sensitization to quaternary ammonium compounds in personal products leading to type I reaction to neuromuscular blocking agents used in anesthesia induction).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Sensitization stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formation of drug-specific IgE normally requires the coordinated actions of B cells and T helper cells. In the most common scenario, the drug or its metabolite forms a drug-protein complex. The drug-protein complex cross-links the immunoglobulin surface receptors on B cells and activates these cells (",
"    <a class=\"graphic graphic_figure graphicRef72596 \" href=\"mobipreview.htm?3/41/3732\">",
"     figure 2",
"    </a>",
"    ). Simultaneously, these B cells process the hapten-carrier complex and present haptenated peptides to T cells. B and T cells interact via MHC-complex and T cell receptor (TCR), and through CD40 and CD40L. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link&amp;anchor=H5#H5\">",
"     \"The humoral immune response\", section on 'Activation signals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These interactions, in conjunction with T cell-derived cytokines, enable immunoglobulin class switching by the stimulated B cells. The B cells then proliferate, mature, and finally secrete drug specific IgE molecules, which diffuse through the circulation and attach to the surface of mast cells and basophils throughout the body. The production of drug-specific IgE and its binding to mast cells and basophils is called sensitization and is clinically asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Effector stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effector stage of a type I drug allergic reaction may develop when the sensitized individual is re-exposed to the medication again. Upon readministration, the drug must again couple to carrier proteins, and this time, must cross-link drug-specific IgE on the surface of mast cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    basophils, resulting in sudden and widespread activation and release of an array of vasoactive mediators (",
"    <a class=\"graphic graphic_figure graphicRef72596 \" href=\"mobipreview.htm?3/41/3732\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    IgE-mediated reactions are referred to as \"immediate\" in onset, as signs and symptoms usually appear within minutes to one hour of drug exposure. The timing of allergic reactions is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/11/1210?source=see_link\">",
"     \"Drug allergy: Classification and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Type II (Antibody mediated cell destruction)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II reactions are uncommon and involve antibody-mediated cell destruction. These reactions require the presence of high titers of preformed drug-specific IgG (or rarely IgM) antibodies, which are only made by a very small percentage of individuals and usually in the setting of high-dose, longer-term drug exposure. The factors predisposing to the formation of these antibodies are not fully understood.",
"   </p>",
"   <p>",
"    Type II reactions arise when drugs bind to surfaces of certain cell types (most often red blood cells or platelets, and occasionally neutrophils) and act as antigens. The drug may haptenate a macromolecule on the surface of the cells. Binding of the antibodies to the cells' surface results in the cells being targeted for clearance by macrophages. Type II reactions sometimes involve complement activation, but this is not true in all cases.",
"   </p>",
"   <p>",
"    Drugs known to cause type II reactions include cephalosporins, penicillins, NSAIDs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    . As mentioned previously, these reactions are usually seen in the setting of high-dose, prolonged, or frequent drug treatment.",
"   </p>",
"   <p>",
"    Specific forms of type II hypersensitivity reactions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/2/20521?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Drug-related immune hemolysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/40/1673?source=see_link\">",
"     \"Drug-induced thrombocytopenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21850?source=see_link\">",
"     \"Drug-induced neutropenia and agranulocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Type III (Immune complex deposition)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type III reactions are mediated by antigen-antibody complexes and present as serum sickness or serum sickness-like reactions, vasculitis, or drug fever. Similar to type II reactions, type III reactions most often develop in the context of high-dose, prolonged drug administration. The drug acts as a soluble antigen and binds drug-specific IgG. Small immune complexes may form and precipitate in various tissues, including blood vessels, joints, and renal glomeruli. These immune complexes activate complement, and an inflammatory response ensues. Reexposure to similar or higher doses of the same drug can cause more rapid and severe symptoms.",
"   </p>",
"   <p>",
"    Specific forms of type III reactions are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2456?source=see_link&amp;anchor=H4#H4\">",
"     \"Drug fever\", section on 'Fever associated with hypersensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Type IV (T cell mediated)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type IV drug reactions involve the activation of T cells and may involve several other cell types, such as macrophages, eosinophils, or neutrophils. Type IV reactions are not mediated by antibodies, in contrast to the other three types above.",
"   </p>",
"   <p>",
"    Clinically, reactions involving T cells present with prominent skin findings, because the skin is a repository for an enormous number of T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/35\">",
"     35",
"    </a>",
"    ]. Many cutaneous T cells are primed memory-effector cells, which react rapidly if immunogenic agents penetrate the skin barrier or reach the skin by diffusing from the circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/36\">",
"     36",
"    </a>",
"    ]. The stimulation of cutaneous T cells may be further facilitated by close contact with various types of MHC-expressing dendritic cells in the skin.",
"   </p>",
"   <p>",
"    An array of different clinical presentations has been attributed to type IV mechanisms. The precise mechanisms responsible for each clinical presentation are largely theoretical. The p-i mechanism probably underlies generalized reactions, such as maculopapular, bullous, or pustular exanthems. The hapten or prohapten interaction is also involved in some generalized reactions and seems to be relevant to contact dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Interaction of drugs with the immune system'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Subdivisions of type IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cells orchestrate different forms of inflammation depending upon the cytokines produced and upon the other types of cells that become involved, leading to the subcategories of types IVa to IVd (",
"    <a class=\"graphic graphic_figure graphicRef75626 \" href=\"mobipreview.htm?8/5/8280\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This system of classifying T cell responses places emphasis on interactions with other effector cells (eg, eosinophils or neutrophils), as reflected in the histology of inflamed tissues and laboratory findings from affected patients. The types of T cells involved include cytotoxic T cells, as well as Th1, Th2, and CXCL8, probably together with Th17 cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only some of these mechanisms have been demonstrated in allergic drug reactions. These interactions between T cells and other cell types are also involved in infectious, autoimmune, and auto-inflammatory diseases. Thus, this system provides a theoretical framework for future study of T cell-mediated reactions in general.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     IVa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type IVa reactions involve Th1 type immune reactions. Th1 cells activate macrophages by secreting large amounts of interferon-gamma, TNFalpha, and interleukin (IL)-18. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link&amp;anchor=H12#H12\">",
"     \"The adaptive cellular immune response\", section on 'Th1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pure type IVa-mediated drug reactions have not been identified, but the inflammation of contact dermatitis appears to involve a component of the type IVa response (as well as type IVc). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=see_link\">",
"     \"Contact dermatitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-drug related examples of type IVa reactions include delayed swelling reaction to a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    , or granuloma formation in sarcoidosis. Type IVa responses by Th1 cells are important in the formation of the complement-fixing antibody isotypes (IgG1, IgG3) involved in Gell and Coombs type II and III reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h4\">",
"     IVb",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type IVb reactions involve a Th2 type immune response. Th2 cells secrete the cytokines IL-4, IL-13 and IL-5, which promote B cell production of IgE and IgG4, macrophage deactivation and mast cell and eosinophil responses. Type IVb reactions may also be involved in the late phase of allergic inflammation, such as that seen in the bronchi of patients with allergic asthma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link&amp;anchor=H13#H13\">",
"     \"The adaptive cellular immune response\", section on 'Th2'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IL-5 leads to eosinophilic inflammation, which is the characteristic inflammatory cell type in many drug hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Morbilliform or maculopapular eruptions that show prominent eosinophil infiltration on biopsy are probably mediated by type IVb T cell responses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Drug-induced hypersensitivity syndrome (DiHS), also called drug rash with eosinophilia and systemic symptoms (DRESS), is a severe drug hypersensitivity reaction involving rash, fever (38 to 40 C), and multi organ failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/39-41\">",
"       39-41",
"      </a>",
"      ]. The liver, kidneys, heart,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lungs are most often affected. Debate is ongoing about the most accurate name for this syndrome, as fewer than one-half of cases show peripheral eosinophilia (eg, those caused by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      typically do not). The presence of circulating atypical lymphocytes (CD8+) is a more consistent finding, which may persist for months after drug withdrawal. One study demonstrated that Epstein-Barr virus specific CD8+ T cells were responsible for the tissue destruction in",
"      <span class=\"nowrap\">",
"       DRESS/DiHS",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43929?source=see_link\">",
"       \"Drug reaction with eosinophilia and systemic symptoms (DRESS)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h4\">",
"     IVc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type IVc reactions involve T cells functioning as cytotoxic effector cells. Cytotoxic T cells can emigrate to the inflamed tissue and kill or induce apoptosis in resident cells, such as hepatocytes or keratinocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/22,43-45\">",
"     22,43-45",
"    </a>",
"    ]. Cytotoxic T cells are believed to be important in the pathogenesis of multiple types of drug-induced delayed type hypersensitivity (DTH) reactions, such as contact dermatitis, maculopapular and bullous drug eruptions, and drug-induced hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the most severe cutaneous drug reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS and TEN), are believed to involve type IVc responses. These disorders are marked by blistering and exfoliation of the skin and mucus membranes, often develop suddenly with generalized signs and symptoms of a fulminant immune reaction (",
"    <a class=\"graphic graphic_picture graphicRef67632 \" href=\"mobipreview.htm?24/48/25345\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef66134 \" href=\"mobipreview.htm?17/63/18419\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68682 \" href=\"mobipreview.htm?41/55/42866\">",
"     picture 3",
"    </a>",
"    ) reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/22,47,48\">",
"     22,47,48",
"    </a>",
"    ]. This dramatic presentation may represent uncontrolled expansion of oligoclonal T cells, which have been massively stimulated by the drug, reminiscent of superantigen-like stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast to milder drug eruptions, cytotoxicity may be mediated not only by granzyme B and perforin or FasL, but also by granulysin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, type IVc T cells responses may be limited to a single organ, without skin involvement. This type of drug reaction presents as isolated, drug induced, immune mediated hepatitis, isolated interstitial nephritis, or isolated pneumonitis, which makes the diagnosis of an drug allergic process more difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h4\">",
"     IVd",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type IVd reactions involve T cell-mediated sterile neutrophilic inflammation. Acute generalized exanthematous pustulosis (AGEP) is an example of a this type of reaction in the skin (",
"    <a class=\"graphic graphic_picture graphicRef56807 \" href=\"mobipreview.htm?39/59/40883\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68610 \" href=\"mobipreview.htm?30/29/31189\">",
"     picture 5",
"    </a>",
"    ). T cells in AGEP release CXCL8 to recruit neutrophils and also prevent neutrophil apoptosis via GM-CSF release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/50\">",
"     50",
"    </a>",
"    ]. Similar mechanisms have been described in Beh&ccedil;et&rsquo;s disease and pustular psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38456/abstract/51\">",
"     51",
"    </a>",
"    ]. Th17 cells, which secrete the neutrophil-activating cytokine IL17, may also be involved in these reactions. AGEP and Th17 cells are reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link&amp;anchor=H1232221#H1232221\">",
"     \"Normal B and T lymphocyte development\", section on 'Th17 cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A drug allergy is an adverse drug reaction that results from a specific immunologic response to a medication. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In order to cause an allergic reaction, drugs must be recognized by the immune system (",
"      <a class=\"graphic graphic_table graphicRef54199 \" href=\"mobipreview.htm?40/2/41004\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Interaction of drugs with the immune system'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Most pharmaceutical agents in their native forms are small, chemically simple molecules that function poorly as antigens. However, they may bind to serum or tissue proteins or be metabolized in to a reactive intermediate, and then form hapten-carrier complexes that act as full antigens.",
"     </li>",
"     <li>",
"      Drugs with multiple repetitive",
"      <span class=\"nowrap\">",
"       motifs/epitopes",
"      </span>",
"      can give rise to antibody-mediated reactions.",
"     </li>",
"     <li>",
"      Some drugs can stimulate T cells directly through the p-i concept.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunologic reactions, including drug allergic reactions, are divided into four categories according to the Gell and Coombs system (",
"      <a class=\"graphic graphic_table graphicRef80466 \" href=\"mobipreview.htm?13/11/13500\">",
"       table 2",
"      </a>",
"      ). Types I, II, and III are antibody-mediated, while type IV is mediated by T cells. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pathogenesis of specific reaction types'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Type I, IgE mediated reactions involve an asymptomatic sensitization stage, in which drug-specific IgE antibodies are formed and bind to the surface of mast cells and basophils throughout the body, and a symptomatic effector stage, in which the patient is re-exposed to the drug and develops immediate symptoms (usually within an hour of administration). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Type I (IgE mediated)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Type II reactions involve IgG (usually)-mediated cell destruction, and arise when drugs bind and modify certain cell types, resulting in the targeting of the affected cells by antibodies for clearance by macrophages. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Type II (Antibody mediated cell destruction)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Type III reactions occur when a drug or drug-carrier complex acts as a soluble antigen and binds drug-specific IgG, forming small immune complexes that precipitate in various tissues and activate complement. An inflammatory response ensues which may take various forms, such as serum sickness, hypersensitivity vasculitis, or drug fever. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Type III (Immune complex deposition)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Type IV reactions are mediated by T cells, in conjunction with other cell types, rather than by antibodies. The resultant reactions can take many forms, depending upon the cytokines produced by the T cells and the other cell types involved, but skin findings are usually prominent. Type IV T cells responses are divided into four subtypes. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Type IV (T cell mediated)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Subdivisions of type IV'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/1\">",
"      Baldo BA, Fisher MM, Pham NH. On the origin and specificity of antibodies to neuromuscular blocking (muscle relaxant) drugs: an immunochemical perspective. Clin Exp Allergy 2009; 39:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/2\">",
"      Vervloet D, Arnaud A, Senft M, et al. Anaphylactic reactions to suxamethonium prevention of mediator release by choline. J Allergy Clin Immunol 1985; 76:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/3\">",
"      Lafaye P, Lapresle C. Fixation of penicilloyl groups to albumin and appearance of anti-penicilloyl antibodies in penicillin-treated patients. J Clin Invest 1988; 82:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/4\">",
"      Padovan E. T-cell response in penicillin allergy. Clin Exp Allergy 1998; 28 Suppl 4:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/5\">",
"      Levine BB. Immunochemical mechanisms of drug allergy. Annu Rev Med 1966; 17:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/6\">",
"      Brander C, Mauri-Hellweg D, Bettens F, et al. Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals. J Immunol 1995; 155:2670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/7\">",
"      Lavergne SN, Wang H, Callan HE, et al. \"Danger\" conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells. J Pharmacol Exp Ther 2009; 331:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/8\">",
"      Naisbitt DJ, Gordon SF, Pirmohamed M, et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol 2001; 133:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/9\">",
"      Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr 1994; 125:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/10\">",
"      Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995; 68:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/11\">",
"      Meekins CV, Sullivan TJ, Gruchalla RS. Immunochemical analysis of sulfonamide drug allergy: identification of sulfamethoxazole-substituted human serum proteins. J Allergy Clin Immunol 1994; 94:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/12\">",
"      Farrell J, Naisbitt DJ, Drummond NS, et al. Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. J Pharmacol Exp Ther 2003; 306:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/13\">",
"      Sanderson JP, Naisbitt DJ, Farrell J, et al. Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol 2007; 178:5533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/14\">",
"      Naisbitt DJ, Farrell J, Gordon SF, et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 2002; 62:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/15\">",
"      Naisbitt DJ, Farrell J, Wong G, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003; 111:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/16\">",
"      Wu Y, Farrell J, Pirmohamed M, et al. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007; 119:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/17\">",
"      Zanni MP, von Greyerz S, Schnyder B, et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998; 102:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/18\">",
"      Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002; 2:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/19\">",
"      Pichler WJ. Direct T-cell stimulations by drugs--bypassing the innate immune system. Toxicology 2005; 209:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/20\">",
"      Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/21\">",
"      Depta JP, Altznauer F, Gamerdinger K, et al. Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity. J Allergy Clin Immunol 2004; 113:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/22\">",
"      Nassif A, Bensussan A, Doroth&eacute;e G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/23\">",
"      Schnyder B, Burkhart C, Schnyder-Frutig K, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 2000; 164:6647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/24\">",
"      Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/25\">",
"      Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/26\">",
"      Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/27\">",
"      Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2012; 13:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/28\">",
"      Yun J, Adam J, Yerly D, Pichler WJ. Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy 2012; 67:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/29\">",
"      Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012; 486:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/30\">",
"      Adam J, Eriksson KK, Schnyder B, et al. Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J Immunol 2012; 42:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/31\">",
"      Wei CY, Chung WH, Huang HW, et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012; 129:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/32\">",
"      Ko TM, Chung WH, Wei CY, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011; 128:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/33\">",
"      Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 2012; 109:9959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/34\">",
"      Norcross MA, Luo S, Lu L, et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012; 26:F21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/35\">",
"      Clark RA, Chong B, Mirchandani N, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006; 176:4431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/36\">",
"      Schaerli P, Ebert L, Willimann K, et al. A skin-selective homing mechanism for human immune surveillance T cells. J Exp Med 2004; 199:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/37\">",
"      Jenkinson C, Jenkins RE, Aleksic M, et al. Characterization of p-phenylenediamine-albumin binding sites and T-cell responses to hapten-modified protein. J Invest Dermatol 2010; 130:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/38\">",
"      Yawalkar N, Shrikhande M, Hari Y, et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000; 106:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/39\">",
"      Ben m'rad M, Leclerc-Mercier S, Blanche P, et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 2009; 88:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/40\">",
"      Peyri&egrave;re H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006; 155:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/41\">",
"      Mauri-Hellweg D, Bettens F, Mauri D, et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/42\">",
"      Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010; 2:46ra62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/43\">",
"      Hertl M, Geisel J, Boecker C, Merk HF. Selective generation of CD8+ T-cell clones from the peripheral blood of patients with cutaneous reactions to beta-lactam antibiotics. Br J Dermatol 1993; 128:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/44\">",
"      Schnyder B, Frutig K, Mauri-Hellweg D, et al. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp Allergy 1998; 28:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/45\">",
"      Schmid S, Kuechler PC, Britschgi M, et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol 2002; 161:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/46\">",
"      Mennicke M, Zawodniak A, Keller M, et al. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant 2009; 9:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/47\">",
"      Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/48\">",
"      Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000; 1:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/49\">",
"      Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/50\">",
"      Britschgi M, Steiner UC, Schmid S, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001; 107:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38456/abstract/51\">",
"      Keller M, Spanou Z, Schaerli P, et al. T cell-regulated neutrophilic inflammation in autoinflammatory diseases. J Immunol 2005; 175:7678.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2072 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-6ABA7822FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38456=[""].join("\n");
var outline_f37_35_38456=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERACTION OF DRUGS WITH THE IMMUNE SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Drugs acting as antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Stimulation of an antibody response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Drugs as haptens and prohaptens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Reactive metabolites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pharmacological interaction of drugs with immune receptors (the p-i concept)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Overlap of mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOGENESIS OF SPECIFIC REACTION TYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Type I (IgE mediated)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Sensitization stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Effector stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Type II (Antibody mediated cell destruction)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Type III (Immune complex deposition)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Type IV (T cell mediated)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Subdivisions of type IV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      IVa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      IVb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      IVc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      IVd",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2072\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2072|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/57/14228\" title=\"figure 1\">",
"      p i concept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/41/3732\" title=\"figure 2\">",
"      Type I drug reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/5/8280\" title=\"figure 3\">",
"      Gell Coombs IVa-d",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2072|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/48/25345\" title=\"picture 1\">",
"      Cutaneous changes of Stevens Johnson Syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/63/18419\" title=\"picture 2\">",
"      Toxic epidermal necrolysis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/55/42866\" title=\"picture 3\">",
"      Stevens-Johnson syndrome - oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/59/40883\" title=\"picture 4\">",
"      AGEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/29/31189\" title=\"picture 5\">",
"      AGEP detail",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2072|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/2/41004\" title=\"table 1\">",
"      Immunogenic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/11/13500\" title=\"table 2\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21049?source=related_link\">",
"      Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=related_link\">",
"      Contact dermatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/11/1210?source=related_link\">",
"      Drug allergy: Classification and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2456?source=related_link\">",
"      Drug fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43929?source=related_link\">",
"      Drug reaction with eosinophilia and systemic symptoms (DRESS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13754?source=related_link\">",
"      Drugs and the liver: Metabolism and mechanisms of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42809?source=related_link\">",
"      Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23594?source=related_link\">",
"      Sulfonamide allergy in non HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_35_38457="Peanut, tree nut, and seed allergy: Clinical features";
var content_f37_35_38457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peanut, tree nut, and seed allergy: Clinical features",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38457/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38457/contributors\">",
"     Hugh A Sampson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38457/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38457/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38457/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38457/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/35/38457/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peanut, tree nut, and seed allergies are some of most common food allergies in both children and adults. These allergies tend to cause severe reactions and usually persist over time.",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, and clinical features of peanut, tree nut, and seed allergies are presented in this topic review. Diagnosis and management of these allergies are discussed separately as is treatment for food-induced anaphylaxis. General discussions of food allergy are presented separately in appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9654?source=see_link\">",
"     \"Peanut, tree nut, and seed allergy: Diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32919?source=see_link\">",
"     \"Peanut, tree nut, and seed allergy: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of peanut allergy is variable worldwide. The highest rates are seen in westernized countries such as the United States, the United Kingdom, Canada, and Australia, where the prevalence is approximately 1 to 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/1-10\">",
"     1-10",
"    </a>",
"    ]. However, rates are lower in other westernized countries such as France (0.3 to 0.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/11\">",
"     11",
"    </a>",
"    ], Denmark (0.2 to 0.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], and Israel (0.04 to 0.17 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/6,14\">",
"     6,14",
"    </a>",
"    ]. Peanut allergy is rare in Asian countries, where peanut is often not found on the list of most common allergenic foods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Regional dietary habits and pollen exposure may influence the epidemiology of allergy to legumes, such as peanut [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/6,18-20\">",
"     6,18-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=see_link\">",
"     \"Food allergens: Overview of clinical features and cross-reactivity\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Pathogenesis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=see_link\">",
"     \"The natural history of childhood food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data suggest that the rate of peanut allergy is increasing in some countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], although it may now be leveling off [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/21\">",
"     21",
"    </a>",
"    ]. The rate appears stable in other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/5\">",
"     5",
"    </a>",
"    ]. Hypotheses regarding the apparent increase in prevalence of food allergies are discussed in detail separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of food allergy\", section on 'Prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tree nuts and seeds are also common food allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/1,23-27\">",
"     1,23-27",
"    </a>",
"    ]. Sesame and mustard are the most common seed allergies reported, but allergy to other seeds can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/25\">",
"     25",
"    </a>",
"    ]. The prevalence of tree nut allergy was similar to that of peanut allergy in a general population survey in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/1\">",
"     1",
"    </a>",
"    ]. Walnut was the most commonly reported tree nut allergy, followed by cashew and almond. In this same study, about one-third of patients with peanut allergy reported coexisting tree nut allergy, and similarly one-third with tree nut allergy had concomitant peanut allergy. The reported prevalence of sesame seed allergy in France, based upon data from the national databank, was 2 percent in children and 5 percent in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/28\">",
"     28",
"    </a>",
"    ]. However, patient-reported food allergy typically exceeds challenge-proven, symptomatic allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPES OF REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most allergic reactions to peanut, tree nuts, and seeds are IgE-mediated. These reactions can range from mild symptoms isolated to the oropharynx to severe anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef79448 \" href=\"mobipreview.htm?19/49/20251\">",
"     table 1",
"    </a>",
"    ). Peanut is also implicated as a trigger in non-IgE mediated or mixed IgE and non-IgE mediated disorders, such as atopic dermatitis and eosinophilic esophagitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Systemic IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of allergic reactions to peanut, tree nuts, or seeds are systemic. Symptoms can be isolated to a single organ system, most commonly the skin (eg, urticaria, angioedema), or involve multiple organ systems (anaphylaxis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In one study of children, 89 percent of initial reactions to peanut or tree nuts involved the skin, half involved the respiratory tract, and one-third affected the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/30\">",
"     30",
"    </a>",
"    ]. Half of all reactions involved two or more organ systems in this study. Similar findings are reported for sesame allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/14,27,31\">",
"     14,27,31",
"    </a>",
"    ]. The clinical features of IgE-mediated reactions are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peanut, tree nut, and seed allergies are among the most common causes of food-induced anaphylaxis. Concomitant asthma and peanut allergy developing at a later age were associated with an increased risk of anaphylaxis in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/8\">",
"     8",
"    </a>",
"    ]. In another study, coexisting atopic diseases of greater severity and lower serum angiotensin-converting enzyme concentrations were associated with increased risk of life-threatening anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/32\">",
"     32",
"    </a>",
"    ]. Peanut and tree nut allergies are risk factors for, and are rarely responsible for, fatal anaphylaxis. Food-induced anaphylaxis and fatal anaphylaxis are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33625?source=see_link\">",
"     \"Unique aspects of anaphylaxis in infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reactions due to skin contact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactions due to skin contact with a food allergen (eg, peanut butter) are typically limited to the site of contact and are unlikely to trigger systemic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. Inadvertent contact in the eye, typically due to rubbing the eye with residual food on the finger, can lead to marked periorbital edema, erythema, and pruritus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of food allergy: Avoidance\", section on 'Skin contact and inhalation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Reactions due to inhalation exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhalation of peanut, tree nut, or seed proteins can trigger allergic reactions in particularly sensitive patients or in patients exposed to large amounts of allergen, such as with an occupational exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. Inhalation exposure can occur when particles become airborne (eg, peanut dust from bags of peanuts or peanut flour) or aerosolized (eg, peanut protein in cooking vapors). The smell of peanut butter, which contains volatile organic compounds, but not peanut protein, did not trigger any reactions in one study of patients with peanut allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of food allergy: Avoidance\", section on 'Airline travel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Reactions due to allergen exposure through saliva",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to allergens such as peanut through another person's saliva (kissing, sharing utensils or straws) can trigger local and systemic allergic reactions in sensitized individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link&amp;anchor=H23#H23\">",
"     \"Management of food allergy: Avoidance\", section on 'Interpersonal contact'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Oral allergy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactions localized and limited to the oropharynx can occur upon ingestion of peanut and certain tree nuts in individuals who are sensitized to homologous plant allergens (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"mobipreview.htm?16/1/16409\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79411 \" href=\"mobipreview.htm?9/46/9952\">",
"     figure 2",
"    </a>",
"    ). As examples, Bet v 1 (birch pollen allergen) cross-reacts with homologous proteins in peanut, hazelnut, almond, and several seeds, and mugwort pollen cross-reacts with mustard and other seeds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/18,43,44\">",
"     18,43,44",
"    </a>",
"    ]. In addition, almond and peanut contain proteins homologous to peach allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/19\">",
"     19",
"    </a>",
"    ]. These reactions tend to occur in older children and adults. Oral allergy syndrome is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5785?source=see_link\">",
"     \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Non-IgE mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peanut allergy is associated with atopic dermatitis that is earlier in onset, more severe, and more persistent than in most patients without peanut allergy. Ingestion of peanut can exacerbate atopic dermatitis in individuals with peanut allergy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Food allergy, including peanut allergy, is associated with allergic gastrointestinal disorders, such as eosinophilic esophagitis. Removal of suspected food allergens from the diet can lead to clinical and histologic improvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44297?source=see_link\">",
"     \"Treatment of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Skin contact with lignin-like molecules in sesame oil can cause delayed-type hypersensitivity reactions, primarily contact dermatitis with angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link\">",
"     \"Overview of dermatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=see_link\">",
"     \"Contact dermatitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nine major and minor allergenic proteins in peanut (Arachis hypogaea), designated Ara h 1-9, have been identified that are responsible for IgE-mediated reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/18,19,46,47\">",
"     18,19,46,47",
"    </a>",
"    ]. The dominant allergens in most populations are Ara h 1-3, which are vicilin, conglutin, and glycinin seed storage proteins, respectively. Ara h 4, 6 and 7 are also seed storage proteins. Ara h 4 is a nearly identical isoform of Ara h 3. Ara h 6 is highly homologous to Ara h 2, and Ara h 7 is also a conglutin.",
"   </p>",
"   <p>",
"    Ara h 5, 8, and 9 are proteins that are associated with pollen-food allergy syndrome (oral allergy syndrome). Ara h 5 is a profilin, Ara h 8 is a Bet v 1 (a birch allergen) homologue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/18\">",
"     18",
"    </a>",
"    ], and Ara h 9 is a nonspecific lipid transfer protein similar to Pru p 3 (a peach allergen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5785?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\", section on 'Allergens in PFAS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States and United Kingdom populations, more than 90 percent of patients with peanut allergy have specific IgE to Ara h 1 and 2, and 45 to 95 percent have specific IgE to Ara h 3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In contrast, specific IgE to Ara h 8 or 9 is more common in individuals with concomitant birch pollen or peach sensitization, especially in northern and southern Europe, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The presence of IgE antibodies to Ara h 2 is most closely associated with clinical reactivity to peanut [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tree nut and seed allergens are less well characterized than peanut allergens, although a number of tree nut and seed allergens have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/43,51\">",
"     43,51",
"    </a>",
"    ]. These allergens include pollen allergen homologues, such as Bet v 1-like proteins and profilins, and more stable allergens, such as seed storage proteins and some lipid transfer proteins. Issues of cross-reactivity between allergens are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=see_link\">",
"     \"Food allergens: Overview of clinical features and cross-reactivity\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H20\">",
"     'Allergies to other foods'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Allergy to peanut, tree nuts, and seeds can develop through primary sensitization to the food itself or through secondary sensitization via sensitization to cross-reactive allergens (eg, birch pollen). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis of food allergy\", section on 'Routes of allergen sensitization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5785?source=see_link\">",
"     \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several reasons have been proposed to explain why peanut (and possibly tree nuts and seeds) are more allergenic than other foods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seed storage proteins contain disulfide bonds that give these proteins high thermostability and resistance to extreme pH values. In addition, these proteins are often glycosylated, which further increases thermal and proteolytic stability. Ara h 1 in the glycosylated form can act as a Th2 adjuvant, activating dendritic cells to induce maturation and proliferation of Th2 cells, which promote IgE production [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23433?source=see_link\">",
"       \"Molecular features of food allergens\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Certain factors involved in harvesting and processing may also make these foods more allergenic. A greater amount of Ara h 1 is found in larger, more mature peanut kernels and in peanuts dried or cured at higher temperatures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/53\">",
"       53",
"      </a>",
"      ]. High heat roasting leads to glycation reactions that increase protein stability and allergenicity.",
"     </li>",
"     <li>",
"      Metabolized vegetable oils, such as peanut oil can serve as adjuvants, increasing the immune response to antigens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/54\">",
"       54",
"      </a>",
"      ]. Whipping or emulsifying peanut butter to prevent the oil from separating from the peanut solids brings more of the water-soluble protein into direct contact with the oil, potentially increasing the immunogenicity of peanut proteins ingested in this manner. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23433?source=see_link\">",
"       \"Molecular features of food allergens\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis of non-IgE mediated peanut, tree nut, and seed allergy is less clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR DEVELOPMENT OF PEANUT ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for the development of peanut allergy include a family or personal history of atopic disease, and a family history of peanut allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/55\">",
"     55",
"    </a>",
"    ]. Peanut allergy is also associated with the use of skin care products containing crude peanut oil in young children with a history of atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/56\">",
"     56",
"    </a>",
"    ]. Other associations, which have been called into question, include maternal ingestion of the allergen during pregnancy and lactation, and consumption of soy products in infancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Specific factors associated with increased risk of tree nut or seed allergy have not been elucidated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Familial factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Siblings of children with peanut allergy are at increased risk of developing peanut allergy. In one study, the prevalence of peanut allergy in siblings of a child with peanut allergy was 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/55\">",
"     55",
"    </a>",
"    ]. From a study of twins, 7 percent of fraternal twins shared peanut allergy, and there was 64 percent concordance among monozygotic twins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/57\">",
"     57",
"    </a>",
"    ]. There is familial aggregation of sensitization (presence of specific IgE) to food allergens, including peanut, walnut, and sesame seed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18236026\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a case-control study, loss-of-function mutations in filaggrin were associated with oral food challenge-positive peanut allergy (odds ratio 5.3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/59\">",
"     59",
"    </a>",
"    ]. These findings were replicated in a different population (OR 1.9).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Skin care products",
"    </span>",
"    &nbsp;&mdash;&nbsp;A British study found that the development of peanut allergy was associated with the use of skin care products that contain peanut protein, in the form of crude oil, in children with atopic dermatitis, particularly those with active eczematous rashes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/56\">",
"     56",
"    </a>",
"    ]. Only highly refined oils are used in skin preparations in the United States. These oils contain almost no detectable allergen. It is not known if there is an association with the use of refined peanut, tree nut, or seed oils in skin care products and the development of peanut allergy. Nor is it known whether there is a similar risk if these oils are applied to non-inflamed skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Timing of first exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of introduction of a food may influence the development of allergy versus tolerance, although this phenomenon has been difficult to study in humans and is a source of ongoing debate. Peanut allergy has doubled in young children in countries where delayed introduction of peanut until at least three years of age was recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. In addition, the rate of peanut allergy is lower in countries where peanuts are introduced at a younger age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/6,14,60\">",
"     6,14,60",
"    </a>",
"    ]. However, dietary advice was generally poorly followed in countries that recommended delayed introduction, so the impact of these recommendations is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/4\">",
"     4",
"    </a>",
"    ]. One study noted that the age at first exposure in children who developed peanut allergy and age at initial reaction (19 and 21 months) was lower during the period in which delayed introduction was recommended, compared with the age of exposure and allergy onset (22 and 24 months) in the period prior to those recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors that may determine whether an individual becomes sensitized or tolerant to a food allergen are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=see_link&amp;anchor=H29#H29\">",
"     \"Pathogenesis of food allergy\", section on 'Factors influencing sensitization or tolerance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5785?source=see_link\">",
"     \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/37/25175?source=see_link&amp;anchor=H12#H12\">",
"     \"Introducing formula and solid foods to infants at risk for allergic disease\", section on 'Introduction of solid foods to high risk infants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Soy consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consumption of soy formula or milk was associated with peanut allergy in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/56\">",
"     56",
"    </a>",
"    ]. However, a subsequent study confirmed the suspicion that this association was not causal, but was due to preferential use of soy",
"    <span class=\"nowrap\">",
"     formula/milk",
"    </span>",
"    in children who had a known or suspected allergy to cow's milk based upon personal and family history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, an increased risk of peanut allergy was not seen in infants fed soy formula in a randomized trial of soy versus extensively hydrolyzed formula in infants with cow's milk allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Maternal ingestion of food allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between maternal ingestion of food allergens during pregnancy and lactation and the development of food allergies in offspring was suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/55\">",
"     55",
"    </a>",
"    ], although whether there is a causal relationship is debated. One subsequent study noted that allergen-specific IgE in cord blood was maternal in origin and IgE specific for the same foods was not found in infant blood at six months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/64\">",
"     64",
"    </a>",
"    ]. Furthermore, findings from a murine model of peanut allergy suggest that ingestion of a low dose of peanut, compared to no peanut, during pregnancy and lactation lowers the risk of peanut allergy in the offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/65\">",
"     65",
"    </a>",
"    ]. In addition, some hypothesize that sensitization occurs as a result of environmental exposure (eg, skin contact) as opposed to ingestion exposure, and the level of maternal consumption of peanut may rather be a marker for the level of environmental exposure in the household [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/66\">",
"     66",
"    </a>",
"    ]. In a large cohort of infants at high risk for developing peanut allergy, a direct correlation was found between the amount of peanut ingested by the mother during pregnancy and the level of peanut-specific IgE in the offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/67\">",
"     67",
"    </a>",
"    ]. However, whether this reflects clinical reactivity to peanut remains to be determined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20119?source=see_link\">",
"     \"Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that have been associated with increased risk of food allergy in general in observational studies include older maternal age, maternal dietary factors, higher parental levels of education and income, delivery via Caesarean section, breastfeeding, vitamin supplementation, and use of antiulcer drugs. However, observational studies are prone to bias, and many of these factors may be confounders. These issues are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=see_link\">",
"     \"Pathogenesis of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Threshold dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical threshold dose for triggering objective symptoms is equivalent to one to three peanut kernels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/68\">",
"     68",
"    </a>",
"    ]. A peanut kernel contains roughly 162 mg of peanut protein, equivalent to about 325 mg of peanut flour. Peanut meal is partially defatted and roasted, and contains approximately 25 percent protein. Peanut flour is defatted and lightly roasted, and contains about 50 percent protein. Patients with severe reactions typically have lower threshold doses of peanut protein than patients with mild symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/69\">",
"     69",
"    </a>",
"    ]. The lowest reported level of peanut triggering an IgE-mediated reaction in both children and adults is 0.05 mg of peanut protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/69-73\">",
"     69-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited data on threshold doses for tree nuts and seeds. The lowest observed adverse effect level (LOAEL) for triggering anaphylaxis was 30 mg for sesame seed and 1 to 5 mL for sesame oil in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Allergies to other foods",
"    </span>",
"    &nbsp;&mdash;&nbsp;One-quarter to one-half of patients with peanut allergy have co-allergy to tree nuts, and about half of the patients with allergy to tree nuts are allergic to more than one nut [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/1,68,75\">",
"     1,68,75",
"    </a>",
"    ]. Some of this co-allergy is due to cross-reactive homologous IgE-binding epitopes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/76-81\">",
"     76-81",
"    </a>",
"    ]. Peanut-specific IgE cross-reacts with pecan, almond, Brazil nut, and hazelnut allergens and certain tree nut pairs commonly cross-react (walnut and pecan, cashew and pistachio, and almond and hazelnut) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/75\">",
"     75",
"    </a>",
"    ]. The rate of sensitization and allergy to multiple nuts increases with age in children with peanut",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tree nut allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Pathogenesis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=see_link&amp;anchor=H9#H9\">",
"     \"Food allergens: Overview of clinical features and cross-reactivity\", section on 'Tree nuts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are limited data on the rate of co-allergy to sesame in patients with peanut allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/75\">",
"     75",
"    </a>",
"    ]. In one retrospective survey, children who had a positive skin test to peanut or tree nuts were more likely to also test positive to sesame [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/83\">",
"     83",
"    </a>",
"    ]. However, there was no systematic evaluation of the clinical outcomes (eg, whether there was a significant risk of clinical allergy to sesame). In contrast, children with peanut and tree nut sensitization or allergy were not more likely to be sensitized or allergic to coconut. One known IgE-binding epitope of the peanut allergen Ara h 1 has 80 percent homology with the corresponding area of the sesame allergen Ses i 3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/84\">",
"     84",
"    </a>",
"    ]. However, the clinical relevance of this homology is not known.",
"   </p>",
"   <p>",
"    Concurrent sensitization and allergy to other foods is common in patients with peanut allergy. In one study, sensitization or co-allergy to other food was seen in two-thirds of patients with peanut allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/61\">",
"     61",
"    </a>",
"    ]. Egg was the most common (53 percent), followed by cow's milk (26 percent), fish (11 percent), shellfish (9 percent), soy (7 percent), wheat (6 percent) and sesame seed (6 percent). Similarly, 70 percent of patients with sesame allergy were allergic to other foods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cross-sensitization to multiple legumes is common in patients with peanut allergy, although there is little clinical cross-reactivity between peanut and most other legumes (eg, soy, peas, green beans) except lupine beans. Thus, less than 5 to 10 percent of patients with peanut allergy have clinical reactions to other legumes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=see_link&amp;anchor=H5#H5\">",
"     \"Food allergens: Overview of clinical features and cross-reactivity\", section on 'Legumes: Peanut, soy, and others'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many seed allergens are seed storage proteins that share IgE epitopes with peanut, tree nuts, kiwi, and other seeds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/25\">",
"     25",
"    </a>",
"    ]. Some of these allergens are cross-reactive. The full clinical implications of these findings are not established. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=see_link&amp;anchor=H12#H12\">",
"     \"Food allergens: Overview of clinical features and cross-reactivity\", section on 'Seeds'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Associated atopic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with peanut, tree nut,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seed allergy have concomitant atopic disease. Over three-quarters of patients with sesame allergy had other atopic conditions in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients with peanut allergy often have asthma (60 to 75 percent), atopic dermatitis (60 to 75 percent),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    allergic rhinitis (55 to 60 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/85\">",
"     85",
"    </a>",
"    ]. Coexisting asthma is a risk factor for anaphylactic reactions to peanut (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Systemic IgE-mediated reactions'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Natural history and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age at first exposure and age at first reaction are commonly between one to two years of age, although allergy to peanut, tree nuts, and seeds can develop later in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/8,31,44,61,86\">",
"     8,31,44,61,86",
"    </a>",
"    ]. Symptoms occur with first known direct ingestion in up to three-quarters of children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/30,87\">",
"     30,87",
"    </a>",
"    ]. Subsequent reactions when the child is older are often more severe than the initial episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/8,29,88\">",
"     8,29,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accidental exposures are relatively common. In one study, the median time from diagnosis of allergy to first accidental ingestion was four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/29\">",
"     29",
"    </a>",
"    ]. In several series, accidental ingestions occurred in 55 to 75 percent of children with peanut allergy and 30 percent of children with tree nut allergy over a period of approximately five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/30,88-90\">",
"     30,88-90",
"    </a>",
"    ]. The annual incidence rate of accidental exposures to peanut was 14 percent in another study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Development of tolerance does occur in children with peanut, tree nut, and seed allergies, although it is uncommon (15 to 20 percent in young children). Allergy to these foods appears to be life-long if allergic symptoms occur after early childhood. Later onset peanut allergy is often associated with oral allergy syndrome due to birch pollen allergy, and may not be life-long. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=see_link&amp;anchor=H16#H16\">",
"     \"The natural history of childhood food allergy\", section on 'Natural history of specific allergies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11082?source=see_link&amp;anchor=H26942027#H26942027\">",
"     \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\", section on 'Birch'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37430?source=see_link\">",
"     \"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The size of the skin test reaction or specific IgE level for peanut and tree nuts are the most reliable predictors of resolution versus persistence of the allergy, although up to 25 percent of children may have mean wheal diameters to peanut &gt;10 mm or peanut-specific IgE &gt;15",
"    <span class=\"nowrap\">",
"     kU/L",
"    </span>",
"    and be nonreactive to oral challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38457/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. In contrast, clinical features do not reliably predict persistence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9654?source=see_link&amp;anchor=H2#H2\">",
"     \"Peanut, tree nut, and seed allergy: Diagnosis\", section on 'IgE-mediated reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=see_link&amp;anchor=H29#H29\">",
"     \"The natural history of childhood food allergy\", section on 'Prognostic factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/35/17971?source=see_link\">",
"       \"Patient information: Peanut allergy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"       \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=see_link\">",
"       \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peanut, tree nut, and seed allergies are among the most common food allergies. The prevalence of these allergies appears to be increasing in some countries, particularly in those with the highest rates of food allergy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most allergic reactions to peanut, tree nuts, and seeds are IgE-mediated and range in severity from mild symptoms isolated to the oropharynx to severe anaphylaxis (",
"      <a class=\"graphic graphic_table graphicRef79448 \" href=\"mobipreview.htm?19/49/20251\">",
"       table 1",
"      </a>",
"      ). Peanut is also implicated as a trigger in non-IgE mediated or mixed disorders, such as atopic dermatitis and eosinophilic esophagitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Types of reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IgE-mediated allergy to peanut, tree nuts, and seeds can develop through primary sensitization to the food itself or through secondary sensitization via sensitization to cross-reactive allergens (eg, birch pollen). The pathogenesis of non-IgE mediated peanut, tree nut, and seed allergy is less clear. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=see_link&amp;anchor=H12#H12\">",
"       \"Pathogenesis of food allergy\", section on 'Routes of allergen sensitization'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5785?source=see_link\">",
"       \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Siblings of children with peanut allergy are at increased risk of developing peanut allergy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Risk factors for development of peanut allergy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is insufficient evidence to suggest that maternal avoidance of food allergens during pregnancy and lactation prevents the development of allergy to those foods. In addition, it is not clear whether early or delayed introduction is more likely to lead to the development of tolerance to allergenic foods such as peanut. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Risk factors for development of peanut allergy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/37/25175?source=see_link\">",
"       \"Introducing formula and solid foods to infants at risk for allergic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peanut, tree nut, and seed allergies are typically lifelong, although a small percentage of patients may outgrow these allergies. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/1\">",
"      Sicherer SH, Mu&ntilde;oz-Furlong A, Sampson HA. Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: a 5-year follow-up study. J Allergy Clin Immunol 2003; 112:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/2\">",
"      Grundy J, Matthews S, Bateman B, et al. Rising prevalence of allergy to peanut in children: Data from 2 sequential cohorts. J Allergy Clin Immunol 2002; 110:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/3\">",
"      Kagan RS, Joseph L, Dufresne C, et al. Prevalence of peanut allergy in primary-school children in Montreal, Canada. J Allergy Clin Immunol 2003; 112:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/4\">",
"      Hourihane JO, Aiken R, Briggs R, et al. The impact of government advice to pregnant mothers regarding peanut avoidance on the prevalence of peanut allergy in United Kingdom children at school entry. J Allergy Clin Immunol 2007; 119:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/5\">",
"      Ben-Shoshan M, Kagan RS, Alizadehfar R, et al. Is the prevalence of peanut allergy increasing? A 5-year follow-up study in children in Montreal. J Allergy Clin Immunol 2009; 123:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/6\">",
"      Du Toit G, Katz Y, Sasieni P, et al. Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. J Allergy Clin Immunol 2008; 122:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/7\">",
"      Kljakovic M, Gatenby P, Hawkins C, et al. The parent-reported prevalence and management of peanut and nut allergy in school children in the Australian Capital Territory. J Paediatr Child Health 2009; 45:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/8\">",
"      Mullins RJ, Dear KB, Tang ML. Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007. J Allergy Clin Immunol 2009; 123:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/9\">",
"      Sicherer SH, Mu&ntilde;oz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol 2010; 125:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/10\">",
"      Ben-Shoshan M, Harrington DW, Soller L, et al. A population-based study on peanut, tree nut, fish, shellfish, and sesame allergy prevalence in Canada. J Allergy Clin Immunol 2010; 125:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/11\">",
"      Morisset M, Moneret-Vautrin DA, Kanny G, Allergo-Vigilance Network. Prevalence of peanut sensitization in a population of 4,737 subjects--an Allergo-Vigilance Network enquiry carried out in 2002. Eur Ann Allergy Clin Immunol 2005; 37:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/12\">",
"      Osterballe M, Hansen TK, Mortz CG, et al. The prevalence of food hypersensitivity in an unselected population of children and adults. Pediatr Allergy Immunol 2005; 16:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/13\">",
"      Osterballe M, Mortz CG, Hansen TK, et al. The prevalence of food hypersensitivity in young adults. Pediatr Allergy Immunol 2009; 20:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/14\">",
"      Dalal I, Binson I, Reifen R, et al. Food allergy is a matter of geography after all: sesame as a major cause of severe IgE-mediated food allergic reactions among infants and young children in Israel. Allergy 2002; 57:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/15\">",
"      Orhan F, Karakas T, Cakir M, et al. Prevalence of immunoglobulin E-mediated food allergy in 6-9-year-old urban schoolchildren in the eastern Black Sea region of Turkey. Clin Exp Allergy 2009; 39:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/16\">",
"      Shek LP, Lee BW. Food allergy in Asia. Curr Opin Allergy Clin Immunol 2006; 6:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/17\">",
"      Santadusit S, Atthapaisalsarudee S, Vichyanond P. Prevalence of adverse food reactions and food allergy among Thai children. J Med Assoc Thai 2005; 88 Suppl 8:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/18\">",
"      Krause S, Reese G, Randow S, et al. Lipid transfer protein (Ara h 9) as a new peanut allergen relevant for a Mediterranean allergic population. J Allergy Clin Immunol 2009; 124:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/19\">",
"      Asarnoj A, Ostblom E, Ahlstedt S, et al. Reported symptoms to peanut between 4 and 8 years among children sensitized to peanut and birch pollen - results from the BAMSE birth cohort. Allergy 2010; 65:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/20\">",
"      Vereda A, van Hage M, Ahlstedt S, et al. Peanut allergy: Clinical and immunologic differences among patients from 3 different geographic regions. J Allergy Clin Immunol 2011; 127:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/21\">",
"      Venter C, Hasan Arshad S, Grundy J, et al. Time trends in the prevalence of peanut allergy: three cohorts of children from the same geographical location in the UK. Allergy 2010; 65:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/22\">",
"      Boulay A, Houghton J, Gancheva V, et al. A EuroPrevall review of factors affecting incidence of peanut allergy: priorities for research and policy. Allergy 2008; 63:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/23\">",
"      Dias RP, Summerfield A, Khakoo GA. Food hypersensitivity among Caucasian and non-Caucasian children. Pediatr Allergy Immunol 2008; 19:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/24\">",
"      Aaronov D, Tasher D, Levine A, et al. Natural history of food allergy in infants and children in Israel. Ann Allergy Asthma Immunol 2008; 101:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/25\">",
"      Gangur V, Kelly C, Navuluri L. Sesame allergy: a growing food allergy of global proportions? Ann Allergy Asthma Immunol 2005; 95:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/26\">",
"      Derby CJ, Gowland MH, Hourihane JO. Sesame allergy in Britain: a questionnaire survey of members of the Anaphylaxis Campaign. Pediatr Allergy Immunol 2005; 16:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/27\">",
"      Agne PS, Bidat E, Agne PS, et al. Sesame seed allergy in children. Eur Ann Allergy Clin Immunol 2004; 36:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/28\">",
"      Lemerdy P, Moneret-Vautrin DA, Rance F, et al. Prevalence of food allergies in pediatric and adult populations. CICBAA Databank Alim'Inter 2003; 8:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/29\">",
"      Chiang WC, Pons L, Kidon MI, et al. Serological and clinical characteristics of children with peanut sensitization in an Asian community. Pediatr Allergy Immunol 2010; 21:e429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/30\">",
"      Sicherer SH, Burks AW, Sampson HA. Clinical features of acute allergic reactions to peanut and tree nuts in children. Pediatrics 1998; 102:e6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/31\">",
"      Cohen A, Goldberg M, Levy B, et al. Sesame food allergy and sensitization in children: the natural history and long-term follow-up. Pediatr Allergy Immunol 2007; 18:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/32\">",
"      Summers CW, Pumphrey RS, Woods CN, et al. Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center. J Allergy Clin Immunol 2008; 121:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/33\">",
"      Simonte SJ, Ma S, Mofidi S, Sicherer SH. Relevance of casual contact with peanut butter in children with peanut allergy. J Allergy Clin Immunol 2003; 112:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/34\">",
"      Wainstein BK, Yee A, Jelley D, et al. Combining skin prick, immediate skin application and specific-IgE testing in the diagnosis of peanut allergy in children. Pediatr Allergy Immunol 2007; 18:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/35\">",
"      Tan BM, Sher MR, Good RA, Bahna SL. Severe food allergies by skin contact. Ann Allergy Asthma Immunol 2001; 86:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/36\">",
"      Sicherer SH, Furlong TJ, DeSimone J, Sampson HA. The US Peanut and Tree Nut Allergy Registry: characteristics of reactions in schools and day care. J Pediatr 2001; 138:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/37\">",
"      Eigenmann PA, Zamora SA. An internet-based survey on the circumstances of food-induced reactions following the diagnosis of IgE-mediated food allergy. Allergy 2002; 57:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/38\">",
"      Furlong TJ, DeSimone J, Sicherer SH. Peanut and tree nut allergic reactions in restaurants and other food establishments. J Allergy Clin Immunol 2001; 108:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/39\">",
"      Crespo JF, Rodr&iacute;guez J, Vives R, et al. Occupational IgE-mediated allergy after exposure to lupine seed flour. J Allergy Clin Immunol 2001; 108:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/40\">",
"      Keskin O, Sekerel BE. Poppy seed allergy: a case report and review of the literature. Allergy Asthma Proc 2006; 27:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/41\">",
"      Hallett R, Haapanen LA, Teuber SS. Food allergies and kissing. N Engl J Med 2002; 346:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/42\">",
"      Maloney JM, Chapman MD, Sicherer SH. Peanut allergen exposure through saliva: assessment and interventions to reduce exposure. J Allergy Clin Immunol 2006; 118:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/43\">",
"      Flinterman AE, Akkerdaas JH, Knulst AC, et al. Hazelnut allergy: from pollen-associated mild allergy to severe anaphylactic reactions. Curr Opin Allergy Clin Immunol 2008; 8:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/44\">",
"      Mittag D, Akkerdaas J, Ballmer-Weber BK, et al. Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy. J Allergy Clin Immunol 2004; 114:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/45\">",
"      Dalal I, Binson I, Levine A, et al. The pattern of sesame sensitivity among infants and children. Pediatr Allergy Immunol 2003; 14:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/46\">",
"      Koppelman SJ, Knol EF, Vlooswijk RA, et al. Peanut allergen Ara h 3: isolation from peanuts and biochemical characterization. Allergy 2003; 58:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/47\">",
"      M&uuml;ller JS, Mihaylova V, Abicht A, Lochm&uuml;ller H. Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission. Expert Rev Mol Med 2007; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/48\">",
"      Rabjohn P, Helm EM, Stanley JS, et al. Molecular cloning and epitope analysis of the peanut allergen Ara h 3. J Clin Invest 1999; 103:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/49\">",
"      Restani P, Ballabio C, Corsini E, et al. Identification of the basic subunit of Ara h 3 as the major allergen in a group of children allergic to peanuts. Ann Allergy Asthma Immunol 2005; 94:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/50\">",
"      Nicolaou N, Murray C, Belgrave D, et al. Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy. J Allergy Clin Immunol 2011; 127:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/51\">",
"      Roux KH, Teuber SS, Sathe SK. Tree nut allergens. Int Arch Allergy Immunol 2003; 131:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/52\">",
"      Shreffler WG, Castro RR, Kucuk ZY, et al. The major glycoprotein allergen from Arachis hypogaea, Ara h 1, is a ligand of dendritic cell-specific ICAM-grabbing nonintegrin and acts as a Th2 adjuvant in vitro. J Immunol 2006; 177:3677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/53\">",
"      Chung SY, Butts CL, Maleki SJ, Champagne ET. Linking peanut allergenicity to the processes of maturation, curing, and roasting. J Agric Food Chem 2003; 51:4273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/54\">",
"      Audibert F, Chedid L. [Increase of immune response by administration of metabolizable vegetable oil emulsions]. C R Acad Sci Hebd Seances Acad Sci D 1975; 280:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/55\">",
"      Hourihane JO, Dean TP, Warner JO. Peanut allergy in relation to heredity, maternal diet, and other atopic diseases: results of a questionnaire survey, skin prick testing, and food challenges. BMJ 1996; 313:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/56\">",
"      Lack G, Fox D, Northstone K, et al. Factors associated with the development of peanut allergy in childhood. N Engl J Med 2003; 348:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/57\">",
"      Sicherer SH, Furlong TJ, Maes HH, et al. Genetics of peanut allergy: a twin study. J Allergy Clin Immunol 2000; 106:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/58\">",
"      Tsai HJ, Kumar R, Pongracic J, et al. Familial aggregation of food allergy and sensitization to food allergens: a family-based study. Clin Exp Allergy 2009; 39:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/59\">",
"      Brown SJ, Asai Y, Cordell HJ, et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol 2011; 127:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/60\">",
"      Levy Y, Broides A, Segal N, Danon YL. Peanut and tree nut allergy in children: role of peanut snacks in Israel? Allergy 2003; 58:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/61\">",
"      Green TD, LaBelle VS, Steele PH, et al. Clinical characteristics of peanut-allergic children: recent changes. Pediatrics 2007; 120:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/62\">",
"      Koplin J, Dharmage SC, Gurrin L, et al. Soy consumption is not a risk factor for peanut sensitization. J Allergy Clin Immunol 2008; 121:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/63\">",
"      Klemola T, Kalimo K, Poussa T, et al. Feeding a soy formula to children with cow's milk allergy: the development of immunoglobulin E-mediated allergy to soy and peanuts. Pediatr Allergy Immunol 2005; 16:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/64\">",
"      B&oslash;nnelykke K, Pipper CB, Bisgaard H. Sensitization does not develop in utero. J Allergy Clin Immunol 2008; 121:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/65\">",
"      L&oacute;pez-Exp&oacute;sito I, Song Y, J&auml;rvinen KM, et al. Maternal peanut exposure during pregnancy and lactation reduces peanut allergy risk in offspring. J Allergy Clin Immunol 2009; 124:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/66\">",
"      Fox AT, Sasieni P, du Toit G, et al. Household peanut consumption as a risk factor for the development of peanut allergy. J Allergy Clin Immunol 2009; 123:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/67\">",
"      Sicherer SH, Wood RA, Stablein D, et al. Maternal consumption of peanut during pregnancy is associated with peanut sensitization in atopic infants. J Allergy Clin Immunol 2010; 126:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/68\">",
"      Sicherer SH, Sampson HA. Peanut allergy: emerging concepts and approaches for an apparent epidemic. J Allergy Clin Immunol 2007; 120:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/69\">",
"      Wensing M, Penninks AH, Hefle SL, et al. The distribution of individual threshold doses eliciting allergic reactions in a population with peanut allergy. J Allergy Clin Immunol 2002; 110:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/70\">",
"      Peeters KA, Koppelman SJ, van Hoffen E, et al. Does skin prick test reactivity to purified allergens correlate with clinical severity of peanut allergy? Clin Exp Allergy 2007; 37:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/71\">",
"      Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/72\">",
"      Flinterman AE, Pasmans SG, Hoekstra MO, et al. Determination of no-observed-adverse-effect levels and eliciting doses in a representative group of peanut-sensitized children. J Allergy Clin Immunol 2006; 117:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/73\">",
"      Kilburn SA, Nordlee JA, Hefle SL, et al. An evaluation of the sensitivity of subjects with peanut allergy to very low doses of peanut protein: a randomized, double-blind, placebo-controlled food challenge study. J Allergy Clin Immunol 1997; 100:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/74\">",
"      Morisset M, Moneret-Vautrin DA, Kanny G, et al. Thresholds of clinical reactivity to milk, egg, peanut and sesame in immunoglobulin E-dependent allergies: evaluation by double-blind or single-blind placebo-controlled oral challenges. Clin Exp Allergy 2003; 33:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/75\">",
"      Maloney JM, Rudengren M, Ahlstedt S, et al. The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy. J Allergy Clin Immunol 2008; 122:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/76\">",
"      Robotham JM, Hoffman GG, Teuber SS, et al. Linear IgE-epitope mapping and comparative structural homology modeling of hazelnut and English walnut 11S globulins. Mol Immunol 2009; 46:2975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/77\">",
"      Roug&eacute; P, Culerrier R, Sabatier V, et al. Mapping and conformational analysis of IgE-binding epitopic regions on the molecular surface of the major Ara h 3 legumin allergen of peanut (Arachis hypogaea). Mol Immunol 2009; 46:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/78\">",
"      Barre A, Jacquet G, Sordet C, et al. Homology modelling and conformational analysis of IgE-binding epitopes of Ara h 3 and other legumin allergens with a cupin fold from tree nuts. Mol Immunol 2007; 44:3243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/79\">",
"      de Leon MP, Drew AC, Glaspole IN, et al. IgE cross-reactivity between the major peanut allergen Ara h 2 and tree nut allergens. Mol Immunol 2007; 44:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/80\">",
"      de Leon MP, Glaspole IN, Drew AC, et al. Immunological analysis of allergenic cross-reactivity between peanut and tree nuts. Clin Exp Allergy 2003; 33:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/81\">",
"      Wallowitz ML, Chen RJ, Tzen JT, Teuber SS. Ses i 6, the sesame 11S globulin, can activate basophils and shows cross-reactivity with walnut in vitro. Clin Exp Allergy 2007; 37:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/82\">",
"      Clark AT, Ewan PW. The development and progression of allergy to multiple nuts at different ages. Pediatr Allergy Immunol 2005; 16:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/83\">",
"      Stutius LM, Sheehan WJ, Rangsithienchai P, et al. Characterizing the relationship between sesame, coconut, and nut allergy in children. Pediatr Allergy Immunol 2010; 21:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/84\">",
"      Beyer K, Bardina L, Grishina G, Sampson HA. Identification of sesame seed allergens by 2-dimensional proteomics and Edman sequencing: seed storage proteins as common food allergens. J Allergy Clin Immunol 2002; 110:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/85\">",
"      Skripak JM, Wood RA. Peanut and tree nut allergy in childhood. Pediatr Allergy Immunol 2008; 19:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/86\">",
"      Savage JH, Limb SL, Brereton NH, Wood RA. The natural history of peanut allergy: Extending our knowledge beyond childhood. J Allergy Clin Immunol 2007; 120:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/87\">",
"      Sicherer SH, Furlong TJ, Mu&ntilde;oz-Furlong A, et al. A voluntary registry for peanut and tree nut allergy: characteristics of the first 5149 registrants. J Allergy Clin Immunol 2001; 108:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/88\">",
"      Vander Leek TK, Liu AH, Stefanski K, et al. The natural history of peanut allergy in young children and its association with serum peanut-specific IgE. J Pediatr 2000; 137:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/89\">",
"      Bock SA, Atkins FM. The natural history of peanut allergy. J Allergy Clin Immunol 1989; 83:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/90\">",
"      Neuman-Sunshine DL, Eckman JA, Keet CA, et al. The natural history of persistent peanut allergy. Ann Allergy Asthma Immunol 2012; 108:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/91\">",
"      Yu JW, Kagan R, Verreault N, et al. Accidental ingestions in children with peanut allergy. J Allergy Clin Immunol 2006; 118:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38457/abstract/92\">",
"      Pucar F, Kagan R, Lim H, Clarke AE. Peanut challenge: a retrospective study of 140 patients. Clin Exp Allergy 2001; 31:40.",
"     </a>",
"    </li>",
"    <li>",
"     Beyer K, personal communication, 2009.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2395 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-27.109.116.13-BCDEC00EAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38457=[""].join("\n");
var outline_f37_35_38457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPES OF REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Systemic IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reactions due to skin contact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Reactions due to inhalation exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Reactions due to allergen exposure through saliva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Oral allergy syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Non-IgE mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RISK FACTORS FOR DEVELOPMENT OF PEANUT ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Familial factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18236026\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Skin care products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Timing of first exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Soy consumption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Maternal ingestion of food allergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Threshold dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Allergies to other foods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Associated atopic diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Natural history and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2395\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2395|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/1/16409\" title=\"figure 1\">",
"      Food-pollen relationships",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/46/9952\" title=\"figure 2\">",
"      OAS food food cross rxn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2395|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/49/20251\" title=\"table 1\">",
"      Manifestations of IgE rxns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11082?source=related_link\">",
"      Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=related_link\">",
"      Contact dermatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=related_link\">",
"      Food allergens: Overview of clinical features and cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/37/25175?source=related_link\">",
"      Introducing formula and solid foods to infants at risk for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37430?source=related_link\">",
"      Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23433?source=related_link\">",
"      Molecular features of food allergens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=related_link\">",
"      Pathogenesis of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5785?source=related_link\">",
"      Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/35/17971?source=related_link\">",
"      Patient information: Peanut allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9654?source=related_link\">",
"      Peanut, tree nut, and seed allergy: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32919?source=related_link\">",
"      Peanut, tree nut, and seed allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20119?source=related_link\">",
"      Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26551?source=related_link\">",
"      Role of allergy in atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=related_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44297?source=related_link\">",
"      Treatment of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33625?source=related_link\">",
"      Unique aspects of anaphylaxis in infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_35_38458="Treatment and prognosis of acute bacterial meningitis in children older than one month of age";
var content_f37_35_38458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38458/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38458/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38458/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38458/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38458/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/35/38458/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/35/38458/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/35/38458/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suspected bacterial meningitis is a medical emergency, and immediate diagnostic steps must be taken to establish the specific cause so that appropriate antimicrobial therapy can be initiated. The mortality rate of untreated bacterial meningitis approaches 100 percent and, even with optimal therapy, morbidity and mortality may occur. Neurologic sequelae are common among survivors.",
"   </p>",
"   <p>",
"    The treatment and prognosis of bacterial meningitis in infants and children older than one month will be reviewed here. The pathogenesis, epidemiology, clinical features and diagnosis of acute bacterial meningitis and the treatment and prognosis of bacterial meningitis in neonates (&lt;1 month of age) and adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38549?source=see_link\">",
"     \"Pathogenesis and pathophysiology of bacterial meningitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16121?source=see_link\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=see_link\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of general principles of antibiotic therapy in patients with bacterial meningitis. The most important initial issues are avoidance of delay in administering therapy and the choice of drug regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Avoidance of delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy should be initiated immediately after lumbar puncture (LP) is performed if the clinical suspicion for meningitis is high (",
"    <a class=\"graphic graphic_algorithm graphicRef74865 \" href=\"mobipreview.htm?34/44/35521\">",
"     algorithm 1",
"    </a>",
"    ). Delay in the administration of appropriate antibiotics can have a deleterious effect on outcome for patients who are deteriorating rapidly.",
"   </p>",
"   <p>",
"    If computed tomography (CT) scan is to be performed before LP, antibiotic therapy should be initiated immediately after blood cultures are obtained. Although the administration of antimicrobial therapy before LP may affect the yield of cerebrospinal fluid (CSF) Gram stain and culture, pathogens other than meningococcus usually can be identified in the CSF up to several hours after the administration of antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Interpretation of CSF in pretreated patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antibiotic regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two general principles of antibiotic therapy for bacterial meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The agent(s) used must be bactericidal against the infecting organism",
"     </li>",
"     <li>",
"      The agent(s) used must be able to penetrate past the blood-brain barrier to reach a sufficient concentration in the CSF",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Bactericidal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the CSF is a site of impaired humoral immunity, a fundamental principle of therapy of bacterial meningitis is that antibiotics must achieve a bactericidal effect within CSF to result in optimal microbiologic cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This principle is supported by clinical observations of poor outcomes in patients receiving bacteriostatic therapy (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/38/28262?source=see_link\">",
"     tetracycline",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/7\">",
"     7",
"    </a>",
"    ], as well as direct experimental evidence in which bactericidal antibiotic therapy resulted in optimal microbiologic cure and survival in animals with pneumococcal meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/35/4664?source=see_link\">",
"     Chloramphenicol",
"    </a>",
"    is a bacteriostatic drug for most enteric Gram-negative rods; however, it usually is bactericidal for",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    ,",
"    <em>",
"     Neisseria meningitidis",
"    </em>",
"    , and",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    and has been used extensively and successfully to treat meningitis caused by these organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Drug entry into CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of bacterial meningitis requires adequate concentration of antibiotics in the CSF. Most drugs reach peak concentrations in the CSF that are only 10 to 20 percent of peak concentrations in the serum. This is because the blood-brain barrier blocks macromolecule entry into the CSF, with small, lipophilic molecules penetrating most easily.",
"   </p>",
"   <p>",
"    The peak concentration of drugs in CSF increases with inflammation of the blood-brain barrier. This was illustrated in one study that sequentially monitored CSF and serum penicillin levels in children with bacterial meningitis. The mean",
"    <span class=\"nowrap\">",
"     CSF/serum",
"    </span>",
"    ratio two hours after administration of the same intravenous dose of penicillin was 42 percent on the first day of therapy but fell to less than 10 percent on the 10",
"    <sup>",
"     th",
"    </sup>",
"    day, when the inflammatory changes had subsided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/10/17576?source=see_link&amp;anchor=H5#H5\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\", section on 'Blood-brain barrier'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the general limitation in antibiotic penetration into the CSF, all patients should be treated with intravenous antibiotics. Oral antibiotics should be avoided, since the dose and tissue levels tend to be considerably lower than with parenteral agents. One exception can be made for",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/35/4664?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , which has been administered successfully by the oral route to treat",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib) meningitis in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of regimen depends upon whether the pathogen is known, since regimens for empiric therapy pose a different set of management issues than do those used to treat known pathogens. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Empiric therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Specific therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;If possible, the pretreatment evaluation of children with suspected bacterial meningitis should include a complete history and physical examination, cerebrospinal fluid (CSF) examination (cell count and differential, glucose, protein, Gram stain and culture), complete blood count (CBC) with differential and platelet count, two aerobic blood cultures, serum electrolytes, glucose, blood urea nitrogen, and creatinine; evaluation of clotting function is especially indicated if petechiae or purpuric lesions are noted (",
"    <a class=\"graphic graphic_algorithm graphicRef74865 \" href=\"mobipreview.htm?34/44/35521\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In cases in which the performance of a lumbar puncture (LP) is delayed by rapidly deteriorating clinical status or the need for neuroimaging, blood cultures should be obtained before the administration of antibiotic therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef74865 \" href=\"mobipreview.htm?34/44/35521\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The pretreatment evaluation of infants and children with suspected bacterial meningitis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IMMEDIATE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate management of children with suspected bacterial meningitis includes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assurance of adequate ventilation and cardiac perfusion (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22327?source=see_link\">",
"       \"Initial assessment and stabilization of children with respiratory or circulatory compromise\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Initiation of hemodynamic monitoring and support at the same time as obtaining appropriate laboratory studies (blood and cerebrospinal fluid [CSF]) (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Establishment of venous access (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8057?source=see_link\">",
"       \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administration of fluids as necessary to treat septic shock, if present (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10346?source=see_link\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      if warranted after assessment of potential benefits and risks before or immediately after the first dose of antimicrobial therapy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4442?source=see_link&amp;anchor=H3#H3\">",
"       \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\", section on 'Dexamethasone'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administration of the first dose of empiric antibiotics (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      [15",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      <strong>",
"       plus",
"      </strong>",
"      either",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      [100",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      [50",
"      <span class=\"nowrap\">",
"       mg/kg])",
"      </span>",
"      (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Empiric regimen'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Administration of glucose (0.25",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      for documented hypoglycemia (serum glucose concentration less than 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.2",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=see_link&amp;anchor=H13#H13\">",
"       \"Approach to hypoglycemia in infants and children\", section on 'Glucose therapy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Treatment of acidosis and coagulopathy if present (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10346?source=see_link\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8697?source=see_link\">",
"       \"Disseminated intravascular coagulation in infants and children\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fluid management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful management of fluid and electrolyte balance is an important aspect of supportive therapy. Both over- and under-hydration are associated with adverse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who are in shock should receive sufficient quantities of isotonic fluid to maintain blood pressure and cerebral perfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/13\">",
"     13",
"    </a>",
"    ]. The management of septic shock in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10346?source=see_link\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who are hypovolemic, but not in shock, should be rehydrated with careful and frequent attention to fluid status. Body weight, urine volume and specific gravity, and serum electrolytes should be monitored regularly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For children who are neither in shock nor hypovolemic, we suggest moderate fluid restriction (1200",
"    <span class=\"nowrap\">",
"     mL/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) initially, especially if the serum sodium is less than 130",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    until evidence of inappropriate secretion of antidiuretic hormone can be excluded. Body weight, urine volume and specific gravity, serum electrolytes, and, if indicated, serum and urine osmolalities, should be carefully monitored. Fluid administration can be liberalized gradually as the serum sodium reaches 135",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    Most children can receive maintenance fluid intake within 24 hours of hospitalization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are being treated for bacterial meningitis should be monitored carefully for complications (eg, increased intracranial pressure, seizure activity, development of infected subdural effusions), particularly during the first two to three days of treatment, when complications are most likely to occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart rate, blood pressure, and respiratory rate should be monitored regularly with a frequency appropriate to the care setting.",
"     </li>",
"     <li>",
"      A complete neurologic examination should be performed daily; rapid assessment of neurologic function should be performed several times per day for the first several days of treatment.",
"     </li>",
"     <li>",
"      Head circumference should be measured daily in children younger than 18 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EMPIRIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The organism causing bacterial meningitis seldom is known at the outset of therapy; as a result, an empiric treatment plan usually needs to be formulated. An awareness of the most likely pathogens, knowledge of local susceptibility patterns, and assessment of the degree of urgency are necessary to devise an optimal empiric treatment strategy. Once culture results are available, treatment should be modified to follow the guidelines for specific pathogens. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Specific therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Major pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most common causes of bacterial meningitis in infants and children who have received a full series of",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib) and pneumococcal conjugate vaccines are",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    and",
"    <em>",
"     N. meningitidis",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/16\">",
"     16",
"    </a>",
"    ]. Among",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    isolates, antibiotic resistance remains a concern. In developing countries that do not routinely immunize against Hib, Hib continues to be a frequent cause of meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Group B streptococcus,",
"    <em>",
"     Escherichia coli",
"    </em>",
"    , and",
"    <em>",
"     Listeria monocytogenes",
"    </em>",
"    are important causes in infants younger than three months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7928?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of bacterial meningitis in the neonate\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Empiric regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The empiric regimen should include coverage for penicillin-resistant",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    and",
"    <em>",
"     N. meningitidis",
"    </em>",
"    , the two most common causes of bacterial meningitis in infants and children. Additional coverage for other organisms may be indicated in children with immune deficiency, recent neurosurgery, penetrating head trauma, and anatomic defects. The cerebrospinal fluid (CSF) Gram stain may provide important clues for the need to add additional antibiotics to cover for more unusual organisms. Broad-spectrum antimicrobial therapy should be continued until CSF culture results are available because Gram stain results are subject to observer misinterpretation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Special circumstances'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An appropriate empiric regimen (ie, one that covers antibiotic-resistant",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     N. meningitidis",
"    </em>",
"    , and Hib) includes high doses of a third-generation cephalosporin (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ) and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"       Cefotaxime",
"      </a>",
"      300",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day intravenously (IV) (maximum dose 12",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 or 4 divided doses, or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 1 or 2 divided doses,",
"      <strong>",
"       plus:",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 4 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    is used, we suggest twice daily dosing to avoid the possibility of inadequate treatment in the event of dosing errors, delayed doses, or missed doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/13\">",
"     13",
"    </a>",
"    ]. Some experts suggest the addition of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    to the empiric regimen if",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    is administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/42/12970?source=see_link&amp;anchor=H19#H19\">",
"     \"Pneumococcal meningitis in children\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consultation with an expert in pediatric infectious diseases is recommended for children in whom cephalosporins or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    are contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Use of dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to neurologic sequelae after bacterial meningitis and the possible role of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy to minimize these complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31656?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4442?source=see_link&amp;anchor=H3#H3\">",
"     \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\", section on 'Dexamethasone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to use",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in children with suspected bacterial meningitis must be individualized. Factors to be weighed in this decision include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The etiologic agent",
"     </li>",
"     <li>",
"      The ability to administer",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      before or within 1 hour of the first dose of antibiotic therapy",
"     </li>",
"     <li>",
"      The empiric antibiotic regimen",
"     </li>",
"     <li>",
"      The potential adverse effects",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics (AAP) Committee on Infectious Diseases suggests that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy may be beneficial in children with Hib meningitis if given before or at the same time as the first dose of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/20\">",
"     20",
"    </a>",
"    ]. The AAP Committee on Infectious Diseases suggests that dexamethasone therapy be considered for infants and children older than six weeks with pneumococcal meningitis after weighing the potential risks and benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In accordance with the AAP Committee on Infectious Diseases, we recommend adjunctive therapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for children with Hib meningitis. We suggest that decisions regarding the use of dexamethasone in children with pneumococcal meningitis, or in those in whom bacterial meningitis is suspected but the etiology unknown, be individualized depending upon careful analysis of the potential risks and benefits. The author of this topic review usually does not administer dexamethasone to children with suspected pneumococcal or meningococcal meningitis. In the same patients, other experts may choose to use dexamethasone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/42/12970?source=see_link&amp;anchor=H16#H16\">",
"     \"Pneumococcal meningitis in children\", section on 'Dexamethasone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the decision is made to use",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , dexamethasone should be given before or concurrently with the first dose of the antimicrobial agent(s); it is probably of no benefit if given more than 1 hour later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/18\">",
"     18",
"    </a>",
"    ]. The regimen for dexamethasone is:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose every 6 hours for 2 to 4 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/13\">",
"       13",
"      </a>",
"      ]. Two days of dexamethasone appear to be as effective as and less toxic than longer courses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Special circumstances",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of bacterial meningitis in children with immune deficiency, recent neurosurgery, anatomic defects, penetrating head trauma, CSF leak, and during epidemics requires consultation with an expert in pediatric infectious diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Immune deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    <strong>",
"     plus",
"    </strong>",
"    either",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    given as described above are reasonable empiric coverage for most children with an underlying defect in host defense. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Empiric regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If a Gram-negative rod is observed on Gram stain of the CSF, the addition of an aminoglycoside (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    ) to these two agents is recommended. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Gram-negative rods'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       Gentamicin",
"      </a>",
"      7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in 3 divided doses,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/43/12984?source=see_link\">",
"       Amikacin",
"      </a>",
"      15 to 22. 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 1.5",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Peak and trough serum concentrations must be monitored when aminoglycosides are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447825222\">",
"    <span class=\"h4\">",
"     Cancer and neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective case series of 40 cases of bacterial or fungal meningitis in 36 neutropenic pediatric cancer patients (two-thirds of whom had recent neurosurgery, a central nervous system [CNS] device, or CSF leak),",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    and",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    were the two most common isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/24\">",
"     24",
"    </a>",
"    ]. Empiric therapy in such patients should be based upon the Gram stain results. Initial therapy typically includes",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    <strong>",
"     plus",
"    </strong>",
"    an aminoglycoside",
"    <strong>",
"     plus",
"    </strong>",
"    either",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    . If there is any concern about",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    or an increased risk for infection caused by an extended-spectrum beta-lactamase (ESBL)-producing organism,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/24/2439?source=see_link\">",
"     meropenem",
"    </a>",
"    may be warranted as an alternative to cefotaxime or ceftriaxone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447825229\">",
"    <span class=\"h4\">",
"     T cell defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    and",
"    <em>",
"     L. monocytogenes",
"    </em>",
"    are the most likely causes of bacterial meningitis in patients with defective cell-mediated immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/25\">",
"     25",
"    </a>",
"    ]. To address these pathogens, the empiric regimen for children with defects in T cell immunity should include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    <strong>",
"     plus",
"    </strong>",
"    either",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , dosed as recommended above, and high-dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Empiric regimen'",
"    </a>",
"    above). The dose of ampicillin is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"       Ampicillin",
"      </a>",
"      300 to 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV per day (maximum dose 10 to 12",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 4 or 6 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Recent neurosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the usual nosocomial pathogens that may complicate any surgical procedure, coagulase-negative staphylococci (such as",
"    <em>",
"     Staphylococcus epidermidis",
"    </em>",
"    ) and",
"    <em>",
"     S. aureus",
"    </em>",
"    are important causes of meningitis in patients who have had recent neurosurgery. Patients who undergo operations that involve a prosthetic device, such as a ventricular shunt or drain, are clearly at risk for developing infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44552?source=see_link\">",
"     \"Infections of central nervous system shunts and other devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have undergone recent neurosurgery also are at increased risk for meningitis with enteric Gram-negative rods, such as",
"    <em>",
"     E. coli",
"    </em>",
"    and",
"    <em>",
"     Klebsiella",
"    </em>",
"    species, as well as",
"    <em>",
"     P. aeruginosa",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/13/16600?source=see_link\">",
"     \"Epidemiology and clinical features of gram-negative bacillary meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empiric therapy in this setting usually consists of a combination of a third-generation cephalosporin and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    . In addition, an aminoglycoside (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    ) should be added if Gram-negative bacilli are noted on CSF Gram stain.",
"   </p>",
"   <p>",
"    Alternative regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 4 divided doses,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/9/12438?source=see_link\">",
"       Cefepime",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 6",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 divided doses,",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/4/14405?source=see_link\">",
"       ceftazidime",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 6",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 divided doses,",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"      120",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 6",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 divided doses",
"      <br/>",
"      <br/>",
"      The local antibiogram can help to guide which of the agents directed against Gram-negative organisms might be most appropriate (eg, a high rate of resistance to ceftazidime suggests meropenem is a better choice).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447825251\">",
"    <span class=\"h4\">",
"     Recent placement of CSF shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants and children who have had",
"    <strong>",
"    </strong>",
"    recent placement of a CSF shunt,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    <strong>",
"     plus",
"    </strong>",
"    either",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    <strong>",
"    </strong>",
"    are recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Anatomic defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with anatomic defects (eg, dermal sinus (",
"    <a class=\"graphic graphic_picture graphicRef79563 \" href=\"mobipreview.htm?7/13/7376\">",
"     picture 1",
"    </a>",
"    ), urinary tract anomalies) are at increased risk for meningitis with",
"    <em>",
"     S. aureus",
"    </em>",
"    or coagulase-negative staphylococcus and enteric Gram-negative rods, such as",
"    <em>",
"     E. coli",
"    </em>",
"    and",
"    <em>",
"     Klebsiella",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/13/16600?source=see_link\">",
"     \"Epidemiology and clinical features of gram-negative bacillary meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empiric therapy in children with anatomic defects should include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    <strong>",
"     plus",
"    </strong>",
"    either",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , dosed as recommended above. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Empiric regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, an aminoglycoside (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    ) should be added if Gram-negative bacilli are noted on CSF Gram stain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       Gentamicin",
"      </a>",
"      7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in 3 divided doses,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/43/12984?source=see_link\">",
"       Amikacin",
"      </a>",
"      15 to 22.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 1.5",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Penetrating head trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with penetrating head trauma are at risk for meningitis with",
"    <em>",
"     S. aureus",
"    </em>",
"    , coagulase-negative staphylococci (such as",
"    <em>",
"     S. epidermidis",
"    </em>",
"    ), and aerobic Gram-negative bacilli, including",
"    <em>",
"     P. aeruginosa",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Empiric therapy in this setting usually consists of a combination of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    &nbsp;",
"    <strong>",
"     plus",
"    </strong>",
"    an extended-spectrum cephalosporin (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/9/12438?source=see_link\">",
"     cefepime",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/4/14405?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ) or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/24/2439?source=see_link\">",
"     meropenem",
"    </a>",
"    ,",
"    <strong>",
"     plus",
"    </strong>",
"    an aminoglycoside [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 4 divided doses,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/9/12438?source=see_link\">",
"       Cefepime",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 6",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 divided doses,",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/4/14405?source=see_link\">",
"       ceftazidime",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 6",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 divided doses,",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"      120",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 6",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 divided doses,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       Gentamicin",
"      </a>",
"      7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in 3 divided doses or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      15 to 22.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 1.5",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     CSF leak",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a CSF leak (CSF rhinorrhea or otorrhea) should be treated for presumed pneumococcal meningitis, since",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    is the most likely organism in this setting. Pneumococcal meningitis in these patients is usually less severe than that caused by hematogenous invasion, and the prognosis is somewhat better. Nevertheless, because of the possibility of an isolate highly resistant to penicillin, such patients should be treated with a third-generation cephalosporin, plus",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    , until culture results return. This regimen also will cover",
"    <em>",
"     H. influenzae",
"    </em>",
"    , which rarely causes meningitis in patients with dural defects. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Empiric regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Epidemics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The empiric treatment of bacterial meningitis during epidemics in which",
"    <em>",
"     N. meningitidis",
"    </em>",
"    is suspected is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25609?source=see_link\">",
"     \"Treatment and prevention of meningococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SPECIFIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the causative agent and its in vitro antimicrobial susceptibility pattern are known, empiric antimicrobial therapy can be altered accordingly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     S. pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of pneumococcal meningitis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/42/12970?source=see_link&amp;anchor=H13#H13\">",
"     \"Pneumococcal meningitis in children\", section on 'Overview of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic options for pneumococcal meningitis according to antibiotic susceptibility profiles are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef79959 \" href=\"mobipreview.htm?32/0/32780\">",
"     table 1",
"    </a>",
"    ). The usual duration of therapy in uncomplicated cases of",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    meningitis is 10 to 14 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     N. meningitidis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningococcal meningitis is best treated with penicillin:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/46/14054?source=see_link\">",
"       Penicillin G",
"      </a>",
"      250,000 to 300,000",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      per day IV (maximum 24 million",
"      <span class=\"nowrap\">",
"       U/day)",
"      </span>",
"      in 4 or 6 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third-generation cephalosporin is an effective alternative to penicillin for children with penicillin allergy that is not characterized by anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=see_link\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Possible regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"       Cefotaxime",
"      </a>",
"      225 to 300",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 12",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 or 4 divided doses,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 1 or 2 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with penicillin allergy characterized by anaphylaxis,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/35/4664?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    is a recommended alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/27\">",
"     27",
"    </a>",
"    ]. Desensitizing the patient to the third-generation cephalosporin is another option.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/35/4664?source=see_link\">",
"       Chloramphenicol",
"      </a>",
"      75 to 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 2 to 4 g per day) in 4 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although scattered cases of",
"    <em>",
"     N. meningitidis",
"    </em>",
"    resistant to penicillin have been reported, such strains are rare. Relative resistance to penicillin occurs more commonly but does not have an impact on the response to penicillin or cephalosporin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25609?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Penicillin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A five- to seven-day duration of therapy is adequate for meningococcal meningitis and eradication of the organism from the cerebrospinal fluid (CSF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/27\">",
"     27",
"    </a>",
"    ]. However, neither penicillin nor",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/35/4664?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    therapy reliably eradicates nasopharyngeal carriage of",
"    <em>",
"     N. meningitidis",
"    </em>",
"    . Patients treated with penicillin or chloramphenicol should receive antimicrobial therapy to eradicate nasopharyngeal carriage before hospital discharge to prevent transmission of the organism to contacts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25609?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Antimicrobial chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     H. influenzae type b",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     Ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    is the treatment of choice for",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    -resistant H. influenzae type b (Hib) meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/20,30-32\">",
"     20,30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"       Cefotaxime",
"      </a>",
"      200",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 12",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 or 4 divided doses,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 1 or 2 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"     Ampicillin",
"    </a>",
"    is effective for susceptible strains:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"       Ampicillin",
"      </a>",
"      300 to 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 10 to 12",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 4 to 6 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with penicillin allergy characterized by anaphylaxis, desensitizing the patient is one option.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/35/4664?source=see_link\">",
"     Chloramphenicol",
"    </a>",
"    is another:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/35/4664?source=see_link\">",
"       Chloramphenicol",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 2 to 4 g per day) in 4 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/61/31701?source=see_link\">",
"     Cefuroxime",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be used to treat Hib meningitis, because it is associated with less rapid sterilization of the CSF and a greater incidence of hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with Hib meningitis should be treated for 7 to 10 days. Pharyngeal colonization persists after curative therapy with agents other than",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    . Patients who are not treated with ceftriaxone or cefotaxime should receive",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    before hospital discharge to prevent transmission of the organism to contacts. For patients who are treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/35/4664?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , rifampin therapy should be delayed until chloramphenicol is discontinued, since concomitant administration of rifampin may reduce serum concentrations of chloramphenicol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention of Haemophilus influenzae infection\", section on 'Antibiotic prophylaxis of close contacts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     L. monocytogenes",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     L. meningitis",
"    </em>",
"    traditionally has been treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    , because resistance to these drugs is quite rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/34\">",
"     34",
"    </a>",
"    ]. Although gentamicin has poor CSF penetration, it is used for synergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"       Ampicillin",
"      </a>",
"      300",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 10 to 12",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 4 to 6 divided doses,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       Gentamicin",
"      </a>",
"      7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV, in 3 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) is an alternative for penicillin-allergic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/36\">",
"     36",
"    </a>",
"    ]. The dose for TMP-SMX is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TMP-SMX 10 to 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of the TMP component and 50 to 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of the SMX component per day, in 4 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/24/2439?source=see_link\">",
"     Meropenem",
"    </a>",
"    , a carbapenem approved for the treatment of pediatric meningitis, has excellent in vitro activity against",
"    <em>",
"     L. monocytogenes",
"    </em>",
"    . It may prove to be useful for listeria infections but has not yet been approved for this indication. Other antibiotics are less effective against",
"    <em>",
"     L. monocytogenes",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    The usual duration of therapy for",
"    <em>",
"     Listeria",
"    </em>",
"    meningitis is 14 to 21 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Group B streptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of group B streptococcal (",
"    <em>",
"     Streptococcus agalactiae",
"    </em>",
"    ) meningitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=see_link&amp;anchor=H33#H33\">",
"     \"Group B streptococcal infection in neonates and young infants\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725269040\">",
"    <span class=\"h2\">",
"     S. aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard therapy for methicillin-susceptible",
"    <em>",
"     S. aureus",
"    </em>",
"    (MSSA) meningitis is",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"     nafcillin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"     oxacillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/18,37\">",
"     18,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"       Nafcillin",
"      </a>",
"      150 to 200",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in 4 doses (maximum daily dose 12 g),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"       Oxacillin",
"      </a>",
"      150 to 200",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in 4 doses (maximum daily dose 12 g)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The preferred therapy for methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) meningitis is",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/18,37,38\">",
"     18,37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 4 divided doses. Some experts recommend the addition of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"       rifampin",
"      </a>",
"      20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided in 2 doses (maximum dose 600",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      to vancomycin, either orally or by intravenous administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternative agents for MRSA meningitis include TMP-SMX or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/18,37,38\">",
"     18,37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TMP-SMX 10 to 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of the TMP component and 50 to 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of the SMX component per day, in 4 divided doses,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"       Linezolid",
"      </a>",
"      &lt;12 years: 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in 3 doses; &ge;12 years: 600 mg twice per day; maximum dose 1200",
"      <span class=\"nowrap\">",
"       mg/day",
"       <br/>",
"       <br/>",
"       Inflammation",
"      </span>",
"      of the meninges does not appear to affect penetration of linezolid into the CSF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/39-42\">",
"       39-42",
"      </a>",
"      ]. Rapid penetration has been demonstrated in children and adolescents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/42\">",
"       42",
"      </a>",
"      ]. However, CSF concentrations are variable, and correlation of CSF and plasma levels is inconsistent. Furthermore, linezolid is not bactericidal, but some case reports document successful linezolid treatment of staphylococcal meningitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/37,43\">",
"       37,43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Gram-negative rods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningitis caused by enteric Gram-negative rods is usually treated with an extended-spectrum cephalosporin and an aminoglycoside [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/44\">",
"     44",
"    </a>",
"    ]. The aminoglycoside often can be discontinued after the first week, once the CSF cultures have been documented to be sterile. Consultation with an expert in pediatric infectious diseases is recommended for children with meningitis caused by a Gram-negative rod. One suggested regimen is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"       Cefotaxime",
"      </a>",
"      200 to 300",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 12",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 4 divided doses",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 2 divided doses,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       Gentamicin",
"      </a>",
"      7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV, in 3 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Organisms such as",
"    <em>",
"     P. aeruginosa",
"    </em>",
"    often are resistant to many commonly used antibiotics.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/4/14405?source=see_link\">",
"     Ceftazidime",
"    </a>",
"    has been the most consistently effective cephalosporin in the treatment of",
"    <em>",
"     P. aeruginosa",
"    </em>",
"    infections, including meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/4/14405?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 6",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/24/2439?source=see_link\">",
"     Meropenem",
"    </a>",
"    is an effective drug in the treatment of meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/46\">",
"     46",
"    </a>",
"    ] and is approved by the US Food and Drug Administration (FDA) for the treatment of bacterial meningitis in children and adolescents. It may be used in patients with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/4/14405?source=see_link\">",
"     ceftazidime",
"    </a>",
"    -resistant strains of various Gram-negative rods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/47\">",
"     47",
"    </a>",
"    ] and is the agent of choice in the treatment of meningitis caused by extended-spectrum beta-lactamase producing Gram-negative enteric organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/48\">",
"     48",
"    </a>",
"    ]. It is dosed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/24/2439?source=see_link\">",
"       Meropenem",
"      </a>",
"      120",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 6",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A repeat CSF sample should be obtained for culture two to three days into therapy to help assess the efficacy of treatment.",
"   </p>",
"   <p>",
"    In addition, we suggest repeating the CSF analysis near the end of therapy, particularly in young infants, to determine whether treatment may be discontinued. CSF findings suggestive of the need for continued therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Percentage of neutrophils &gt;30 percent, or",
"     </li>",
"     <li>",
"      CSF glucose concentration &lt;20",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasionally, intraventricular administration of an antibiotic (generally an aminoglycoside) for several days is necessary to sterilize the CSF. Intraventricular therapy should be undertaken in consultation with specialists in pediatric infectious diseases and neurosurgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25930?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnosis and treatment of gram-negative bacillary meningitis\", section on 'Intrathecal and intraventricular therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antimicrobial therapy depends upon the causative organism and the clinical course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Positive CSF culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence from high-quality studies to guide the duration of treatment for bacterial meningitis. We suggest the following durations of therapy for uncomplicated meningitis caused by the following organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/20,27\">",
"     20,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      &ndash; 10 to 14 days",
"     </li>",
"     <li>",
"      <em>",
"       N. meningitidis",
"      </em>",
"      &ndash; 5 to 7 days",
"     </li>",
"     <li>",
"      <em>",
"       H. influenzae",
"      </em>",
"      type b (Hib) &ndash; 7 to 10 days",
"     </li>",
"     <li>",
"      <em>",
"       L. monocytogenes",
"      </em>",
"      &ndash; 14 to 21 days",
"     </li>",
"     <li>",
"      <em>",
"       S. aureus",
"      </em>",
"      &ndash; at least 2 weeks",
"     </li>",
"     <li>",
"      Gram-negative bacilli &ndash; 3 weeks or a minimum of 2 weeks beyond the first sterile culture, whichever is longer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A multicenter trial in resource-limited countries found that outcomes were similar among children treated with 5 versus 10 days of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    for meningitis caused by",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     N. meningitidis",
"    </em>",
"    , or Hib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/49\">",
"     49",
"    </a>",
"    ]. Children (2 months to 12 years) whose repeat cerebrospinal fluid (CSF) cultures at 48 to 72 hours were negative and who were &ldquo;clinically stable&rdquo; after five days of ceftriaxone were randomly assigned to an additional five days of therapy with ceftriaxone or placebo. The setting, methodology, and lack of organism-specific outcome information preclude generalizability to resource-rich settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. We continue to suggest organism-specific durations of therapy, as outlined above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Outpatient therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In highly selected patients, a portion of antibiotic therapy may be administered in the outpatient setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/18,51\">",
"     18,51",
"    </a>",
"    ]. Advantages of completion of therapy in the outpatient setting include: decreased risk of nosocomial infection, improved quality of life, and decreased cost of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/33,52-54\">",
"     33,52-54",
"    </a>",
"    ]. Several observational studies have shown that with careful selection and close monitoring, completion of antimicrobial therapy in the outpatient setting can be safe and effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One group of investigators used the following criteria for outpatient antimicrobial therapy in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Completion of at least six days of inpatient therapy; serious adverse complications of meningitis are exceedingly rare after three or four days of therapy, particularly in children who are clinically well and afebrile [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/14,15,51\">",
"       14,15,51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Afebrile for at least 24 to 48 hours before initiation of outpatient therapy",
"     </li>",
"     <li>",
"      No significant neurologic dysfunction or focal findings",
"     </li>",
"     <li>",
"      No seizure activity",
"     </li>",
"     <li>",
"      Clinical stability",
"     </li>",
"     <li>",
"      Ability to take fluids by mouth",
"     </li>",
"     <li>",
"      First dose of outpatient antibiotic is administered in the hospital",
"     </li>",
"     <li>",
"      Outpatient antibiotic therapy is administered in the office or emergency department setting or by qualified home health nursing",
"     </li>",
"     <li>",
"      Daily examination is performed by a clinician",
"     </li>",
"     <li>",
"      Parents are reliable and have transportation and a telephone",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Negative CSF culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with negative CSF cultures at 48 to 72 hours, the duration of antibiotic therapy is individualized depending upon the remainder of the CSF evaluation, blood culture result, and clinical status:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For those who have a normal CSF profile, and negative blood and CSF culture, we usually discontinue antimicrobial therapy if cultures remain sterile after 48 to 72 hours of incubation.",
"     </li>",
"     <li>",
"      For those who have a CSF pleocytosis and positive blood culture, but negative CSF culture, treat for meningitis caused by the organism isolated from the blood culture (ie, management is the same as if the CSF culture was positive for the same organism).",
"     </li>",
"     <li>",
"      For those who have a CSF pleocytosis, negative blood culture, and negative CSF culture, we individualize the duration of meningitic doses of antimicrobial therapy based on clinical parameters. Consultation with a specialist in pediatric infectious diseases is suggested if the clinician is uncertain how to manage such children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to therapy is monitored clinically (eg, fever curve, resolution of symptoms and signs). Repeat examination of the spinal fluid and neuroimaging may be necessary in some patients. In children who had a positive blood culture at initial evaluation, blood cultures should be repeated to document sterility of the blood stream. The follow-up blood culture is usually obtained when it is known that the initial blood culture is positive.",
"   </p>",
"   <p>",
"    In patients with prolonged obtundation, irritability, seizures, focal neurologic abnormalities, or increased head circumference, neurologic complications (eg, subdural empyema, cerebral vascular thrombosis, ventricular dilation, brain abscess) should be considered, and neuroimaging may be warranted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31656?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Duration of fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of fever is typically four to six days after the initiation of adequate therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Fever lasts longer than five days in approximately 13 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/57\">",
"     57",
"    </a>",
"    ]; secondary fever (eg, recurrence of fever after being afebrile for at least 24 hours) occurs in approximately 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/55,57\">",
"     55,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persistence of fever beyond eight days and secondary fever have a number of causes, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/23,55\">",
"     23,55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inadequate treatment",
"     </li>",
"     <li>",
"      Development of nosocomial infection (eg, infected intravenous catheters, urinary tract infection, viral infection); nosocomial infection is more often associated with secondary fever than with persistent fever [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Discontinuation of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"     </li>",
"     <li>",
"      Development of a suppurative complication (pericarditis, pneumonia, arthritis, subdural empyema)",
"     </li>",
"     <li>",
"      Drug fever (a diagnosis of exclusion)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with persistent or secondary fever, suppurative and nosocomial complications should be carefully sought and the need for repeat evaluation of the cerebrospinal fluid (CSF) considered on an individual basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/51\">",
"     51",
"    </a>",
"    ]. In many cases, a specific cause of prolonged fever cannot be determined. In the patient who is improving daily but has unexplained fever despite careful evaluation, it is thought that the individual's host response to infection is responsible for the prolonged fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Repeat CSF analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Re-examination of the CSF is recommended for patients who have a poor clinical response despite 24 to 36 hours of appropriate antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/18\">",
"     18",
"    </a>",
"    ]. This is particularly true for children with cephalosporin-resistant pneumococcal meningitis and for children with pneumococcal meningitis who were treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (since dexamethasone may interfere with the ability of the clinician to assess clinical response such as resolution of fever).",
"   </p>",
"   <p>",
"    Re-examination of the CSF also may be indicated in children with persistent or recurrent fever, as discussed above. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Duration of fever'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, re-examination of the CSF is necessary after two to three days of treatment for Gram-negative bacillary meningitis to determine appropriate duration of therapy. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Gram-negative rods'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Repeat CSF cultures should be sterile. Extension of the duration of therapy is indicated if organisms are seen on Gram stain or isolated from CSF cultures of the repeat CSF examination. Extension of duration of treatment also is indicated if CSF examination at the conclusion of the standard duration of treatment shows &gt;30 percent neutrophils, CSF glucose of &lt;20",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    or CSF-to-blood glucose ratio of &lt;20 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging (with computed tomography [CT] or magnetic resonance imaging [MRI]) may be indicated during the course of treatment for acute bacterial meningitis in the following circumstances (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31656?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in children\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/51,55\">",
"     51,55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal neurologic signs, increasing head circumference, or prolonged obtundation, irritability, or seizures (&gt;72 hours after the start of treatment)",
"     </li>",
"     <li>",
"      Persistently positive CSF cultures despite appropriate antibiotic therapy",
"     </li>",
"     <li>",
"      Persistent elevation of CSF neutrophils at the completion of standard duration of therapy (more than 30 to 40 percent)",
"     </li>",
"     <li>",
"      Recurrent meningitis (to evaluate the possibility of a communication between the nasal passage or ear and the meninges); sectional (2 mm) coronal cranial CT has been reported to be a relatively easy, noninvasive method of delineating anatomic abnormalities in children with recurrent meningitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, neuroimaging of infants with Gram-negative meningitis sometime during their treatment is recommended to detect hydrocephalus or other complications of the meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/59\">",
"     59",
"    </a>",
"    ]. This is particularly true for infants with",
"    <em>",
"     Citrobacter",
"    </em>",
"    or",
"    <em>",
"     Enterobacter sakazakii",
"    </em>",
"    (also known as",
"    <em>",
"     Cronobacter",
"    </em>",
"    ) meningitis. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Gram-negative rods'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case fatality rates for meningitis in children older than one month in the United States range from 0 to 15 percent, depending upon the infecting organism and when the survey was performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/16,19,60-63\">",
"     16,19,60-63",
"    </a>",
"    ]. Among 2780 children in the United States with bacterial meningitis between 2001 and 2006, mortality was 4.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of prospectively enrolled cohorts of 4920 children from 1955 to 1993 found a mortality rate of 4.8 percent in developed countries and 8.1 percent in developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/61\">",
"     61",
"    </a>",
"    ]. The mortality rate in developed countries varied by organism, ranging from 3.8 percent for",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib) to 7.5 percent for",
"    <em>",
"     N. meningitidis",
"    </em>",
"    to 15.3 percent for",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/61\">",
"     61",
"    </a>",
"    ]. In the more recent multicenter pneumococcal meningitis surveillance study (1993 to 1996), mortality for pneumococcal meningitis was 7.7 percent in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/42/12970?source=see_link&amp;anchor=H32#H32\">",
"     \"Pneumococcal meningitis in children\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Neurologic sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent neurologic sequelae are common in children who survive an episode of bacterial meningitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31656?source=see_link&amp;anchor=H3#H3\">",
"     \"Neurologic complications of bacterial meningitis in children\", section on 'Incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible role of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy in mitigating neurologic complications of bacterial meningitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4442?source=see_link&amp;anchor=H4#H4\">",
"     \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors related to the outcome of bacterial meningitis in children include level of consciousness at the time of admission, etiologic agent, prolonged or complicated seizures, low cerebrospinal fluid (CSF) glucose concentration, delayed sterilization of the CSF, and nutritional status, as discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/19,23,64-69\">",
"     19,23,64-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glasgow coma score &ndash; In post hoc multivariate analysis of data from 654 children with bacterial meningitis, Glasgow coma score (GCS) (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"mobipreview.htm?2/58/2989\">",
"       table 2",
"      </a>",
"      ) was the only independent predictor of death or neurologic sequelae [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Etiologic agent &ndash; The risks of mortality and neurologic sequelae are higher in children with pneumococcal meningitis than with meningococcal or Hib meningitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/19,70\">",
"       19,70",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/42/12970?source=see_link&amp;anchor=H32#H32\">",
"       \"Pneumococcal meningitis in children\", section on 'Mortality'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The risk of hearing impairment is also related to etiologic agent. Hearing loss occurs in approximately 31 percent of children with pneumococcal meningitis, 11 percent of children with meningococcal meningitis, and 6 percent of children with Hib meningitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/19,67,71\">",
"       19,67,71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Seizures &ndash; In a multicenter pneumococcal meningitis surveillance study, the occurrence of seizures more than 72 hours after initiation of appropriate antimicrobial therapy was associated with increased risk of neurologic sequelae [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/19\">",
"       19",
"      </a>",
"      ]. In a series of children with Hib meningitis, seizures were associated with subtle cognitive and learning problems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CSF glucose concentration &ndash; Decreased CSF glucose concentration (&lt;20",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.1",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      at the time of admission appears to be associated with hearing loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/19,65,66\">",
"       19,65,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Delayed sterilization of the CSF &ndash; Delayed sterilization of the CSF (persistently positive culture 16 to 18 hours after the initiation of therapy) is associated with adverse outcomes, including moderate to profound sensorineural hearing loss, seizures, hemiparesis, and abnormal neurologic findings at the time of discharge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nutritional status &ndash; Malnutrition is associated with increased morbidity and mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]. In a multicenter study of 482 Latin American children with bacterial meningitis, the risk of death was increased among those who were underweight (odds ratio [OR] 1.98, 2.55, and 5.85 in mild, moderate, and severe underweight, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/69\">",
"       69",
"      </a>",
"      ]. The risk of severe neurologic sequelae was also increased in severely underweight children (OR 5, 95% CI 1.6-16).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Hearing evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing evaluation should be performed at the time of or shortly after discharge from the hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/51\">",
"     51",
"    </a>",
"    ]. Hearing may be assessed by pure tone audiometry; evoked response audiometry may be used in young children or those who cannot cooperate with pure tone audiometry. Hearing evaluation should be repeated if the results of the initial evaluation suggest more than a minor conductive hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young children who have been treated for meningitis are at risk for developmental delay. Those who are younger than three years of age may be eligible to receive Early Intervention Services in the United States (eligibility criteria vary by state). Appropriate referrals should be made as indicated. Developmental surveillance should continue throughout childhood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=see_link&amp;anchor=H18501566#H18501566\">",
"     \"Developmental-behavioral surveillance and screening in primary care\", section on 'When to perform developmental-behavioral screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients admitted to the hospital with meningitis should be placed on standard precautions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/20,21,27\">",
"     20,21,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H2#H2\">",
"     \"General principles of infection control\", section on 'Standard precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, droplet precautions are recommended for patients",
"    <em>",
"     with N. meningitidis",
"    </em>",
"    and",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib) meningitis until they have received 24 hours of effective therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/20,27\">",
"     20,27",
"    </a>",
"    ]. Patients should be in private rooms, and hospital personnel should wear a face mask when they are within 3 feet (1 meter) of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Chemoprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoprophylaxis, which is recommended for certain contacts of patients with meningococcal and Hib meningitis, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25609?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Antimicrobial chemoprophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention of Haemophilus influenzae infection\", section on 'Antibiotic prophylaxis of close contacts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it does not have a role in preventing the spread of pneumococcal meningitis, chemoprophylaxis is an important aspect of prevention of invasive pneumococcal infections in children with functional or anatomic asplenia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link&amp;anchor=H11#H11\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of sickle cell disease\", section on 'Infection control and prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Basilar skull fractures with underlying dural tears are associated with cerebrospinal fluid (CSF) leaks and predispose patients to meningitis because of the potential for direct communication of bacteria in the upper respiratory tract with the central nervous system. There is no evidence that antibiotics given prophylactically are efficacious for preventing meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/35/38458/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccines directed against each of the major pathogens causing bacterial meningitis in children are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link\">",
"       \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=see_link&amp;anchor=H5#H5\">",
"       \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Indications'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <em>",
"       N. meningitidis",
"      </em>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link\">",
"       \"Meningococcal vaccines\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hib (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=see_link&amp;anchor=H2#H2\">",
"       \"Prevention of Haemophilus influenzae infection\", section on 'Immunization'",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"       \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/43/3763?source=see_link\">",
"       \"Patient information: Meningitis in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/1/31762?source=see_link\">",
"       \"Patient information: Bacterial meningitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/48/1796?source=see_link\">",
"       \"Patient information: Meningitis in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Immediate and supportive care",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic therapy should be initiated immediately after the lumbar puncture (LP) is performed if the clinical suspicion for meningitis is high (",
"      <a class=\"graphic graphic_algorithm graphicRef74865 \" href=\"mobipreview.htm?34/44/35521\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Avoidance of delay'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pretreatment evaluation of children with suspected bacterial meningitis should include a complete history and physical examination, cerebrospinal fluid (CSF) examination (cell count and differential, glucose, protein, Gram stain and culture), complete blood count (CBC) with differential and platelet count, blood cultures, serum electrolytes, glucose, blood urea nitrogen, creatinine; evaluation of clotting function is indicated if petechiae or purpuric lesions are noted (",
"      <a class=\"graphic graphic_algorithm graphicRef74865 \" href=\"mobipreview.htm?34/44/35521\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate management of children with suspected bacterial meningitis includes assessment and stabilization of ventilation and perfusion, and initiation of hemodynamic monitoring and support while obtaining appropriate laboratory studies and establishing venous access. Empiric antibiotic therapy and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , if warranted, should be administered as soon as possible after lumbar puncture. Hypoglycemia, acidosis, and coagulopathy should be treated as necessary. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Immediate management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children who are neither in shock nor dehydrated, we suggest moderate fluid restriction (1200",
"      <span class=\"nowrap\">",
"       mL/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) until evidence of inappropriate secretion of antidiuretic hormone can be excluded (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Fluid management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Antibiotic and dexamethasone therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that the empiric regimen for infants and children older than one month with bacterial meningitis include coverage for antibiotic-resistant",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      ,",
"      <em>",
"       Neisseria meningitidis",
"      </em>",
"      , and",
"      <em>",
"       Haemophilus influenzae",
"      </em>",
"      type b (Hib) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Major pathogens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Empiric regimen'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      An appropriate empiric regimen includes",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 4 divided doses",
"      <strong>",
"       plus",
"      </strong>",
"      high doses of either",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      300",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day intravenously (IV) (maximum dose 12",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 3 or 4 divided doses or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV (maximum dose 4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 1 or 2 divided doses. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Empiric regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      for children with Hib meningitis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Use of dexamethasone'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4442?source=see_link&amp;anchor=H3#H3\">",
"       \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\", section on 'Dexamethasone'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decisions regarding the use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in children with pneumococcal meningitis, or in whom bacterial meningitis is suspected but the etiology unknown, must be individualized after careful analysis of the potential risks and benefits. The author of this topic review usually does not administer dexamethasone to children with suspected pneumococcal or meningococcal meningitis. In the same patients, other experts may choose to use dexamethasone. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Use of dexamethasone'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/42/12970?source=see_link&amp;anchor=H16#H16\">",
"       \"Pneumococcal meningitis in children\", section on 'Dexamethasone'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4442?source=see_link&amp;anchor=H3#H3\">",
"       \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\", section on 'Dexamethasone'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend not using",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      if more than one hour has elapsed since the first dose of antimicrobial therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Use of dexamethasone'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4442?source=see_link&amp;anchor=H3#H3\">",
"       \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\", section on 'Dexamethasone'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The empiric regimen may need to be broadened in infants and children with immune deficiency, recent neurosurgery, penetrating head trauma, and anatomic defects. Patients with these conditions should be managed in consultation with a specialist in pediatric infectious diseases. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Special circumstances'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the causative agent and its in vitro antimicrobial susceptibility pattern are known, empiric antimicrobial therapy can be altered accordingly. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Specific therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of antimicrobial therapy depends upon the causative organism and the clinical course. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Response to treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The response to therapy is monitored clinically (eg, fever curve, resolution of symptoms and signs). Repeat examination of the spinal fluid may be necessary in some patients. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Re-examination of CSF is indicated for patients who have a poor clinical response despite 24 to 36 hours of appropriate antimicrobial therapy. This is particularly true for children with third-generation cephalosporin-resistant pneumococcal meningitis and for children with pneumococcal meningitis who were treated with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      . In addition, re-examination of the CSF is necessary after two to three days of treatment for Gram-negative bacillary meningitis to determine appropriate duration of therapy. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Repeat CSF analysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31\">",
"       'Gram-negative rods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuroimaging is indicated in infants and children with signs or symptoms of complications",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recurrent meningitis. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Prognosis and follow-up",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall mortality for bacterial meningitis in infants and children is approximately 5 percent in developed countries and 8 percent in developing countries. (See",
"      <a class=\"local\" href=\"#H41\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic sequelae, including deafness, intellectual disability, spasticity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      paresis, and seizures occur in 15 to 25 percent of survivors. (See",
"      <a class=\"local\" href=\"#H42\">",
"       'Neurologic sequelae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who have been treated for bacterial meningitis should undergo hearing evaluation at the time of or shortly after discharge. They should also be followed closely for other neurologic sequelae including gross motor and cognitive impairment. (See",
"      <a class=\"local\" href=\"#H44\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chemoprophylaxis is recommended for certain contacts of patients with meningococcal meningitis and Hib meningitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=see_link&amp;anchor=H15#H15\">",
"       \"Prevention of Haemophilus influenzae infection\", section on 'Antibiotic prophylaxis of close contacts'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25609?source=see_link&amp;anchor=H20#H20\">",
"       \"Treatment and prevention of meningococcal infection\", section on 'Antimicrobial chemoprophylaxis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/1\">",
"      Geiseler PJ, Nelson KE, Levin S, et al. Community-acquired purulent meningitis: a review of 1,316 cases during the antibiotic era, 1954-1976. Rev Infect Dis 1980; 2:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/2\">",
"      Talan DA, Hoffman JR, Yoshikawa TT, Overturf GD. Role of empiric parenteral antibiotics prior to lumbar puncture in suspected bacterial meningitis: state of the art. Rev Infect Dis 1988; 10:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/3\">",
"      Kanegaye JT, Soliemanzadeh P, Bradley JS. Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. Pediatrics 2001; 108:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/4\">",
"      Lutsar I, McCracken GH Jr, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998; 27:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/5\">",
"      Finberg RW, Moellering RC, Tally FP, et al. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 2004; 39:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/6\">",
"      Friedland IR, Paris M, Ehrett S, et al. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993; 37:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/7\">",
"      Cherubin CE, Marr JS, Sierra MF, Becker S. Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults. Am J Med 1981; 71:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/8\">",
"      Scheld WM, Sande MA. Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits. J Clin Invest 1983; 71:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/9\">",
"      Hieber JP, Nelson JD. A pharmacologic evaluation of penicillin in children with purulent meningitis. N Engl J Med 1977; 297:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/10\">",
"      Tuomanen EI, Powell KR, Marks MI, et al. Oral chloramphenicol in the treatment of Haemophilus influenzae meningitis. J Pediatr 1981; 99:968.",
"     </a>",
"    </li>",
"    <li>",
"     Fleisher GR. Infectious disease emergencies. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.783.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/12\">",
"      Maconochie I, Baumer H, Stewart ME. Fluid therapy for acute bacterial meningitis. Cochrane Database Syst Rev 2008; :CD004786.",
"     </a>",
"    </li>",
"    <li>",
"     Feigin RD, Cutrer WB. Bacterial meningitis beyond the neonatal period. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.439.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/14\">",
"      Feigin RD, McCracken GH Jr, Klein JO. Diagnosis and management of meningitis. Pediatr Infect Dis J 1992; 11:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/15\">",
"      Outpatient management of bacterial meningitis. Pediatr Infect Dis J 1989; 8:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/16\">",
"      Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011; 364:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/17\">",
"      Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/18\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/19\">",
"      Arditi M, Mason EO Jr, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 1998; 102:1087.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Haemophilus influenzae infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.345.",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Pneumococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th Ed, Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.571.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/22\">",
"      Syrogiannopoulos GA, Lourida AN, Theodoridou MC, et al. Dexamethasone therapy for bacterial meningitis in children: 2- versus 4-day regimen. J Infect Dis 1994; 169:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/23\">",
"      Ch&aacute;vez-Bueno S, McCracken GH Jr. Bacterial meningitis in children. Pediatr Clin North Am 2005; 52:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/24\">",
"      Sommers LM, Hawkins DS. Meningitis in pediatric cancer patients: a review of forty cases from a single institution. Pediatr Infect Dis J 1999; 18:902.",
"     </a>",
"    </li>",
"    <li>",
"     Bortolussi R, Mailman T. Listeriosis. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.1420.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/26\">",
"      Marhoum el Filali K, Noun M, Chakib A, et al. Ceftriaxone versus penicillin G in the short-term treatment of meningococcal meningitis in adults. Eur J Clin Microbiol Infect Dis 1993; 12:766.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Meningococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.500.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/28\">",
"      Jackson LA, Tenover FC, Baker C, et al. Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. Meningococcal Disease Study Group. J Infect Dis 1994; 169:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/29\">",
"      Brown EM, Fisman DN, Drews SJ, et al. Epidemiology of invasive meningococcal disease with decreased susceptibility to penicillin in Ontario, Canada, 2000 to 2006. Antimicrob Agents Chemother 2010; 54:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/30\">",
"      Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N Engl J Med 1988; 319:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/31\">",
"      Schaad UB, Suter S, Gianella-Borradori A, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990; 322:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/32\">",
"      Vallejo JG, Kaplan SL, Mason EO Jr. Treatment of meningitis and other infections due to ampicillin-resistant Haemophilus influenzae type b in children. Rev Infect Dis 1991; 13:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/33\">",
"      American Academy of Pediatrics Committee on Infectious Diseases: Treatment of bacterial meningitis. Pediatrics 1988; 81:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/34\">",
"      Charpentier E, Gerbaud G, Jacquet C, et al. Incidence of antibiotic resistance in Listeria species. J Infect Dis 1995; 172:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/35\">",
"      Cherubin CE, Appleman MD, Heseltine PN, et al. Epidemiological spectrum and current treatment of listeriosis. Rev Infect Dis 1991; 13:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/36\">",
"      Spitzer PG, Hammer SM, Karchmer AW. Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. Rev Infect Dis 1986; 8:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/37\">",
"      Aguilar J, Urday-Cornejo V, Donabedian S, et al. Staphylococcus aureus meningitis: case series and literature review. Medicine (Baltimore) 2010; 89:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/38\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/39\">",
"      Beer R, Engelhardt KW, Pfausler B, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 2007; 51:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/40\">",
"      Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006; 50:3971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/41\">",
"      Villani P, Regazzi MB, Marubbi F, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002; 46:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/42\">",
"      Yogev R, Damle B, Levy G, Nachman S. Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. Pediatr Infect Dis J 2010; 29:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/43\">",
"      Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007; 41:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/44\">",
"      Kaplan SL, Patrick CC. Cefotaxime and aminoglycoside treatment of meningitis caused by gram-negative enteric organisms. Pediatr Infect Dis J 1990; 9:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/45\">",
"      Fong IW, Tomkins KB. Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 1985; 7:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/46\">",
"      Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995; 39:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/47\">",
"      S&aacute;ez-Llorens X, McCracken GH Jr. Antimicrobial and anti-inflammatory treatment of bacterial meningitis. Infect Dis Clin North Am 1999; 13:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/48\">",
"      Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/49\">",
"      Molyneux E, Nizami SQ, Saha S, et al. 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study. Lancet 2011; 377:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/50\">",
"      Snape MD, Kelly DF. Fine with five? Shorter antibiotic courses for childhood meningitis. Lancet 2011; 377:1809.",
"     </a>",
"    </li>",
"    <li>",
"     Feigin RD, Dodge PR. Personal experience: Unpublished data for prospective studies of bacterial meningitis, 1974-1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/52\">",
"      Waler JA, Rathore MH. Outpatient management of pediatric bacterial meningitis. Pediatr Infect Dis J 1995; 14:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/53\">",
"      Tice AD, Strait K, Ramey R, Hoaglund PA. Outpatient parenteral antimicrobial therapy for central nervous system infections. Clin Infect Dis 1999; 29:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/54\">",
"      Bradley JS, Ching DK, Phillips SE. Outpatient therapy of serious pediatric infections with ceftriaxone. Pediatr Infect Dis J 1988; 7:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/55\">",
"      Klein JO, Feigin RD, McCracken GH Jr. Report of the Task Force on Diagnosis and Management of Meningitis. Pediatrics 1986; 78:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/56\">",
"      Arditi M, Herold BC, Yogev R. Cefuroxime treatment failure and Haemophilus influenzae meningitis: case report and review of literature. Pediatrics 1989; 84:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/57\">",
"      Lin TY, Nelson JD, McCracken GH Jr. Fever during treatment for bacterial meningitis. Pediatr Infect Dis 1984; 3:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/58\">",
"      Steele RW, McConnell JR, Jacobs RF, Mawk JR. Recurrent bacterial meningitis: coronal thin-section cranial computed tomography to delineate anatomic defects. Pediatrics 1985; 76:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/59\">",
"      Pong A, Bradley JS. Bacterial meningitis and the newborn infant. Infect Dis Clin North Am 1999; 13:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/60\">",
"      Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997; 337:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/61\">",
"      Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 1993; 12:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/62\">",
"      Mongelluzzo J, Mohamad Z, Ten Have TR, Shah SS. Corticosteroids and mortality in children with bacterial meningitis. JAMA 2008; 299:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/63\">",
"      Nigrovic LE, Kuppermann N, Malley R, Bacterial Meningitis Study Group of the Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Children with bacterial meningitis presenting to the emergency department during the pneumococcal conjugate vaccine era. Acad Emerg Med 2008; 15:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/64\">",
"      Roine I, Peltola H, Fern&aacute;ndez J, et al. Influence of admission findings on death and neurological outcome from childhood bacterial meningitis. Clin Infect Dis 2008; 46:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/65\">",
"      Fortnum HM. Hearing impairment after bacterial meningitis: a review. Arch Dis Child 1992; 67:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/66\">",
"      Wald ER, Kaplan SL, Mason EO Jr, et al. Dexamethasone therapy for children with bacterial meningitis. Meningitis Study Group. Pediatrics 1995; 95:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/67\">",
"      Dodge PR, Davis H, Feigin RD, et al. Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis. N Engl J Med 1984; 311:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/68\">",
"      Pelkonen T, Roine I, Monteiro L, et al. Risk factors for death and severe neurological sequelae in childhood bacterial meningitis in sub-Saharan Africa. Clin Infect Dis 2009; 48:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/69\">",
"      Roine I, Weisstaub G, Peltola H, LatAm Bacterial Meningitis Study Group. Influence of malnutrition on the course of childhood bacterial meningitis. Pediatr Infect Dis J 2010; 29:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/70\">",
"      Kornelisse RF, Westerbeek CM, Spoor AB, et al. Pneumococcal meningitis in children: prognostic indicators and outcome. Clin Infect Dis 1995; 21:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/71\">",
"      Kaplan SL, Schutze GE, Leake JA, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 2006; 118:e979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/72\">",
"      Taylor HG, Schatschneider C, Watters GV, et al. Acute-phase neurologic complications of Haemophilus influenzae type b meningitis: association with developmental problems at school age. J Child Neurol 1998; 13:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/73\">",
"      Lebel MH, McCracken GH Jr. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. Pediatrics 1989; 83:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/35/38458/abstract/74\">",
"      Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures. Cochrane Database Syst Rev 2006; :CD004884.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6010 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38458=[""].join("\n");
var outline_f37_35_38458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H51\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Avoidance of delay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antibiotic regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Bactericidal agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Drug entry into CSF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IMMEDIATE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fluid management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EMPIRIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Major pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Empiric regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Use of dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Special circumstances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H447825222\">",
"      Cancer and neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H447825229\">",
"      T cell defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Recent neurosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H447825251\">",
"      Recent placement of CSF shunt",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Anatomic defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Penetrating head trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - CSF leak",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Epidemics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SPECIFIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      S. pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      N. meningitidis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      H. influenzae type b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      L. monocytogenes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Group B streptococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H725269040\">",
"      S. aureus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Gram-negative rods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Positive CSF culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Outpatient therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Negative CSF culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Duration of fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Repeat CSF analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Neurologic sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Hearing evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Isolation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Immediate and supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Antibiotic and dexamethasone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Response to treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Prognosis and follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6010\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6010|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?34/44/35521\" title=\"algorithm 1\">",
"      Management of suspected meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6010|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/13/7376\" title=\"picture 1\">",
"      Dermal sinus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6010|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/0/32780\" title=\"table 1\">",
"      Drugs pneumococcal meningitis children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/58/2989\" title=\"table 2\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/10/17576?source=related_link\">",
"      Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7928?source=related_link\">",
"      Clinical features and diagnosis of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4442?source=related_link\">",
"      Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25930?source=related_link\">",
"      Diagnosis and treatment of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/13/16600?source=related_link\">",
"      Epidemiology and clinical features of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44552?source=related_link\">",
"      Infections of central nervous system shunts and other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22327?source=related_link\">",
"      Initial assessment and stabilization of children with respiratory or circulatory compromise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31656?source=related_link\">",
"      Neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38549?source=related_link\">",
"      Pathogenesis and pathophysiology of bacterial meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/1/31762?source=related_link\">",
"      Patient information: Bacterial meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/48/1796?source=related_link\">",
"      Patient information: Meningitis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/43/3763?source=related_link\">",
"      Patient information: Meningitis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/42/12970?source=related_link\">",
"      Pneumococcal meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16121?source=related_link\">",
"      Treatment and outcome of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=related_link\">",
"      Treatment of bacterial meningitis caused by specific pathogens in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8057?source=related_link\">",
"      Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_35_38459="SCFE outcome by severity";
var content_f37_35_38459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Outcome of slipped capital femoral epiphysis according to the severity of slip*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Severity",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patients with this degree of severity",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Iowa hip score",
"        <sup>",
"         &Delta;",
"        </sup>",
"        of hips at latest follow-up",
"       </td>",
"       <td class=\"subtitle1\">",
"        Osteonecrosis",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chondrolysis",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Data from 155 hips in 124 patients with SCFE followed for a mean of 41 years.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Mild slips are &lt;30 degrees of femoral head-shaft angle deviation from the contralateral side; moderate slips are between 30 and 50 degrees; severe slips are &gt;50 degrees.",
"      <br>",
"       &Delta; The Iowa hip score is a standardized instrument that gives points for function, freedom from pain, gait, absence of deformity and range of motion; normal score = 100.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Carney BT, Weinstein SL, Noble J. J Bone Joint Surg Am 1991; 73:667.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38459=[""].join("\n");
var outline_f37_35_38459=null;
var title_f37_35_38460="Opioid withdrawal treatment medications";
var content_f37_35_38460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications used in management of opioid withdrawal",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial dose (adult)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Opioid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methadone",
"       </td>",
"       <td>",
"        10 mg&nbsp;intramuscularly or 20 mg orally",
"       </td>",
"       <td>",
"        <p>",
"         Naturally occurring withdrawal.",
"        </p>",
"        <p>",
"         Not recommended for management of acute withdrawal triggered by an antagonist (naloxone, naltrexone).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Non-opioid adjunctive medications*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clonidine",
"       </td>",
"       <td>",
"        0.1 to 0.3 mg&nbsp;orally every&nbsp;hour with monitoring of blood pressure and heart rate",
"       </td>",
"       <td>",
"        Anxiety,&nbsp;restlessness, dysphoria&nbsp;with elevated or normal blood pressure and heart rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diazepam",
"       </td>",
"       <td>",
"        1 to 10 mg orally, IV or intramuscularly",
"       </td>",
"       <td>",
"        Anxiety, restlessness, dysphoria, insomnia, muscle cramping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Promethazine",
"       </td>",
"       <td>",
"        25 to 50 mg intramuscularly (preferred) or IV (venous irritant)",
"       </td>",
"       <td rowspan=\"3\">",
"        Nausea, vomiting, restlessness, insomnia",
"        <br/>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diphenhydramine",
"       </td>",
"       <td>",
"        50 mg IV, intramuscularly or orally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydroxyzine",
"       </td>",
"       <td>",
"        50 to 100 mg intramuscularly or orally&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Loperamide",
"       </td>",
"       <td>",
"        4 mg orally, followed by 2 mg every loose stool",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea, stomach cramps",
"        <br/>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Octreotide",
"       </td>",
"       <td>",
"        50 micrograms&nbsp;subcutaneously every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bismuth subsalicylate",
"       </td>",
"       <td>",
"        524 mg orally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acetaminophen",
"       </td>",
"       <td>",
"        650 mg orally",
"       </td>",
"       <td rowspan=\"2\">",
"        Pain, myalgia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ibuprofen",
"       </td>",
"       <td>",
"        600 mg orally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Baclofen",
"       </td>",
"       <td>",
"        5 to 10 mg orally",
"       </td>",
"       <td>",
"        Muscle cramping",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    For additional information on managing symptoms of withdrawal in patients cared for in&nbsp;a non-emergency setting, refer to topic on&nbsp;Opioid detoxification during treatment for addiction.",
"    <div class=\"footnotes\">",
"     <p>",
"      * If withdrawal is naturally-occurring, the physician may opt to manage the patient with either opioid or non-opioid adjunctive medication. If withdrawal is triggered by an antagonist, only&nbsp;non-opioid adjunctive medications should be used to manage emergent withdrawal.&nbsp;Refer to UpToDate topics on opioid withdrawal in adults.",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38460=[""].join("\n");
var outline_f37_35_38460=null;
var title_f37_35_38461="Glucagon resp in prolonged fast";
var content_f37_35_38461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F64700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F64700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plasma glucose responses to glucagon after a prolonged fast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 279px; height: 318px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship between the plasma glucose concentration after a prolonged fast and the increase in plasma glucose after the administration of 1 mg of intravenous glucagon in normal subjects and patients with an insulinoma. In patients who become hypoglycemic, an increase in plasma glucose of &ge;25 mg/dL (1.4 mmol/L) after glucagon is suggestive of an insulinoma. To convert plasma glucose values to mmol/L multiply by 0.056.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Service, FJ, N Engl J Med 1995; 332:1144.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38461=[""].join("\n");
var outline_f37_35_38461=null;
var title_f37_35_38462="MPI algorithm post PCI";
var content_f37_35_38462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Proposed algorithm for the appropriate use of stress MPI after PCI with respect to the nature and timing of symptoms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 290px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * ACC/AHA practice guidelines favor selective evaluation in patients considered to be at particular high risk (eg, patients with decreased left ventricular function, multivessel coronary disease, proximal left anterior descending disease, previous sudden death, diabetes mellitus, hazardous occupations, and suboptimal PCI results).",
"     <br>",
"      &bull; Stress MPI is specifically indicated in patients who have an abnormal ECG response to exercise or baseline ECG changes that may interfere with identification of ischemia induced during exercise. Stress MPI can also be performed during initial exercise ECG testing because it provides added value with respect to risk stratification and possible therapy.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38462=[""].join("\n");
var outline_f37_35_38462=null;
var title_f37_35_38463="CNS Listeria CT";
var content_f37_35_38463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography (CT) scan showing a brain lesion in a patient with listeriosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan in a 72-year-old, previously healthy man with acute left hemiplegia and fever. A hypolucent area is present in a temporoparietal distribution. Blood cultures grew Listeria monocytogenes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_35_38463=[""].join("\n");
var outline_f37_35_38463=null;
